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Summary	
Vulval	intraepithelial	neoplasia	(VIN)	is	a	condition	of	vulval	skin	that	is	often	chronic	in	nature.	The	diagnosis	is	made	histologically	and	can	be	delayed	due	to	VINs	variable	clinical	presentation.	Frequently	reported	symptoms	of	pain	and	itching	can	be	very	distressing	for	patients.	If	left	untreated,	VIN	has	the	potential	to	become	malignant.	The	current	standard	treatment	for	VIN	is	surgical	excision.	However	this	approach	is	not	ideal;	it	can	be	disfiguring	and	lead	to	significant	psychosexual	morbidity.	There	are	also	potentially,	significant	post-operative	complications	(e.g.	infection)	and	a	high	rate	of	recurrence.	Alternative	treatments	are	needed.	The	efficacy	of	cidofovir	and	imiquimod	treatment	was	investigated	in	the	RT3	VIN	clinical	trial,	and	complete	responses	were	observed	in	57%	and	61%	of	patients	respectively.		The	Human	Papillomavirus	(HPV)	plays	a	major	aetiological	role	in	the	development	of	VIN.	To	further	understanding	of	HPV	pathogenesis	in	VIN,	HPV	prevalence,	HPV	integration,	HPV	methylation	and	HPV	gene	expression	were	investigated	in	167	tissue	biopsies	from	patients	participating	in	the	RT3	VIN	trial.	High	HPV	prevalence	of	98.2%	was	detected.	HPV	biology	was	found	to	be	heterogeneous:	HPV	integration	was	detected	in	71/136	(52.5%)	cases;	HPV	DNA	methylation	ranged	from	0.0%	-	94.4%,	and	there	was	variable	expression	of	HPV	genes.	Strong	correlations	were	found	between	HPV	integration,	high	levels	of	methylation,	low	levels	of	E2	gene	expression	and	deregulated	oncogene	expression.	Variable	HPV	biology	in	VIN	3	meant	that	HPV	characteristics	had	a	potential	role	as	predictive	biomarkers.	HPV	E2	region	methylation	demonstrated	greatest	potential.	E2	methylation	>4%	predicted	response	to	cidofovir	with	88.2%	sensitivity	and	84.6%	specificity;	while	E2	methylation	<4%	predicted	response	to	imiquimod	with	70.6%	sensitivity	and	62.5%	specificity.	Further	investigation	of	this	biomarker	in	a	large	prospective	study	is	justified.		
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1 Background	
1.1 Vulval	Intraepithelial	Neoplasia	(VIN)	
VIN	is	a	chronic	condition	of	vulval	skin	diagnosed	histologically	by	the	identification	of	cellular	changes	associated	with	a	pre-malignant	state.	It	has	a	variable	clinical	presentation,	can	be	very	distressing	for	patients	and	can	often	take	a	long	time	to	diagnose.	If	left	untreated,	VIN	has	the	potential	to	become	malignant.		
1.1.1 Classification	Evidence	of	intraepithelial	neoplasia	was	probably	first	reported	by	Williams	et	al.	1886	who	observed	that	the	epithelium	adjacent	to	cervical	carcinomas	was	frequently	abnormal.	Early	methods	of	classification	of	these	abnormalities	in	the	cervix	developed	in	1955	when	Raegans	et	al.	suggested	the	terminology	atypical	hyperplasia	of	slight,	moderate	and	marked	degree.	The	current	classification	system	used	for	cervical	intraepithelial	neoplasia	was	first	established	in	1967	by	Richart	et	al.	who	defined	cervical	intraepithelial	neoplasia	grade	I,	II	and	III.	The	classification	was	extended	to	vulval	disease	much	later	and	presently,	two	methods	of	classification	of	VIN	exist;	both	based	on	histologically	identifiable	characteristics	in	a	tissue	biopsy.	The	first	method	was	established	in	1986	when	the	International	Society	for	the	Study	of	Vulvovaginal	Disease	(ISSVD)	developed	the	term	VIN	to	describe	the	precursor	lesions	of	vulval	squamous	cell	carcinoma	on	the	basis	of	the	terminology	used	for	cervical	disease	(CIN).	Histological	features,	comparable	to	those	seen	in	CIN,	including	epidermal	thickening	with	hyperkeratosis/parakeratosis,	loss	of	cell	maturation,	increased	nuclear	to	cytoplasmic	ratio	with	nuclear	hyperchromasia,	pleomorphism	and	numerous	mitotic	cell	are	required	to	make	the	diagnosis.	Lesions	are	further	classified	based	on	the	degree	of	epithelial	involvement	as,	VIN	1,	2	or	3	(Ridley	et	al.	1989),	(Figure	1.1).	It	was	thought	that	the	natural	history	of	disease	was	progressive	from	VIN	1	to	VIN	3	and	in	some	cases	invasive	cancer.	Recently,	use	of	the	term	VIN	1	has	been	discouraged	based	on	the	lack	of	evidence	supporting	the	morphologic	continuum	of	VIN	1-3	synonymous	with	CIN	(van	Seters	et	al.	2005).	The	histological	changes	previously	identified	as	VIN	1	are	now	thought	to	represent	the	early	reactive	atypia	associated	with	new	HPV	infection	and	are,	more	often	than	not,	totally	reversible	making	labelling	as	a	pre-malignant	state	misleading	(Preti	et	al.	2015;	Del	Pino	et	al.	2013;	Reyes	&	Cooper	2014;	McCluggage	2009).		
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Figure	1.1	Traditional	VIN	classification.	Figure	represents	the	vulval	epithelium	with	increasing	grade	of	VIN	moving	from	left	to	right.	VIN	1	illustrated	involving	<1/3	of	epithelium,	VIN	2	involving	up	to	2/3	of	epithelium	and	VIN	3	involving>2/3	of	epithelium.	Histological	features	labelled.	Invasive	cancer	displays	invasion	through	the	basement	membrane.	Adapted	from	figure	drawn	by	Dr	Amanda	Tristram.		The	classification	was	modified	in	2004	by	the	ISSVD	upon	the	recognition	of	two	different	modes	of	pathogenesis	leading	to	disease;	the	more	common	usual	VIN	(uVIN)	being	HPV	dependent	and	the	less	common	differentiated	VIN	(dVIN),	which	is	HPV	independent	(Sideri	et	al.	2005).	The	subtypes	are	differentiated	histologically.	Histological	features	of	uVIN	remain	the	same	as	those	used	for	CIN.	The	histological	features	for	dVIN	are	subtle,	and	include:	•	 Atypical	keratinocytes	in	the	context	of	a	fully	differentiated	vulval	epithelium	•	 Thickened	epidermis	with	parakeratotic	surface	reaction	•	 Elongated	rete	ridges,	frequently	branched	•	 A	significant	number	of	abnormal	enlarged	squamous	cells	with	large	vesicular	nuclei	and	macronuclei.	
Normal' VIN'1' VIN'2' VIN'3' Invasive'cancer'
'
Increased)
nuclear,
cytoplasmic)ra3o)
Nuclear)
hyperchromasia)
Mito3c)bodies)
Increasing)depth)of)epithelial)involvement)
Pleomorphism)
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•	 Abundant	and	brightly	eosinophilic	cytoplasm	(Figure	1.2).		
	
Figure	1.2	VIN	histological	subtypes.	Images	A	and	C	are	of	dVIN	demonstrating	histological	features	including	abnormally,	enlarged	squamous	cell	nuclei,	elongated	rete	ridges	and	thickened	epidermis.	Image	C	shows	diffuse	p53	staining.	Images	B	and	D	are	of	uVIN	demonstrating	histological	features	such	as	loss	of	cell	maturation,	increased	nuclear-cytoplasmic	ratio	and	numerous	mitotic	bodies.	Photographs	kindly	provided	by	Dr	Gareth	Rowlands,	Consultant	Histopathologist,	University	Hospital	of	Wales,	Cardiff.		The	new	terminology	(uVIN,	dVIN)	has	not	been	broadly	adopted	in	the	UK	yet,	with	many	departments	preferring	the	traditional	method	analogous	to	CIN	(VIN	1,	2	and	3).	This	may	be	a	result	of	the	histological	characteristics	of	dVIN	being	subtle	and	less	well	defined	than	its	uVIN	counterpart	leading	to	increased	likelihood	of	intra-observer	variation	(Preti	et	al.	2000).		It	may	also	be	a	result	of	several	studies	reporting	HPV	positivity	in	cases	of	VIN	histologically	defined	as	dVIN	(see	section	1.2.4).	Based	on	both	these	factors,	it	seems	unlikely	that	the	disease	can	be	easily	classified	into	these	subtypes	and	further;	the	clinical	utility	of	such	a	classification	system	is	questionable.	The	biopsies	used	for	this	research	came	from	a	multi-centre	UK-based	clinical	trial	(RT3	VIN),	which	adopted	the	traditional	classification	method	in	order	to	ensure	consistency	and	familiarity	by	all	participating	centres.	For	this	reason,	the	traditional	terminology	is	used	in	this	thesis.	However,	HPV	DNA	testing	was	performed	on	all	biopsies	as	a	proxy	for	uVIN	(HPV	positive)	and	dVIN	(HPV	negative).	
A"
B"
C"
D"
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1.1.2 Epidemiology	Vulval	intraepithelial	neoplasia	(of	either	subtype)	is	an	uncommon	condition	with	incidence	rates	of	approximately	2	per	100,000	with	a	peak	at	30-49	years	of	age	(De	Vuyst	et	al.	2009;	van	Seters	et	al.	2005;	R.	W.	Jones	et	al.	2005).	Incidence	has	been	rising	over	recent	decades	particularly	in	younger	women.	Usual	VIN	is	the	most	common	VIN	type.	In	some	countries	the	incidence	of	uVIN	in	particular	has	almost	doubled	over	the	last	10	years	(Preti	et	al.	2015).	Interestingly,	despite	this,	the	incidence	of	vulval	cancer	has	remained	relatively	stable.	Possible	explanations	for	this	disparity	include:	an	increased	awareness	of	the	disease	by	healthcare	professionals	increasing	the	number	of	diagnoses;	treatment	of	lesions	prior	to	the	development	of	malignancy;	and,	increased	prevalence	of	HPV	infection	leading	to	more	cases	of	uVIN	which	has	a	lower	risk	of	malignant	progression	(Preti	et	al.	2015).	
1.1.2.1 Usual	VIN	Usual	VIN	is	strongly	associated	with	HPV	infection	and,	in	particular,	HPV	16	infection.	The	largest	single	study	of	HPV	prevalence	in	VIN	to	date	examined	587	paraffin	embedded	vulval	specimens	histologically	diagnosed	with	VIN	and	found	the	overall	HPV	prevalence	to	be	88.7%,	of	which	77.3%	were	HPV	16	positive.	They	further	differentiated	cases	as	either	uVIN	or	dVIN	and	reported	HPV	prevalence	as	90.3%	in	uVIN	(de	Sanjosé	
et	al.	2013).	A	meta-analysis	performed	in	2009	reported	overall	HPV	prevalence	in	VIN	2/3	as	87.7%	(De	Vuyst	et	al.	2009).	Usual	VIN	presents	in	younger	women	than	dVIN	and	this	reflects	the	differing	aetiologies	(Trimble	et	al.	1996;	Del	Pino	et	al.	2013;	McCluggage	2009).	Human	papillomavirus	is	a	sexually	transmitted	infection	and	is	therefore	more	common	in	younger	women.	Factors	that	increase	the	likelihood	of	contracting	and	maintaining	HPV	infection,	including	increased	number	of	sexual	partners,	smoking	and	impaired	immunological	status,	are	all	associated	with	the	development	of	uVIN	(De	Vuyst	
et	al.	2009;	Sykeset	al.	2002;	Preti	et	al.	2005;	van	der	Avoort	et	al.	2006;	Fox	&Wells	2003).	
1.1.2.2 Differentiated	VIN	Differentiated	VIN	is	less	common	than	uVIN.	Differentiated	VIN	occurs	more	frequently	in	older	women	with	a	peak	incidence	seen	in	the	5-6thth	decades	of	life,	and	often	in	association	with	chronic	skin	disease	such	as	lichen	sclerosus	and	lichen	planus	(Sideri	et	
al.	2005;	Jones	2001;	van	de	Nieuwenhof	et	al.	2009;	Jones	et	al.	2005).	There	are	reports	of	HPV	being	found	in	specimens	from	patients	diagnosed	with	dVIN;	the	significance	of	the	HPV	in	these	cases	is	uncertain	and	could	be	incidental.	
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1.1.3 Clinical	Presentation	Vulval	intraepithelial	neoplasia	may	be	symptomless	and	diagnosed	as	an	incidental	finding	during	examination	of	the	female	genital	tract,	but	in	60%	of	cases,	symptoms	exist.		Clinical	symptoms	are	variable	and	include:	pain,	itching,	irritation,	dyspareunia,	discharge	and	bleeding.	The	lesions	can	be	variable	in	their	colour,	number,	size,	shape,	and	location	on	the	vulva	(Figure	1.3).	Lesions	can	be	subtle	and,	in	combination	with	the	symptom	profile,	disease	can	be	confused	with	vulval	candidiasis,	which	may	result	in	delayed	diagnosis	and	treatment	(Rodolakis	et	al.	2003;	Reyes	&	Cooper	2014).	Usual	VIN	is	often	multifocal	and	multi-centric	in	its	presentation	and	the	likelihood	of	concurrent	disease	at	other	regions	of	the	genital	tract	such	as	the	anus,	vagina	and	cervix	is	high	(approximately	40%	of	cases)	(Preti	et	al.	2015).	For	this	reason,	upon	diagnosis,	examination	of	the	complete	lower	genital	tract	should	take	place.	Differentiated	VIN	is	often	discovered	as	a	solitary	lesion	within	a	field	of	lichen	sclerosus	or	adjacent	to	invasive	disease	(van	de	Nieuwenhof	et	al.	2011).		
	
	
			
	
1.1.4 Malignant	Potential	Establishing	the	malignant	potential	of	VIN	is	challenging.	Studies	published	vary	in	duration	of	follow	up,	treatment	modes,	treatment	regimes	and	inclusion	and	exclusion	criteria	making	comparisons	difficult.	Overall,	the	malignant	potential	of	VIN	is	relatively	low.	Not	all	cases	of	VIN	progress	to	cancer;	spontaneous	regression	occurs	in	1%-2%	of	women	(Jones	et	al.	2005).	Without	treatment,	rates	of	malignant	progression	range	from	9%	to	18.5%	(Jones	&	Rowan	2000;	Jones	&	Rowan	1995;	Jones	et	al.	2005).	An	additional	
A" B"
Figure	1.3	Clinical	appearance	of	VIN.	Image	A	-	extensive	VIN	3	covering	all	aspects	of	the	vulval	epithelium.	Lesions	are	raised,	warty,	white,	brown	and	red.	Image	B	-	Less	extensive	VIN	3	affecting	the	skin	fold	between	the	right	labia.	Lesions	are	flat	and	white	with	occasional	brown	patches	
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study	reported	malignant	progression	rates	of	87.5%	in	untreated	women,	however,	this	study	cohort	consisted	of	patients	with	unusually	high	levels	of	co-morbidities	(Jones	&	Rowan	1995).	This	range	may	be	explained	by	variation	in	the	duration	of	follow	up	of	patients	between	studies	as	well	as	differing	proportions	of	dVIN	and	uVIN	in	the	cohorts;	dVIN	has	a	higher	risk	of	progression	to	malignancy	than	usual	VIN	(33%	versus	5.7%	respectively).	Even	with	treatment,	the	rates	of	recurrence	are	relatively	high	and	progression	to	malignancy	varies	from	1%	to	6.5%	(van	Seters	et	al.	2005;	Hillemanns	et	
al.	2006;	Jayne	&	Kaufman	2002).	
1.1.5 Management	The	aims	of	clinical	management	of	VIN	include:	reduction	in	risk	of	malignant	progression;	symptom	alleviation	(Sykes	et	al	2002);	and,	confirmation	of	the	absence	of	stromal	invasion	as	occult	malignancies	are	reported	in	3.2%	of	cases	(van	Seters	et	al.	2005).	Decisions	regarding	the	management	of	VIN	should	also	consider	patient	desires,	co-morbidities,	and	extent,	location	and	duration	of	disease.	Low-grade	disease,	termed	VIN	1	using	the	traditional	classification	method,	is	generally	managed	conservatively	with	regular	vulvoscopy	and	biopsy	of	any	suspicious	area.	For	high-grade	disease	(VIN	2/3,	or	uVIN	and	dVIN	in	new	classification)	treatment	is	usually	recommended	due	to	the	higher	chance	of	malignant	progression.	
1.1.5.1 Surgery	The	overall	aim	of	surgery	is	to	relieve	symptoms	and	exclude	any	underlying	malignancy,	whilst	at	the	same	time,	preserving	vulval	anatomy	and	function	as	much	as	possible.	Surgical	options	are	either	excisional	or	ablative	techniques.	Most	cases	of	VIN	are	managed	with	excisional	surgery	in	order	to	remove	the	diseased	tissue	and	allow	histological	evaluation	to	ensure	there	is	no	underlying	malignancy.	The	degree	of	surgical	excision	required	is	dependent	on	the	extent	of	disease	and	can	range	from	local	excision	to	partial	or	complete	vulvectomy	with	reconstructive	surgery.	Figure1.4	shows	a	case	of	extensive	recurrent	VIN	3	requiring	complete	vulvectomy	with	reconstructive	surgery	before,	during	and	after	surgery.		
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Figure	1.4	Surgical	vulvectomy	images.	The	image	on	the	left	is	of	a	patient	with	extensive,	recurrent	VIN	3	having	had	multiple	excisional	procedures	previously.	The	central	image	was	taken	following	the	vulvectomy,	demonstrating	the	extent	of	surgery	required.	The	image	on	the	right	was	taken	following	the	reconstructive	surgery	performed	by	the	plastic	surgeon	(both	aspects	of	procedure	take	place	on	the	same	day).	Skin	flaps	were	taken	from	the	patient’s	buttocks.	A	urinary	catheter	is	in-situ	to	aid	functional	healing	of	the	urethra.	Due	to	the	location	of	disease,	even	after	small	excisions,	rates	of	wound	infection	and	wound	breakdown	are	high.	Wound	breakdown	can	be	very	problematic	requiring	further	surgery,	prolonged	hospital	stays	and	poorer	cosmetic	outcomes.	These	procedures	can	be	disfiguring	affecting	the	anatomy	and	occasionally	the	function	of	the	vulva.	With	an	increasingly	younger	population	presenting	with	the	disease,	surgical	excision	is	an	increasingly	unattractive	option	for	both	patients	and	clinicians	due	to	the	significant	psychosexual	and	surgical	morbidity	that	potentially	follows.	Studies	have	shown	that	following	vulval	surgery,	women	report	a	reduction	in	sexual	function	and	quality	of	life	(Corney	et	al.	1993;	Andersen	&	Hacker	1983;	Aerts	et	al.	2012;	Likes	et	al.	2006;	Likes	et	
al.	2007).	Despite	the	excision	of	disease,	recurrence	rates	are	unacceptably	high,	meaning	repeated	procedures	are	often	required	(Kaushik	et	al.	2014).	For	example,	a	systematic	review	performed	in	2005	revealed	recurrence	rates	of	19%	following	complete	vulvectomy,	18%	following	partial	vulvectomy	and	22%	following	local	excision	(van	Seters	et	al.	2005).	Ablative	surgery	such	as	carbon	dioxide	(CO2)	laser	ablation,	cryocoagulation	and	loop	electrosurgical	excision	procedure	(LEEP)	are	alternative	techniques	involving	destruction	of	diseased	tissue.	These	techniques	have	become	less	favoured	over	recent	years	in	the	UK	due	to	the	lack	of	an	adequate	tissue	sample	to	send	for	histological	evaluation,	meaning	that	underlying	malignancy	can	never	be	excluded	with	certainty.	Furthermore	disease	recurrence	rates	following	laser	vaporization	have	been	reported	as	23%	and	following	cryocoagulation	up	to	56%	(van	Seters	et	al.	2005)	conferring	no	therapeutic	advantage	in	terms	of	reduced	surgical	episodes.	
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1.1.5.2 Medical	Efforts	are	being	made	to	develop	alternative,	less	invasive	medical	treatment	options	for	VIN	to	reduce	the	impact	the	treatment	has	on	the	patient.	There	are	however,	currently	no	medical	treatments	approved	by	the	European	Medicines	Agency	(EMA)	for	treatment	of	VIN.	In	the	1980s	chemotherapeutic	interventions	such	as	5-Flourouracil	(Sillman	et	al.	1985;),	Bleomycin	(Roberts	et	al.	1980)	and	trinitrochlorobenzene	(Foster	&	Woodruff	1981)	were	investigated;	these	medications	were	associated	with	intolerable	side	effects	and	are	no	longer	used	(Pepas	et	al.	2014).	More	recently,	imiquimod,	cidofovir,	photodynamic	therapy,	interferon	alpha	(α-IFN),	phytochemical	indole-3-carbinol	(I3C)	and	therapeutic	vaccines	have	been	investigated	with	varying	degrees	of	success	and	are	discussed	in	more	detail	below.	
1.1.5.2.1 Imiquimod	Imiquimod,	1-(2-methylpropyl)-1H-imidazo[4,	5-c]quinolin-4-amine,	is	a	non-nucleoside	heterocyclic	amine,	which	acts	as	an	immune-response	modifier.	It	induces	activity	of	interferon	α	(IFNα),	tumour	necrosis	factor	α	(TNFα)	and	interleukin-6,	and	has	demonstrated	both	anti-tumour	and	anti-viral	activity	in	animal	studies	(Schön	&	Schön	2007;	Stanley	2002).	Imiquimod	5%	is	a	topical	treatment	licensed	for	use	in	the	treatment	of	anogenital	warts	and	basal	cell	carcinoma.	There	are	several	studies	into	its	efficacy	in	the	treatment	of	VIN	demonstrating	success	rates	ranging	from	20.0%-80.9%	(see	Table	1	4).	Imiquimod	is	one	of	the	two	treatments	that	this	thesis	focuses	on	and	is	discussed	in	depth	in	section	1.4.	
1.1.5.2.2 Cidofovir	Cidofovir	is	an	acyclic	nucleoside	analogue	with	broad-spectrum	antiviral	activity.	Its	licenced	use	is	in	the	treatment	of	cytomegalovirus	retinitis	in	HIV	patients	but	has	demonstrated	efficacy	in	the	treatment	of	VIN	3	in	pilot	work.		In	a	pilot	study	of	cidofovir	treatment	in	12	patients	with	VIN,	10/12	women	completed	follow	up,	four	of	whom	demonstrated	complete	response,	three	patients	had	a	reduction	in	lesion	size	>50%	and	three	failed	to	respond	(Tristram	&	Fiander	2005).	Cidofovir	treatment	is	a	focus	of	this	thesis	and	is	discussed	in	depth	in	section	1.3.	
1.1.5.2.3 Photodynamic	Therapy	Photodynamic	therapy	(PDT)	is	a	two-step	process.	Firstly,	a	non-toxic,	photosensitiser	(e.g.	5-aminolaevulinic	acid)	is	applied	to	the	visibly	affected	tissue.	Secondly,	a	visible	light	of	appropriate	wavelength	is	applied	to	activate	the	photosensitizer	that	leads	to	the	production	of	reactive	oxygen	species	that	cause	cell	death.	The	benefit	of	PDT	lies	in	its	ability	to	treat	multi-focal	disease	without	tissue	loss;	there	is	minimal	tissue	destruction	
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and	excellent	cosmesis.	An	additional	advantage	of	this	procedure	is	its	suitability	for	administration	in	the	outpatient	setting.	Challenges	associated	with	this	treatment	option	include	pain	(some	patients	are	unable	to	tolerate	it);	the	absence	of	histology	to	confirm	diagnosis	and	risk	of	damage	to	the	surrounding	tissue	should	the	photosensitiser	leak.	Several	studies	have	been	performed	to	investigate	the	efficacy	of	treating	VIN	with	PDT,	and	reported	histological	response	rates	varying	from	0%-67%	(Hillemanns	et	al.	2000;	Martin-Hirsch	et	al.	1998;	Zawislak	et	al.	2009;	Daayana	et	al.	2011;	Fehr	et	al.	2001).	
1.1.5.2.4 Interferon	Alpha	(α-IFN)	The	immunotherapy	α-IFN,	was	investigated	as	a	potential	treatment	modality	for	VIN	in	the	1980s	and	1990s	with	no	work	having	been	published	more	recently.	Interferons	have	broad	antiviral	activity	and	also	possess	immunoregulatory	and	antiproliferative	properties	(Cirelli	&	Tyring	1994).	Interferon	has	been	shown	to	directly	inhibit	viral	replication	and	proliferation	in	infected	cells.	It	has	also	been	demonstrated	to	stimulate	the	expression	of	HPV	associated	cell	surface	antigens	making	HPV	infected	cells	more	recognizable	by	the	immune	system	(Beglin	et	al.	2009).	A	study	of	21	patients	investigating	the	use	of	α-IFN,	within	a	randomized	trial	setting,	assigned	patients	to	receive	α-IFN	with	or	without	the	addition	of	1%	nonoxynol-9	(thought	to	enhance	the	effect	of	α-IFN).	No	benefit	of	the	addition	of	1%	nonoxynol-9	was	found,	a	37.5%	complete	response	rate	was	reported	with	a	further	29.5%	of	patients	experiencing	a	partial	response	(Spirtos	et	al.	1990).	
1.1.5.3 Phytochemical	indole-3-carbinol	(I3C)	Indole-3-carbinol	is	a	substance	found	in	cruciferous	vegetables	such	as	broccoli,	sprouts,	cabbage	and	cauliflower.	Animal	models	have	demonstrated	I3C	to	have	a	role	in	the	prevention	of	oestrogen	dependent	cancers	(Jin	et	al.	1999).	Although	one	small,	randomised	placebo-controlled	trial	showed	an	effect	in	the	treatment	of	premalignant	lesions	of	the	cervix	(CIN),	this	effect	was	not	demonstrated	in	a	larger	randomised	trial	of	its	dimer,	diindolylmethane	(DIM),	(Bell	et	al.	2000;	Castanon	et	al	2012).	A	single	study	investigating	the	efficacy	of	I3C	in	the	treatment	of	VIN	found	that	despite	improvement	in	clinical	appearance	and	symptomatology	of	VIN,	there	was	no	histological	evidence	of	response	to	treatment	(Naik	et	al.	2006).	
1.1.5.4 Prophylactic	vaccines	A	program	of	prophylactic	HPV	vaccination	has	been	implemented	in	the	UK.		As	this	prevents	infection	with	HPV	types	16	and	18,	it	is	projected	that	with	good	uptake,	it	could	potentially	prevent	75%	of	VIN	that	is	associated	with	these	HPV	types	(De	Vuyst	et	al.	2009).	Benefits	from	the	vaccine	are	likely	to	start	being	seen	approximately	20	years	
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from	implementation.	However,	the	longer	the	vaccine	program	is	in	place,	the	more	benefit	that	that	will	be	seen	(including	that	obtained	from	the	‘herd	effect’).	By	50	years	post	implementation,	it	is	likely	that	significant	benefits	will	be	seen	with	present	uptake	rates.			
1.1.6 Conservative	Conservative	management	involves	regular	outpatient	follow-up	and	biopsy	of	any	lesions	suspicious	of	invasion.	Patient	counselling	regarding	the	risks	of	invasion	and	signs	to	look	out	for	is	paramount	as	well	as	an	assurance	that	the	patient	will	attend	follow	up	appointments.	This	approach	is	generally	reserved	for	women	with	VIN	1and	women	with	asymptomatic	high-grade	disease	who	wish	to	avoid	the	morbidity	of	treatment.		VIN	1	is	more	likely	to	regress	without	medical	intervention,	however,	even	high-grade	VIN	will	spontaneously	regress	in	a	minority	of	women	(Sideri	et	al.	2005;	Jones	&	Rowan	2000;	Stephenson	&	Denehy	2012).		
1.1.7 Recurrent	VIN	One	of	the	difficulties	in	managing	VIN	is	its	recurring	nature.	Rates	of	recurrence	are	reported	up	to	79%	(Küppers	et	al.	1997;	Herod	et	al.	1996;	Rodolakis	et	al.	2003;	van	Seters	et	al.	2005)	and	are	strongly	influenced	by	treatment	modality.	The	recurring	nature	of	the	disease	poses	problems	both	in	terms	of	optimum	follow	up	and	management.	Kuppers	et	al.	1997	followed	102	patients	with	VIN	and	discovered	that	disease	grade	and	disease	focality	were	risk	factors	for	recurrent	disease	(higher	disease	grade	and	multifocal	disease	being	more	likely	to	recur).	To	support	this,	Rodalakis	et	al.	2003,	found	a	strong	correlation	between	multi-focality	and	recurrence	but	did	not	find	a	relationship	between	grade	of	disease	and	recurrence.		Regarding	mode	of	treatment,	in	terms	of	surgical	approaches	a	systematic	review	of	68	studies	revealed	recurrence	rates	of	19%	following	vulvectomy,	18%	following	partial	vulvectomy,	22%	following	local	excision,	23%	following	laser	vaporisation	and	56%	following	cryocoagulation	(van	Seters	et	al.	2005).	Data	on	recurrence	rates	following	medical	management	of	the	condition	are	limited.	In	summary,	current	management	of	VIN	is	associated	with	high	rates	of	recurrence.	Alternative	treatment	options	offering	more	definitive	clearance	of	disease	are	urgently	required.	
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1.2 Human	Papillomavirus	
The	papillomaviruses	(PV)	are	a	diverse	group	of	viruses	that	infect	many	mammals	and	birds.	Human	papillomaviruses	(HPV)	have	circular,	double-stranded	DNA	genomes	of	approximately	8	kb.	Their	genomes	consist	of	six	early	(E)	open	reading	frames	(ORFs)	(E1-E2	and	E4-E7),	two	late	(L)	ORFs	(L1	and	L2)	and	a	long	non-coding	region	known	as	the	long	control	region	(LCR),	(Figure	1	8).	Functions	of	individual	proteins	are	discussed	in	more	detail	below.	The	L1	ORF	is	the	most	conserved	region	within	the	genome	and	is	therefore	used	for	classification	of	PV.	The	PV	family	consists	of	18	genera	(different	genera	share	less	than	60%	nucleotide	sequence	identity	in	the	L1	ORF)	and	more	than	210	different	genotypes	(based	on	>10%	sequence	variation	in	the	L1	ORF)	(Doorbaret	
al.2012).	There	are	more	than	150	human	papillomavirus	genotypes	that	belong	to	five	of	the	18	different	PV	genera:		Alpha,	Beta,	Gamma,	Nu	and	Mu;	the	majority	of	HPV’s	belong	to	the	Alpha	and	Beta	genera.	Alpha	viruses	are	the	most	researched	genera	as	these	viruses	are	those	associated	with	the	development	of	anogenital	and	oropharyngeal	malignancies	(Doorbar	et	al.	2012).	Beta	papillomaviruses	are	commonly	associated	with	unapparent,	cutaneous	infections	but,	can	be	associated	with	skin	cancer	development	in	immunocompromised	patients	(Doorbar	2006).	Gamma,	Mu	and	Nu	viruses	are	more	typically	associated	with	more	benign	clinical	conditions	such	as	warts	and	verrucae	(Doorbar	2006).	HPVs	are	further	categorized	as	high	and	low	risk	genotypes	depending	on	the	strength	of	their	association	with	cancers.	The	International	Agency	for	Research	on	Cancer	(IARC)	has	identified	12	high-risk	HPV	‘cancer-causing’	genotypes:	HPV	16,	18,	31,	33,	35,	39,	45,51,	52,	56,	58	and	59.	HPV	68	and	73	have	been	identified	as	possible	cancer-causing	types.	The	remaining	HPV	types	are	categorised	as	low	risk	(World	Health	Organisation	International	Agency	for	Research	on	Cancer	2005).	
1.2.1 HPV	Infection	and	Life	Cycle	The	HPV	lifecycle	and	the	functions	of	the	majority	of	the	HPV	gene	products	are	discussed	in	this	section.	
1.2.1.1 The	Target	Tissue	–	The	Squamous	Epithelium:	The	natural	host	tissue	for	the	complete	infection	cycle	of	all	HPVs	is	the	squamous	epithelium.	The	squamous	epithelium	is	a	multi-layered	structure,	each	layer	possessing	a	particular	profile	of	gene	expression,	protein	composition	and	keratinocyte	cellular	architecture	that	changes	as	the	keratinocytes	progress	through	differentiation.	Most	body	openings	are	lined	with	stratified	squamous	epithelium	but	more	internally	the	epithelium	
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becomes	columnar.	The	junction	between	the	two	epithelia	is	referred	to	as	the	squamo-columnar	junction.	
1.2.1.2 HPV	Transmission	and	Primary	Infection	Transmission	from	person	to	person	requires	direct	mucosal/dermal	contact	e.g.	sexual	intercourse.	The	risk	of	contracting	HPV	infection	is	increased	with:	•	 Early-age	onset	of	sexual	activity	•	 Increased	number	of	sexual	partners	•	 Lack	of	use	of	barrier	contraception	•	 Smoking	•	 Immunodeficiency	•	 Young	age	•	 Use	of	oral	contraception	(Braaten	&	Laufer	2008;	Frazer	2009)	Upon	transmission,	HPV	needs	access	to	immature	dividing	basal	cells	in	the	basal	epithelial	layer.	This	access	is	typically	achieved	through	small	deficiencies	in	the	integrity	of	the	superficial	layers	of	the	epithelium	(micro-wounds)	present	as	a	result	of	minor	trauma	through	sexual	intercourse	etc.	It	is	hypothesized	that	the	increased	susceptibility	of	cells	within	the	transformation	zone	to	infection	and	subsequently,	malignant	transformation,	is	linked	to	the	increased	accessibility	and	proliferation	of	the	basal	cell	layers	at	this	metaplastic	epithelial	site	(Doorbar	et	al.	2012).	Interaction	with	heparin	sulphate	proteoglycans	(Johnson	et	al.	2009)	results	in	conformational	changes	in	the	viral	capsid	leading	to	internalization	and	subsequent	transfer	to	the	nucleus	(Doorbar	et	al.	2012).	The	HPV	life	cycle	is	closely	linked	to	cellular	differentiation,	and	is	discussed	below.	
1.2.1.3 HPV	Genome	Maintenance	and	Cell	Proliferation	The	HPV	early	promoter	(P97),	located	at	the	3’	end	of	the	long	control	region	(LCR)	regulates	the	transcription	of	the	early	genes.	Various	cellular	transcription	factors	are	involved	in	its	regulation	as	well	as	the	viral	E2	gene	products	(Thain	et	al.	1996;	Kämmer	&	Warthorst	2000).	In	the	early	stages	of	infection,	P97	is	activated	by	cellular	transcription	factors	that	lead	to	the	expression	of	low	levels	of	E1	and	E2	gene	products	(Kadaja	2009;	Steger	&	Corbach	1997).	The	E1	protein	works	in	conjunction	with	E2	and	binds	to	the	viral	origin	of	replication	where	it	forms	an	active	hexamer	complex	(Sanders	&	Stenlund	1998).	This	complex	exhibits	ATPase	activity	and	helicase	activity	causing	the	unwinding	and	separation	of	the	DNA	double	helix	with	exposure	of	base	sequences	necessary	for	DNA	replication	(Longworth	&	Laimins	2004;	Lin	et	al.	2002;	Conger	et	al.	
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1999).	The	E2	protein	plays	an	important	role	in	establishing	productive	infection	through	the	segregation	of	episomal	genomes	into	daughter	cells	during	mitosis	(You	et	al.	2004;	Van	Tine	et	al.	2004).	The	E2	protein	is	also	involved	in	the	regulation	of	P97;	at	low	levels	E2	positively	regulates	P97	whereas	at	high	levels,	E2	negatively	regulates	P97.	Stable	levels	of	E2	control	P97	activity	such	that	a	stable	environment	of	balanced	E6	and	E7	expression	is	created,	promoting	relatively	stable	genome	replication	in	undifferentiated	cells.	HPV	does	not	encode	its	own	DNA	polymerases	and	therefore	requires	cellular	polymerases,	produced	in	mitotically	active	cells,	for	its	own	replication.	As	keratinocytes	begin	to	differentiate,	the	E6	and	E7	genes	become	expressed	at	low	levels.	E7	binds	the	pRb	(retinoblastoma	protein)	family	of	proteins	targeting	them	for	degradation,	this	disrupts	associations	between	pRb	and	E2F	transcription	factors	which	in	turn,	leads	to	the	transactivation	of	certain	cellular	factors	required	for	viral	DNA	replication	(Dyson	et	
al.	1989).	E6	targets	p53	for	degradation,	which	results	in	the	inhibition	of	apoptosis	what	would	have	resulted	from	E7	mediated	cell	cycle	entry	in	differentiated	epithelial	layers	(Doorbar	2006).	In	summary,	low	levels	of	E6	and	E7	enable	on-going	cell	cycling	in	differentiated	keratinocytes	thereby	maintaining	an	environment	conducive	to	on-going	viral	genome	replication	and	production	of	viral	progeny.	In	these	early	stages	of	the	lifecycle,	viral	copy	number	is	maintained	at	approximately	50	copies	per	cell	(Middleton	
et	al.	2003;	Stanley	et	al.	2007)	
1.2.1.4 Genome	Amplification	The	basal	cells	form	the	reservoir	of	infection,	and	in	these	cells,	the	viral	genome	is	maintained	in	episomal	form	at	a	low	copy	number	expressing	the	early	genes	at	low	levels	(Stoler	&	Broker	1986;	Frattini	et	al.	1996).	As	the	basal	cells	divide	and	differentiate,	they	produce	daughter	cells	that	are	detached	from	the	basement	membrane	and	pushed	outwards	towards	the	epithelial	surface	(Stanley	et	al.	2007).	Upon	detachment	differentiation	begins	and	in	more	terminally	differentiated	cells,	activation	of	the	HPV	late	promoter	(E2	independent)	P670	takes	place.	This	results	in	increased	levels	of	the	proteins	involved	in	viral	DNA	replication	(E1,	E2,	E4	and	E5)	increasing	the	rate	of	viral	DNA	replication	resulting	in	increased	viral	copy	number	to	approximately	1000	copies	per	cell	(Flores	&	Lambert	1997).	
1.2.1.5 Viral	Assembly	and	Distribution	The	L1	and	L2	proteins	begin	to	accumulate	following	genome	amplification	and	viral	assembly	is	the	result	of	a	series	of	coordinated	interactions	between	L1,	L2	and	E2	
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proteins	(Doorbar	2006).	HPV	virions	are	then	distributed	and	spread	via	epithelial	desquamation	(Woodman	et	al.	2007).	
1.2.1.6 E4	and	E5	
1.2.1.6.1 E4	This	is	the	most	divergent	protein	in	sequence	and	length	among	the	different	types	of	HPV.	The	exact	functions	of	this	highly	abundant	protein	remain	to	be	elucidated.	Most	research	to	date	indicates	that	it	is	most	active	during	the	vegetative	viral	DNA	replication	phase.	The	functions	appear	to	be	regulated	by	post-transcriptional	modification	–	oligomerisation,	phosphorylation	and	proteolytic	cleavage.	The	majority	of	evidence	indicates	that	E4’s	role	is	primarily	to	facilitate	viral	shedding	(Doorbar	et	al.	1991).	E4	has	been	shown	to	interact	with	and	disrupt	the	keratin	cytoskeleton	as	well	as	the	cornified	cell	envelope	(CCE),	both	of	which	compromise	the	structural	integrity	of	the	cell.	This	reduced	structural	integrity	facilitates	easy	cell	rupture	during	desquamation,	leading	to	effective	viral	shedding	at	the	end	of	cellular	differentiation	(Roberts	et	al.	1994;	Roberts	et	al.	1997;	Brown	&	Bryan	2000;	Doorbar	et	al.	1991).	E4	has	also	been	shown	to	interact	with	cellular	mitochondria	causing	a	reduction	in	their	membrane	potential	that	leads	to	apoptosis	(Raj	et	al.	2004).	This	supports	the	hypotheses	that	E4	facilitates	viral	shedding	not	only	through	disruption	to	cell	structural	integrity	but	also	through	the	induction	of	apoptosis.	Additional	functions	of	E4	include	its	involvement	with	the	dispersal	of	nuclear	domain	(ND)	10s.	Dispersal	of	ND10s	may	be	relevant	to	virion	assembly,	as	they	have	been	shown	to	recruit	the	structural	proteins	L1	and	L2.	Finally,	the	expression	of	E4	has	been	shown	to	induce	G2	cell	cycle	arrest.	This	may	have	the	advantage	of	keeping	the	cell	in	a	metabolically	active	state	without	competing	with	host	DNA	synthesis	and	may	therefore	boost	viral	genome	replication	(Davy	et	al.	2002;	Nakahara	et	al.	2002)	
1.2.1.6.2 E5	The	precise	role	of	E5	in	the	viral	life	cycle	is	poorly	understood.	E5	is	now	considered,	along	with	E6	and	E7,	to	be	a	transforming	protein.	It	is	a	small	multifunctional	membrane	protein,	predominantly	localized	to	the	endoplasmic	reticulum.	It	interacts	with	vacuolar	ATPase	and	prevents	acidification	of	early	endosomes,	thereby	altering	the	trafficking,	turnover,	and	signal	transduction	or	epidermal	growth	factor	receptor	(EGFR)	and	related	receptor	tyrosine	kinases,	hence	modulating	cell	growth.	It	is	therefore	thought	that	E5	may	have	an	important	role	in	establishing	and	expanding	the	infected	basal/parabasal	cell	population	during	the	tissue	repair	phase	after	the	episode	during	which	the	virus	first	
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gained	entry	(Doorbaret	al.2012).	Other	functions	of	E5	indicating	its	role	as	a	transforming	protein	have	been	demonstrated	in	mouse	work	and	include:	
• The	transformation	of	cultured	murine	fibroblasts	and	keratinocytes.	
• The	enhanced	immortalization	potential	of	E6	and	E7	proteins.	
• Stimulated	proliferation	of	mouse	primary	cells	in	conjunction	with	E7.	
• Enhanced	activity	of	the	epidermal	growth	factor	receptor	(EGFR)	interfering	with	several	signalling	pathways.	
• Inhibition	of	gap-junction	intercellular	communication	isolating	cells	from	homeostatic	control	of	neighbouring	cells.	
• Inhibition	of	apoptosis	(World	Health	Organisation	International	Agency	for	Research	on	Cancer	2005). The	HPV	genome	is	illustrated	in	Figure	1.5	along	with	a	summary	of	gene	functions.
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Figure	1.5	The	HPV	16	genome.	HPV	16	is	broadly	representative	of	all	HPV	genomes	and	is	composed	of	circular,	double-stranded	DNA	with	six	early	genes	(E1,	E2,	E4,	E5,	E6	and	E7)	and	two	late	genes	(L1	and	L2).	The	grey	box	represents	the	long	control	region.	Green	lines	represent	polyadenylation	sites.	The	main,	known	functions	of	each	protein	are	described	in	the	boxes.	Central	image	of	genome	from	Dr	Ned	Powell		
1.2.2 Transforming	HPV	Infection	The	malignant	transformation	of	a	host	cell	by	a	persistent	HPV	infection	is	an	accidental	event	(Ho	et	al.	1995).	No	evolutionary	benefit	is	gained	by	HPV	as	a	result	of	malignant	transformation,	as	the	cell	is	rendered	incapable	of	viral	amplification	and	the	late	gene	expression	required	for	the	production	of	virions	(Münger	&	Howley	2002).	Deregulated	expression	of	the	viral	oncogenes,	E6	and	E7	plays	a	central	role	in	HPV	carcinogenesis	(Stanley	2002;	Kessis	et	al.	1993;	Duensing	&	Münger	2004;	Pierry	et	al.	2012;	Doorbar	2006;	Tsimplaki	et	al.	2012).	Deregulated	expression	of	these	viral	oncogenes	alters	the	typical	cell	biology	in	several	ways	leading	to	neoplastic	transformation.	
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1.2.2.1 Induction	of	Proliferation	The	E6	and	E7	oncoproteins	induce	inappropriate	cellular	proliferation	in	four	main	ways.	These	are	described	below	and	summarised	in	Figure	1.6.	
1.2.2.1.1 Activation	of	E2F	The	E2F	family	of	transcription	factors	regulates	the	expression	of	genes	involved	in	G1/S	phase	cell	cycle	progression.	Additional	roles	include	regulation	of	cellular	differentiation	and	regulation	of	apoptosis	(Johnson	&	DeGregori	2006).	In	a	normal	cell,	the	retinoblastoma	protein	(pRb)	binds	to	E2F	preventing	it	from	binding	to	the	E2F	dependent	promoters	of	many	genes	involved	in	cell	cycle	progression.	Specifically,	for	normal	cell	cycle	progression,	at	the	end	of	G1,	pRb	becomes	phosphorylated	by	cyclin-dependent	kinases,	freeing	the	E2F,	enabling	binding	to	E2F	dependent	promoters	(Classon	&	Harlow	2002).	In	transforming	HPV	infections,	the	E7	protein	binds	to	and	disrupts	the	pRb-E2F	complex	prematurely,	causing	release	of	E2F,	constitutive	expression	of	E2F	dependent	genes,	and	inappropriate	cell	cycle	progression.	
1.2.2.1.2 Increased	Cyclin-Dependent	Kinase	Activity	Appropriate	cell	cycle	progression	is	also	reliant	on	the	interaction	between	cyclin-dependent	kinases	(CDK)	and	their	inhibitors,	particularly	p21	and	p27.	In	the	presence	of	p21	and	p27	(triggered	by	noxious	stimuli),	G1/S	cell	cycle	progression	is	prevented	through	inhibition	of	CDK.	In	HPV	infection	the	E7	protein	is	able	to	bind	p21	and	p27,	neutralising	their	inhibitory	effect	leading	to	persistently	high	CDK	activity	and	inappropriate	cellular	proliferation	(Jones,	Alani	et	al.	1997;	Jones,	Thompson	et	al.	1997;	Funk	et	al.	1997).	
1.2.2.1.3 Ubiquitination	of	p53	Ubiquitination	of	the	tumour	suppressor	protein,	p53,	by	the	E6	oncoprotein	represents	the	third	mechanism	by	which	HPV	infection	leads	to	inappropriate	cellular	proliferation.	In	the	absence	of	E6,	the	cellular	effects	of	E7	would	lead	to	increased	levels	of	p53	leading	to	growth	inhibition	and	apoptosis	(Demers	et	al.	1994).	However,	E6	is	able	to	recruit	cellular	E3	ubiquitin	ligase	E6-associated	protein	(E6AP)	and	cause	ubiquitylation	and	degradation	of	p53	excluding	it	from	the	cells	normal	surveillance	machinery	(Scheffner	et	
al.	1990;	Scheffner	et	al.	1993).	
1.2.2.1.4 Increased	Telomerase/TERT	Activity	The	E6	protein	has	been	shown	to	activate	telomerase	and	telomerase	reverse	transcriptase	(TERT)	through	its	interaction	with	E6AP	enabling	the	replication	of	telomeres;	another	key	step	in	immortalization	(Howie	et	al.	2009;	Wise-Draper	&	Wells	2008).	
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Figure	1.6	HPV	induced	cellular	proliferation	during	transforming	infection.	The	tumour	suppressor	protein	p53	plays	a	critical	role	at	the	G1/S	checkpoint,	at	which	time	it	is	activated	following	stress	exposures,	such	as	DNA	damage,	in	the	normal	cell.	P53	determines	whether	a	cell	is	fit	for	transition	from	G1	to	S	phase.	The	retinoblastoma	family	of	proteins	(pRb)	are	also	involved	in	G1/S	phase	transition	through	regulation	of	the	E2F	transcription	factors.	Binding	of	E2F	by	Rb	prevents	progression	from	G1	to	S	phase.	In	HPV	infected	cells,	the	E6	oncoprotein	causes	the	ubiquitination	of	p53	rendering	it	inactive	and	unable	to	halt	cell	cycle	progression	in	the	event	of	cellular	stress.	E6	also	acts	to	increase	the	expression	of	telomerase	and	telomerase	reverse	transcriptase	(TERT)	to	enable	cellular	proliferation.	The	E7	oncoprotein	binds	to	pRb	and	disrupts	the	Rb/E2F	complex	resulting	in	constitutive	expression	of	E2F	responsive	genes	also	leading	to	on-going	cell	cycle	progression	despite	cellular	stress.	It	also	binds	the	CDK	inhibitors	p21	and	p27	increasing	CDK	activity	thereby	driving	cell	cycle	progression.		
1.2.2.2 Genomic	Instability	Although	E6	and	E7	proteins	are	necessary	for	the	development	of	a	transforming	infection,	they	are	not	sufficient	alone.	The	E6	and	E7	proteins	contribute	to	the	development	of	genomic	instability	(discussed	below)	however,	genomic	instability	is	also	detected	in	HPV	associated	lesions	prior	to	HPV	integration,	indicating	that	alternative	causes	of	genomic	instability	also	play	a	role	(White	et	al.	1994).	The	concept	of	the	presence	of	alternative	causes	of	genomic	instability	is	supported	firstly	by	the	fact	that	significant	clinical	disease	(pre-cancer	and	cancer)	only	develops	in	approximately	10%	of	
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newly	acquired	HPV	infection	(Schiffman	et	al.	2007).	Secondly,	it	is	supported	by	the	>5	year	lag	time	between	initial	HPV	infection	and	appearance	of	first	precancerous	lesions	(Woodman	et	al.	2001)	and	crude	estimates	from	large	studies	of	pre-cancers	indicating	a	20-30%	risk	of	invasion	over	a	5-10	year	period	(Schiffman	et	al.	2007;	Chang	et	al.	1990).	Additional	causes	of	genomic	instability	include	exposure	to	exogenous	genotoxic	agents	such	as	tobacco	smoke;	smoking	is	a	well-established	risk	factor	for	the	development	of	persistent	HPV	infection	and	cervical	cancer	(Collins	et	al.	2010).	HPV	infection	contributes	to	genomic	instability	through	the	effects	of	the	E6	and	E7	proteins,	which	work	together	to	induce	centrosome	abnormalities	that	have	the	potential	to	lead	to	chromosomal	missagregation	and	aneuploidy.	The	E6	and	E7	proteins	have	been	shown	to	cause	bypass	of	mitotic	checkpoints;	this	is	likely	to	be	important	in	viral	replication	but	could	also	lead	to	genomic	instability	in	infected	cells.	Accumulation	of	genomic	alterations	over	years	of	infection	may	eventually	lead	to	a	growth	advantage	and	ultimately	malignant	progression	(Duensing	&	Münger	2002a;	Duensing	&	Münger	2002b;	Moody	&	Laimins	2010).		Activation	of	certain	DNA	damage	repair	pathways	such	as	the	ATM-ATR	pathways	(ataxia	telangiectasia-mutated-ATM	and	RAD3-related	DNA	damage	repair	pathway)	have	also	been	implicated	in	HPV	transformation	promoting	differentiation-dependent	genome	amplification.	Degradation	of	claspin,	a	key	regulator	of	the	ATM-CHK1	DNA	damage	pathway	by	the	E7	protein,	alters	G2/M	checkpoint	recovery	(Spardy	et	al.	2009)	permitting	cell	cycle	progression	in	the	presence	of	damaged	DNA	(Moody	&	Laimins	2010).	
1.2.2.3 Apoptosis	HPV	has	been	shown	(as	detailed	above)	to	block	apoptosis	through	the	E6	mediated	degradation	of	p53.	Other	mechanisms	by	which	E6	and	E7	proteins	lead	to	the	avoidance	of	apoptosis	have	also	been	reported.	One	such	mechanism	is	the	inhibition	of	anoikis	(Chiarugi	&	Giannoni	2008).	Anoikis	is	an	apoptotic	pathway	induced	by	the	detachment	of	anchorage-dependent	cells	from	the	surrounding	extracellular	matrix	(ECM)	leading	to	loss	of	essential	growth	signal	stimulation	required	for	cell	survival.	In	normal	cells	integrins	on	the	cell	membrane	interact	with	the	ECM	and	regulate	growth	signal	transduction	through	focal	adhesion	kinase	(FAK).	Anoikis	occurs	when	this	communication	is	lost.	HPV	positive	cells	express	high	levels	of	FAK,	which	enable	cell	proliferation	despite	the	loss	of	adherence	to	the	ECM	(McCormack	et	al.	1997).	Another	action	of	the	E6	protein	is	its	ability	to	bind	tumour	necrosis	factor	receptor-1	(TNFR1).	TNFR1	is	a	cell	membrane	‘death’	receptor	capable	of	activating	extrinsic	apoptotic	pathways	when	stimulated	by	the	inflammatory	cytokines	tumour	necrosis	factor	(TNFα).	Upon	binding,	E6	blocks	the	transduction	of	apoptotic	signals	promoting	cell	survival.	
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Finally,	the	E6	and	E7	interact	with	the	normal	cellular	response	to	interferon	(IFN).	Interferon	is	expressed	as	part	of	the	innate	immune	response	to	viral	infection.	The	E6	and	E7	proteins	are	able	to	repress	the	transcription	of	signal	transducer	and	activator	of	transcription	1	(STAT1),	which	is	a	key	transcription	factor	regulating	cellular	response	to	interferon	(Beglin	et	al.	2009).	A	summary	of	mechanisms	of	HPV	induced	cellular	transformation	is	show	in	Figure	1.7.		
	
Figure	1.7	Summary	of	mechanisms	of	HPV	induced	cellular	transformation.		
1.2.2.4 Mechanisms	of	Deregulated	E6	and	E7	Expression	Integration	of	HPV	DNA	into	the	host	genome	leading	to	disruption	of	the	E2	ORF	is	broadly	acknowledged	to	lead	to	deregulated	expression	of	the	E6	and	E7	ORF’s	(Stanley	2002;	Doorbar	2006;	Pett	&	Coleman	2007;).	However,	there	are	a	proportion	of	cases	of	advanced	CIN	(CIN	II/III)	and	cervical	carcinoma	in	which	HPV	does	not	exist	in	an	integrated	form,	suggesting	that	other	factors	controlling	E6/E7	expression	must	exist	(Doorbar	2006;	Deng	et	al.	2012;	Häfner	et	al.	2008;	Gray	et	al.	2010).	HPV	DNA	methylation	is	one	such	epigenetic	mechanism	that	has	been	shown	to	correlate	with	a	high	risk	of	cervical	cancer	development	(Mirabello,	Sunet	al.	2012;	Ding	et	al.	2009;	Badal	
et	al.	2003;	Ghosh	et	al.	2012).	The	biology	of	HPV	integration	and	methylation	specifically	in	VIN	is	discussed	in	more	detail	below.	
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1.2.2.4.1 HPV	Integration	Following	infection,	HPV	viral	genomes	are	typically	maintained	as	intact	episomes	independent	of	the	human	genome.	In	a	small	proportion	of	cases,	the	HPV	genome	integrates	into	the	host	cell	genome	and	this	is	thought	to	represent	a	key	event	in	HPV	associated	carcinogenesis	(Pett	&	Coleman	2007;	Hillemanns	&	X.	Wang	2006;	Ho	et	al.	2011).	Cells	containing	integrated	HPV	have	a	selective	growth	advantage	over	cells	containing	episomal	HPV	in	vivo	(Jeon	&	Lambert	1995).	Integration	of	HPV	has	been	found	to	frequently	disrupt	the	E1/E2	region	of	the	virus,	altering	expression	of	these	genes,	leading	to	deregulated	expression	of	the	E6	and	E7	oncogenes	(Romanczuk	&	Howley	1992).	No	specific	‘hot-spots’	for	HPV	integration	have	been	identified	in	human	DNA	however;	regions	of	known	host	genomic	instability	known	as	common	fragile	site	(CFS)	have	been	shown	to	be	commonly	involved	(Ziegert	et	al.	2003;	Smith	et	al.	1992).	HPV	16	integration	has	been	found	to	be	present	in	>50%	of	cervical	cancer	cases	and	in	nearly	all	HPV	18	associated	cases	(Choo	et	al.	1987).	The	presence	of	HPV	integration	has	also	been	correlated	with	the	risk	of	CIN	progression	(Arias-Pulido	et	al.	2006).	Incidence	of	HPV	integration	in	vulval	intraepithelial	neoplasia	and	vulval	cancer	is	less	well	characterized.	
1.2.2.4.2 HPV	Integration	in	VIN	HPV	integration	was	studied	in	30	cases	of	VIN	using	a	PCR	based	protocol	for	the	amplification	of	papillomavirus	oncogene	transcripts	(APOT).	Viral	integration	was	detected	in	8/21	(38.1%)	ofHPV	16/18	positive	cases	(Hillemanns	&	Wang	2006).	Van	de	Nieuwenhof	et	al.	investigated	the	aetiological	role	of	HPV	in	130	cases	of	vulval	cancer.	Having	defined	cases	histologically	as	uVIN	ordVIN	in	advance,	in	situ	hybridization	was	carried	out	to	determine	the	physical	state	of	any	HPV	infection	present.	25/130	(19.2%)	cases	were	found	to	be	associated	with	uVIN,	of	which	all	were	high-risk	HPV	positive	and	24/25	(96%)	contained	HPV	in	an	integrated	from.	105/130	(80.8%)	were	found	to	be	dVIN	associated,	of	which	11	(10.5%)	were	found	to	be	high-risk	HPV	positive,	none	of	which	were	found	to	contain	HPV	in	an	integrated	form.	They	concluded	that	these	findings	indicated	that	although	high-risk	HPV	may	be	present	in	cases	of	squamous	cell	vulval	cancer,	its	role	is	unlikely	to	be	aetiological	(van	de	Nieuwenhof,	van	Kempenet	al.	2009).	Another	study	conducted	by	Bryant	et	al.	found	HPV	integration	events	present	in	8/25	cases	of	HPV	16	positive	intraepithelial	neoplasia	(22	cases	of	VIN	3,	one	case	of	VaIN	3,	one	case	of	AIN	2	and	one	normal	vulval	biopsy).	The	E1	ORF	was	most	frequently	disrupted	(3/8	(37.5%)	cases)	followed	by	the	E2	and	L2	ORF’s	(each	in	2/8	(25.0%	cases)	and	E4	involvement	in	1/8	(12.5%)	cases	(Bryant,	Onions,	et	al.	2014).	
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1.2.2.4.3 HPV	DNA	Methylation	DNA	methylation	is	a	common	form	of	epigenetic	modification	(Feinberg	2007;	Yamada	&	Watanabe	2010;	Gonzalo	et	al.	2010;	Ikegami	et	al.	2009).	DNA	methylation	frequently	occurs	at	CpG	dinucleotides	where	a	methyl	group	is	covalently	bound	to	the	C-5	position	of	cytosine	(Figure	1.8).	Methylation	represents	an	important	mechanism	regulating	gene	expression.	Methylation	regulates	gene	expression	by	preventing	transcription	factors	from	recognising	their	binding	sites	or	by	attracting	proteins	that	bind	methylated	DNA	and	recruit	chromatin	modifying	enzymes	to	condense	adjacent	chromatin	(Bird	&	Wolffe	1999;	Thain	et	al.	1996;	Jones	&	Takai	2001;	Kuroda	et	al.	2009).							
		Both	viral	and	host	genes	can	be	targeted	by	the	cellular	methylation	machinery.	In	vitro	studies	have	shown	that	methylation	of	HPV	genomes	leads	to	silencing	of	transcription.	This	de	novo	methylation	of	HPV	DNA	could	be	a	host	defence	mechanism	to	suppress	transcription	of	foreign	DNA,	or	a	viral	strategy	to	maintain	a	long-term	infection	(Doorbaret	al.	2012;	Badal	et	al.	2003).	Evidence	supporting	the	latter	comes	from	the	ability	of	the	HPV	E7	protein	to	directly	activate	DNA	methyltransferase	(DNMT)	a	crucial	enzyme	involved	in	methylation	(Doorbaret	al.2012;	Burgers	et	al.	2007).	A	series	of	publications	investigating	the	role	of	HPV	DNA	methylation	in	HPV	associated	disease	have	discovered	that	methylation	of	HPV	genomes	is	consistently	higher	in	carcinomas	compared	to	pre-cancerous	lesions	(Badal	et	al.	2003;	Ding	et	al.	2009;	Kalantari	et	al.	2004).	There	is	also	a	growing	body	of	evidence	showing	that	increased	HPV	genome	methylation	is	found	in	association	with	viral	integration	(Fernandez	et	al.	2008;	Kalantari	et	al.	2008;	Kalantari	et	al.	2010;	Bryant,	Onions,	et	al.	2014).	This	could	
Figure	1-8	Schematic	drawing	of	cytosine	methylation.	Figure	courtesy	of	Dr	Dean	Bryant.	
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indicate	the	susceptibility	of	HPV	integrants	to	methylation	induced	silencing	upon	recognition	by	the	host.	A	small	number	of	studies	have	specifically	investigated	methylation	of	the	E2	binding	site	(E2BS),	located	within	the	HPV	upstream	regulatory	region.	Methylation	of	the	E2BS	has	been	shown	to	inhibit	E2	protein	binding	(Thain	et	al.	1996).	This	could	inhibit	the	transcriptional	control	E2	has	on	E6	and	E7	gene	expression	(Kim	et	al.	2003)	however,	no	studies	have	yet	demonstrated	a	direct	correlation	between	methylation	state	and	E6/7	transcription.	A	study	conducted	by	Bryant	et	al.	aimed	to	determine	if	E2BS	HPV	DNA	methylation	could	act	as	an	alternative	transforming	event	in	the	absence	of	HPV	integration	(Bryant,	Onions	et	al.	2014).	Methylation	levels	of	the	E2BS	were	compared	between	integrated	infections	and	episomal	infection	in	same	disease	grade;	no	difference	was	found.	In	summary	HPV	DNA	methylation	is	correlated	with	viral	integration	and	increasing	disease	grade	but	has	not	yet	been	shown	to	correlate	with	increased	expression	of	E6	or	
E7	genes.	This	thesis	describes	investigation	of	methylation	levels	of	the	E2BS,	the	E2	ORF	and	the	L1	and	L2	ORF	in	the	largest	studied	cohort	of	VIN	3	to	date.	Relationships	with	viral	integration	and	viral	gene	expression	were	explored	to	investigate	the	hypothesis	that	methylation	provides	an	alternate	means	of	deregulating	E6/E7	expression	in	the	absence	of	HPV	integration.	Finally,	the	suitability	of	HPV	DNA	methylation	as	a	potential	biomarker	predictive	of	response	to	treatment	of	VIN	3	with	cidofovir	and	imiquimod	therapy	was	assessed.	In	this	thesis,	the	term	‘transforming	HPV	infection’	is	used	to	denote	an	infection	where	the	HPV	infection	displays	one	of	the	characteristics	described	above	(integrated	DNA,	highly	methylated	DNA	or	deregulated	oncogene	expression).	
1.2.3 HPV	and	Disease	Burden	HPV	is	the	most	common	sexually	transmitted	infection	worldwide	(Centers	for	Disease	Control	2013).	The	majority	of	sexually	active	individuals	will	acquire	an	HPV	infection	at	some	point;	however,	only	in	the	minority	of	individuals	will	significant	disease	ensue	(Forman	et	al.	2012).	Benign	diseases	resulting	from	HPV	infection	are	genital	warts	(the	commonest	sexually	transmitted	disease	in	the	UK),	verrucae	and	a	rare	condition	known	as	recurrent	respiratory	papillomatosis	(RRP)	where	benign	growths	develop	in	the	respiratory	tract	often	requiring	repeated	surgery.	Genital	warts	(predominantly	caused	by	HPV	types	6	and	11)	pose	a	significant	disease	burden	worldwide.	In	the	UK	in	2012	there	were	220,	875	cases	of	genital	warts,	which	cost	£58.4	million	to	treat	(Coles	et	al.	
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2015).	HPV	also	causes	pre-malignant	change	of	the	cervix,	vulva,	vagina	and	penis	known	as	intraepithelial	neoplasia,	as	well	as	malignancies	of	the	cervix,	vulva,	vagina,	anus,	penis	and	oropharynx.	HPV	infection	accounts	for	approximately	2%	of	the	cancer	burden	in	developed	countries	and	for	approximately	7%	in	less	developed	countries.	In	Europe	in	2008,	there	were	estimated	3.2million	new	cases	of	cancer	in	total,	of	which,	110,000	cases	occurred	in	HPV	affected	sites,	of	which,	80,000	were	estimated	to	be	directly	attributable	to	HPV	infection.	This	equates	to	a	2.5%	contribution	by	HPV	to	the	total	cancer	burden	in	Europe.		Breakdown	per	affected	site	is	illustrated	in	Figure	1.9	(Forman	
et	al.	2012).	
	
	
1.2.4 HPV	Prevalence	in	VIN	Establishing	accurate	HPV	prevalence	rates	in	VIN	is	challenging	but	important.	Knowledge	of	HPV	prevalence	in	VIN	contributes	to	vaccination	program	planning	on	a	global	scale,	but	is	likely	to	become	increasingly	important	at	the	level	of	the	individual.	Two	aetiologies	for	VIN	are	now	established,	and	are	defined	as	two	different	histological	subtypes:	uVIN	being	directly	attributed	to	HPV	infection	and	dVIN	being	HPV	independent	(section	1.1).	HPV	prevalence	rates	will	be	directly	related	to	the	nature	of	the	VIN	being	studied.	The	importance	of	defining	study	cohorts	based	on	the	new	
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Figure	1-9	HPV	associate	cancer	burden	Europe	2008.	Of	all	cancer	cases	directly	attributed	to	HPV	infection	in	Europe	in	2008	(80,000),	55.000	cases	were	cervical	cancer,	8,100	were	oropharyngeal	cancer,	7,400	were	vulva/vagina	cancer,	6,800	cases	were	anal	cancer	and	2,400	were	penile	cancer	(Foreman	et	al.	2012).	
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histological	classification	is	arguable	and	likely	guided	by	the	nature	of	the	study	and	its	specific	aims.	However,	the	two	disease	aetiologies	follow	different	courses	in	terms	of	malignant	progression,	and	will	be	affected	differently	by	HPV	vaccination.	They	are	also	likely	to	respond	differently	to	therapies.	It	can	be	presumed	therefore	that	in	most	contexts,	knowledge	of	the	histological	subtype	being	studied	will	be	informative.	A	review	of	the	literature	discovered	32	studies	reporting	HPV	prevalence	in	high-grade	VIN	(Table	1.1).	The	mean	HPV	prevalence	across	all	studies	was	85.1%	with	a	range	of	30.8%	-	100%.	A	meta-analysis	conducted	by	De	Vuyst	et	al.	reported	a	similar	overall	HPV	prevalence	of	85.3%	in	1061	cases	of	high-grade	VIN	(De	Vuyst	et	al.	2009).	Although	the	overall	HPV	prevalence	reported	by	studies	is	generally	high,	the	range	is	broad	(30.8%	-	100%).		A	study	conducted	by	Van	Seters	et	al.	reported	a	particularly	low	HPV	prevalence	(30.8%);	however,	this	may	be	explained	by	selection	of	cases	with	diagnoses	of	both	VIN	and	lichen	sclerosus,	which	conferred	a	selection	bias	towards	HPV	negative	cases.	It	is	interesting	that	all	the	VIN	in	the	van	Seters	study	was	found	to	be	undifferentiated	subtype	(n=26).	Lichen	sclerosus	is	traditionally	thought	to	be	associated	with	dVIN	but	van	Seters	et	al.	discovered	that	this	relationship	is	supported,	in	the	majority,	by	research	involving	cases	of	coexistent	vulval	SCC	(van	Seters	et	al.	2007).	Reports	of	lichen	sclerosus	and	dVIN	in	the	absence	of	SCC	at	the	time	of	the	Van	Seters	study	were	limited	to	five	cases.	Van	Seters	et	al.	hypothesised	that	their	study	indicated	the	possibility	of	a	different	aetiology	or	classification	for	VIN	with	perhaps	a	different	prognosis.	This	highlights	the	first	challenge	that	arises	when	establishing	HPV	prevalence	in	VIN,	which	comes	from	the	two	aetiologies.	Very	few	studies	reporting	HPV	prevalence	rates	define	the	VIN	sub-type.	Many	studies	adhere	to	the	traditional	VIN	classification,	reporting	VIN	as	high-grade	or	VIN	2/3,	which	amalgamates	the	uVIN	and	dVIN	subtypes.	HPV	prevalence	rates	reported	by	studies	including	cases	of	VIN	of	the	dVIN	sub-type	will	likely	be	lower	than	studies	reporting	on	uVIN	alone.	It	is	important	to	account	for	this	when	considering	HPV	prevalence	rates	in	VIN.	It	is	of	worthy	note	that	although	it	is	not	thought	that	HPV	directly	contributes	to	dVIN	pathology,	several	studies	do	report	presence	of	HPV	in	dVIN.	For	example,	the	de	Sanjose	study	(de	Sanjosé	et	al.	2013)	reported	HPV	prevalence	rates	of	48.9%	in	48	cases	of	dVIN,	and	reported	HPV	prevalence	rates	of	90.3%	in	uVIN.	It	is	thought	that	in	these	cases,	HPV	is	an	incidental	finding.	This	is	based	on	the	lack	of	the	viral	physical	features	associated	with	disease	e.g.	viral	integration,	methylation	and	altered	gene	expression	profiles.	More	research	investigating	the	exact	role	of	HPV	in	dVIN	would	be	worthwhile.	
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Samples	used	in	this	study	were	all	classified	as	VIN	3	based	on	the	traditional	histological	classification.	This	decision	was	made	to	ensure	that	all	centres	participating	in	the	study	were	familiar	with	the	classification	system	and	also	to	reduce	the	effect	of	inter-observer	variability	(Preti	et	al.	2000).
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Table	1-1	HPV	prevalence	in	VIN	
Ref	 Year	 n=	 Assay	 uVIN	or	dVIN	 HPV	Prev.	
(%)	
HPV	
16	
prev.	
(%)**	Hording	et	
al.	1991	 1991	 19	 HPV	16	type-specific	PCR	 N/S	 78.9	 78.9	Nuovo	et	al.	1991	 1991	 22	 MY09/11	 N/S	 59.1	 40.9	Park	et	al.	1991	 1991	 30	MY09/11	and	type-specific	HPV	6/11/16/18	 N/S	 53.3	 53.3	Torre	et	al.	1992	 1992	 7	 HPV	16	type-specific	PCR	 N/S	 100	 100	Pilotti	et	al.	1995	 1995	 5	 HPV	16	type-specific	PCR	 N/S	 100	 100	Junge	et	al.	1995	 1995	 58	 HPV	6/11/16/18/31/33	type-specific	PCR				
N/S	 88	 77.6	
Van	Beurden	et	
al.	1995	 1995	 46	 CpI/IIG	 N/S	 95.7	 89.1	Trimble	et	
al.	1996	 1996	 54	 Digene	 N/S	 89	 N/S	Nagano	et	
al.	1996	 1996	 6	 L1	PCR	 N/S	 100	 66.7	Madeleine	
et	al.	1997	 1997	 253	 MY09/11	and	TS	HPV	6/11/16/18/45/31	 N/S	 71.5	 61.7	Pinto	et	al.	1999	 1999	 16	 PCR	L1	Consensus	primers	 uVIN	 67	 N/S	Carter	et	al.	2001	 2001	 18	 PGMY9/11	 N/S	 91	 74.6	Abdel-Hady	
et	al.	2001	 2001	 19	 GP5+/6+	and	TS	HPV	6/11/16/18/31/33	 N/S	 73.7	 64.3	Logani	et	al.	2003	 2003	 6	 SPF10	 uVIN	 100	 66.6	Riethdorf	et	
al.	2004	 2004	 39	 GP5+/6+	and	HPV	16	E6/E7	ISH	 N/S	 100	 100	Bryndorf	et	
al.	2004	 2004	 11	 SPF10	 N/S	 81.8	 63.6	Todd	et	al.	2004	 2004	 10	 GP5+/6+	 N/S	 90.0	 50.0	Bonvicini	et	
al.	2005	 2005	 25	 MY09/11	 uVIN	(n=18)dVIN	(n=7)	 61.1	0	 50	0	Rufforny	et	
al.	2005	 2005	 21	 HPV	16	type-specific	 N/S	 100	 100	Van	der	Avoort	et	al.	2006	 2006	 37	 SPF10	 uVIN	 66	 65	
Chapter	1	 	 Background		
	HPV	Biology	in	VIN:	Viral	Biomarkers	to	Predict	Response	to	Treatment			 29	
	
	
	
	
	
	
	
	
	
	
	
	
		
	
*Van	Seters	et	al	2007	only	studied	cases	of	VIN	associated	with	lichen	sclerosus.	**HPV	16	prevalence	is	reported	as	percentage	prevalence	of	all	cases,	not	just	HPV	positive.	N/S	=	Not	specified.It	is	somewhat	surprising	that	even	in	studies	that	do	define	the	cohort	based	on	the	new	histological	subtype,	HPV	prevalence	in	uVIN	is	not	always	100%.		Studies	reporting	HPV	prevalence	in	uVIN	specifically,	quote	rates	varying	from	67%	-	100%.	This	may	reflect	the	difficulties	of	histological	diagnosis	of	VIN.	Distinguishing	VIN	from	atypical	inflammatory	changes	in	normal	skin	can	lead	to	over-diagnosis	and	the	diagnosis	of	dVIN	can	be	easily	missed	because	of	its	highly	differentiated	features	and	absence	of	widespread	architectural	disarray	(Reyes	&	Cooper	2014).	These	challenges	inevitably	play	some	role	in	the	lower	than	expected	HPV	prevalence	figures.	However,	limitations	of	the	biological	methods	used	to	detect	HPV	are	likely	to	be	more	important,	and	are	discussed	in	the	following	section.			
Srodon	et	al.	2006	 2006	 34	 PGMY09/11	and	SPF10	 N/S	 100	 91	Hample	et	
al.	2007	 2007	 49	 GP5+/6+	and	MY09/11	 N/S	 91.8	 67.3	Skapa	et	al.	2007	 2007	 33	 GP5+/6+	 uVIN	 100	 76.1	Van	Seters	
et	al.	2007	 2007	 26	 GP5+/6+	 uVIN	 30.8	 26.9	(van	Seters,	Beckmanet	
al.	2008)	 2008	 52	 GP5+/6+	 N/S	 96.2	 78.8	Van	de	Nieuwenhof,	van	Kempen	
et	al.	2009	 2009	 13	 PCR	L1	 uVIN	 100	 44	Garland	et	
al.	2009	 2009	 62	 PCR	 uVIN	 84	 42	Smith	et	al.	2009	 2009	 65	 PGMY9/11	 N/S	 98	 50	Gargano	et	
al.	2012	 2011	 66	 PGMY9/11	 N/S	 94	 48	Tachezy	et	
al.	2011	 2011	 46	 GP5+/6+	 uVIN	 100	 71.7	Tsimplaki	et	
al.	2012	 2012	 28	 PapilloCheck	 uVIN	 71	 65	De	Sanjose	
et	al.	2013	 2013	 583	 SPF10	 uVIN	n=535dVIN	n=48	 90.3	48.9	 Overall	77.3	Bryant,	Onions	et	al.	2014	 2014	 10	 GP5+/6+	 N/S	 80.0	 N/S	
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1.2.4.1 HPV	Detection	Methods	Because	of	the	link	between	the	viral	lifecycle	and	epithelial	differentiation,	HPV	is	very	difficult	to	propagate	in	culture	so	traditional	microbiological	techniques	are	of	limited	use	(Doorbar	2006).	Current	methods	of	HPV	detection	predominantly	use	molecular	biology	techniques	that	rely	upon	the	detection	of	nucleic	acids	through	nucleic	acid	hybridization	followed	by	signal	amplification,	or	nucleic	acid	amplification	(Abreu	et	al.	2012).	The	majority	of	assays	target	the	well-conserved	L1	ORF	of	the	virus,	some	target	the	E1	and	others	target	E6/E7	mRNA	(Table	1.2).	Nucleic	acids	are	prone	to	degradation	due	to	exposure	to	DNases/RNAses	in	the	environment	and	freeze	thawing.	The	quality	of	material	being	investigated	in	terms	of	DNA/RNA	integrity,	concentration	and	purity	will	vary	from	study	to	study	and	inevitably	affects	the	ability	of	any	molecular	biology	technique	to	detect	the	presence/absence	of	HPV	accurately.	It	is	rarely	possible	to	obtain	optimum	fresh	tissue	samples	from	the	clinical	setting	for	laboratory	analysis	but	efforts	should	be	made	to	ensure	that	the	best	quality	DNA/RNA	is	obtained	from	what	is	available.	When	assessing	reports	of	HPV	prevalence	rates	from	the	literature,	consideration	should	be	given	to	the	quality	of	tissue/sample.		An	additional	challenge	posed	by	detecting	HPV	nucleic	acids	is	the	reliance	on	the	targeted	DNA	or	RNA	not	being	subject	to	recombination.	Integration	of	HPV	DNA	into	the	host	genome	is	a	significant	step	in	HPV	pathogenesis.	Studies	have	demonstrated	the	incidence	of	HPV	integration	is	11%	-	60%	in	cases	of	VIN/CIN	(van	de	Nieuwenhof,	van	Kempen	et	al.	2009,	Hillemanns,	Wang	2006;	Häfner	et	al.	2008;	Bryant,	Onions	et	al.	2014).	Although	these	integration	events	can	involve	any	part	of	the	HPV	DNA,	the	E1,	E2,	L1	and	L2	ORF’s	are	most	frequently	involved	(Hillemanns,	Wang	2006;	Häfner	et	al.	2008;	Choo	et	al.	1987;	Wang	et	al.	2013;	Corden	et	al.	1999).	The	L1	ORF	is	the	most	frequently	used	target	region	(Table	1.3),	probably	because	sequence	variation	in	this	region	is	used	to	define	HPV	genotypes.	Further	to	this,	HPV	integration	is	more	common	in	higher-grade	disease	(e.g.	CIN	3	and	VIN	3)	making	disruption	to	the	DNA	more	likely	in	more	advanced	disease.	One	of	the	hypotheses	investigated	in	this	thesis	is	that	HPV	assays	may	falsely	identify	a	sample	as	HPV	negative	if	integration	has	disrupted	the	targeted	viral	region,	and	that	this	is	more	likely	to	happen	in	cases	of	more	advanced	disease.	
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Table	1-2	HPV	detection	methods.	
	N/A	=	not	applicable,	N/S	=	not	specified.	Target	size	describes	the	length	of	region	of	DNA	or	RNA	targeted	by	the	primers	in	the	assay.				
Assay	 Manufacturer	 HPV	target	
region	
Target	size	 Target	type	
(DNA/RNA)	GP5+	GP6+	PCR	EIA	 N/A	 L1	 150	bp	 DNA	MY09/11	and	PGMYop/11	 N/A	 L1	 450	bp	 DNA	PapilloCheck®	 Greiner	Bio	One	 E1	 350	bp	 DNA	ProDect®	HPV	Chip	 Bcs	Biotech	 L1	and	E6/E7	 N/S	 DNA	CLART®	HPV	2	 Genomica	 L1	 450	bp	 DNA	Cobas®	4800	system	 Roche	 L1	 200	bp	 DNA	Digene	HPV	genotyping	PS	test	 Qiagen	 L1	(GP5+	GP6+	above)	 150	bp	 DNA	Cobas®	Amplicor	 Roche	 L1	 165	bp	 DNA	Aptima®	 Gen-Probe	 E6/E7	 N/S	 mRNA	AID	HPV	Screening	kit	 GenID	GMBH	 E1	 N/S	 DNA	Pretect	HPV-Proofer	 Norchip	 E6/E7	 N/S	 mRNA	NucliSENS	EasyQ®	HPV	 BioMerieux	 E6/E7	 N/S	 mRNA	HPV	OncoTect™	 IncellDx	 E6/E7	 	 mRNA	INNO	Lipa	 Innogenetics	 L1	 65	bp	 DNA	SPF10-LiPA25	 Labo	Biomedical	Products	 L1	 65	bp	 DNA	HPV	DNA	Chip	 BioMedLab	 L1	(GP5+	GP6+	above)	 150bp	 DNA	Linear	Array®	HPV	genotyping	kit	 Roche	 L1	 450	bp	 DNA	Full	Spectrum	HPV	Assay	 GenoID	 L1	 N/S	 DNA	Digene	HC2	HPV	DNA	test	 Qiagen	 N/S	 N/S	 DNA	RealTime	High	Risk	HPV	 Abbott	Molecular	 L1	 N/S	 DNA	f-HPV	typing™	 GENOMED	 E6/E7	 N?S	 mRNA	Cervista®	HPV	 Hologic	 N/S	 N/S	 DNA	
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1.3 Cidofovir:	
	(S)-1-[3-hydroxy-2-(phosphonomethoxy)-propyl]cytosine	dihydrate,	HPMPC	or	cidofovir	(CDV)	(Figure	1.10)	is	a	cytosine	analogue	that	inhibits	viral	replication	in	a	broad	spectrum	of	DNA	viruses	including	herpesviruses,	poxviruses	and	papillomaviruses	(Tempesta	et	al.	2008;	Andrei,	Snoeck	2010;	Snoeck	et	al.	2001;	Tristram,	Fiander	2005).	Its	only	licensed	use	however,	is	for	treating	cytomegalovirus	(CMV)	retinitis	in	human	immunodeficiency	virus	(HIV)	positive	patients	(Plosker,	Noble	1999).	At	the	time	of	writing,	cidofovir	was	no	longer	available	in	the	UK,	having	been	withdrawn	from	the	UK	in	October	2014	due	to	poor	cost	efficacy.	It	was	however,	previously	supplied	by	Gilead	Sciences	Ltd,	Cambridge	at	a	price	of	£653.22	for	a	vial	of	75mg/ml.								
		
1.3.1 Metabolism	and	Mechanism	of	Action	Cidofovir	enters	cells	through	fluid-phase	endocytosis.	Once	inside	the	cell,	cidofovir	undergoes	two	phosphorylation	steps,	mediated	by	host	enzymes,	to	reach	its	active	diphosphate	derivative,	CDVpp.	Firstly,	cidofovir	is	phosphorylated	to	CDVp	by	nucleoside	monophosphate	kinase	(NMK).	A	second	phosphorylation	then	occurs,	primarily	by	pyruvate	kinase	(PK)	and	to	a	lesser	degree,	nucleoside	diphosphate	kinase	(NDK)	(Johnson	&	Gangemi	1999)	resulting	in	CDVpp.	In	disease	associated	with	viruses	that	encode	their	own	DNA	polymerase,	during	viral	DNA	replication,	CDVpp	acts	as	a	competitive/alternative	substrate	to	the	normal	substrate	(dCTP)	leading	to	its	incorporation	into	the	growing	DNA	strand	and	ultimately	to	chain	termination	(De	Clercq	1996),	(Figure	1.11).	The	selective	antiviral	activity	of	cidofovir	is	thought	to	result	from	its	higher	affinity	for	viral	DNA	polymerase	than	cellular	DNA	polymerase	(De	Clercq	
Figure	1.10	Chemical	structure	of	cidofovir	
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2007).	HPV	does	not	encode	its	own	DNA	polymerase	therefore	the	mechanism	of	action	in	this	context	must	differ;	this	is	discussed	in	the	following	sections.			
	
1.3.2 Cidofovir	and	VIN	
1.3.2.1 Efficacy	There	are	few	clinical	trials	investigating	the	role	of	cidofovir	in	the	treatment	of	VIN.	A	prospective	study	of	12	women	with	histologically	confirmed	VIN	3	conducted	by	Tristram,	Fiander	et	al.	assessed	use	of	cidofovir	1%	topical	treatment,	applied	by	the	patient	on	alternate	days	for	16	weeks.	10	women	completed	follow	up,	of	whom,	four	
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Figure	1-11	Cellular	metabolism	of	cidofovir.	CDV=cidofovir	for	the	purposes	of	this	figure.	Upon	cell	entry,	the	host	enzyme	nucleoside	monophosphate	kinase	phosphorylates	CDV	to	its	monophosphate	derivative	CDVp.	CDVp	is	then	further	phosphorylated	to	its	biologically	active	form	CDVpp	by	pyruvate	kinase	and	to	a	lesser	degree,	nucleoside	diphosphate	kinase.	Choline	phosphate	cytidyltransferase	is	an	enzyme	responsible	for	regulating	phosphatidylcholine	content	in	cell	membranes	but	is	also	responsible	for	the	conversion	of	CDVp	and	CDVpp	to	CDVp-choline,	which	can	act	as	a	reversible	reservoir	of	the	drug	or	be	excreted.	
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(40.0%)	patients	had	complete	resolution	of	all	symptoms	and	of	visible	lesion(s),	confirmed	by	histological	examination	and	viral	clearance.	Three	(30.0%)	women	had	a	partial	response	to	treatment	(reduction	in	lesions	size	by	at	least	50%).	Of	the	three	remaining	women,	one	showed	a	complete	symptomatic	response	but	the	biopsy	of	the	remaining	lesion	demonstrated	invasive	disease;	she	underwent	radical	excision	of	the	remaining	disease.	The	final	two	patients	did	not	respond.	Potential	reasons	for	non-response	were:	involvement	of	hair	follicles,	non-compliance	due	to	pain,	and	previously	undiagnosed	invasive	disease.	Side	effects	of	treatment	were	limited	to	pain,	which	usually	lasted	for	a	few	days	after	application	and	was	occasionally	associated	with	ulceration	of	the	diseased	area	but	not	the	surrounding	tissue	(Tristram,	Fiander	2005).	A	phase	IIa	prospective	study	(Stier	et	al.	2013)	investigated	the	efficacy	of	treatment	of	high-grade	VIN	and	AIN	in	HIV	positive	patients.	Of	the	33	patients	enrolled	in	the	trial,	26	(79%)	completed	the	treatment	protocol.	Of	these,	five	(15.0%)	had	a	complete	response,	12	(36.0%)	had	a	partial	response,	seven	(26%)	had	stable	disease	and	two	patients	(6%)	had	progressive	disease.	It	is	possible	that	the	deficient	host	immunity	caused	by	HIV	in	these	patients,	impacted	on	the	efficacy	of	cidofovir	treatment.	In	a	study	of	15	women	with	CIN	treated	with	3	g	of	1%	cidofovir	gel	(applied	by	a	gynaecologist)	every	other	day	for	six	days,	7/15	(46.7%)	patients	completely	responded	to	treatment	and	a	further	5/15	(33.3%)	patients	had	a	partial	response	to	treatment	(Snoeck	et	al.	2000).	A	randomised,	controlled	study	(Snoeck	et	al.	2001)	evaluated	cidofovir	(1%	gel	applied	5	days	a	week,	every	other	week	for	a	maximum	of	6	cycles)	as	a	topical	treatment	for	genital	warts.	Of	30	patients,	19	received	cidofovir	and	11	received	placebo.	The	most	frequently	reported	adverse	events	included	pain,	pruritus	and	a	rash	at	the	site	of	application.	A	complete	response	was	seen	in	9/19	(47%)	patients	treated	with	cidofovir;	no	patients	had	a	complete	response	in	the	placebo	group.	There	were	7/19	(36.8%)	patients	in	the	cidofovir	group	who	had	a	partial	response	compared	to	2/11	(18%)	of	the	placebo	group.	Of	all	the	patients	who	had	a	complete	response	1/9	(11.1%)	had	a	recurrence	of	disease	during	the	follow	up	period	(168	days).	
1.3.2.2 Treatment	Regime	Cidofovir	is	licensed	for	intravenous	use	in	the	treatment	of	CMV	retinitis	in	HIV	positive	patients.	No	license	exists	for	its	use	in	topical	form.	Due	to	the	limited	research,	the	treatment	regime	is	not	yet	optimized.	Cidofovir	has	been	formulated	in	a	variety	of	ointments	and	gels	and	applied	using	regimes	varying	in	both	frequency	and	duration	
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(Table	1	3).	Should	cidofovir	show	utility	in	the	management	of	VIN,	the	optimum-dosing	regime	will	need	to	be	determined.		
Table	1-3	Summary	of	treatment	regimes	reported	in	studies	using	topical	cidofovir	for	HPV	
related	anogenital	disease.		
	
1.3.2.3 Recurrence	Rates	The	limited	research	available	makes	it	impossible	to	determine	recurrence	rates	of	VIN	following	treatment	with	cidofovir.	
1.3.2.4 Side	Effects	of	Cidofovir	The	European	Medicines	Agency	(EMA)	reports	neutropenia,	headache,	nausea	and	vomiting,	alopecia,	rash,	proteinuria	and	fever	to	be	very	common	(<1:10)	side	effects	and	iritis,	dyspnoea,	diarrhoea	and	renal	failure	to	be	common	(>1:10	but	<1:100)	side	effects	(EMA,	Vistide	2015).	It	is	important	to	remember	that	these	reports	are	based	on	the	intravenous	systemic	administration	of	the	drug,	and	it	is	likely	that	the	side	effect	profile	associated	with	topical,	localized	treatment	will	differ.	Side	effects	commonly	reported	in	the	literature	following	topical	treatment	include	pain,	pruritus,	itching,	irritation	and	ulceration	at	the	site	of	treatment.	
Study	 Formulation	 Strength	 Dosing	Snoeck	et	al.	2001	 Gel	(20%	propylene	glycol,	2%	hydroxyethylcellulose,	0.18%	methylparaben,	0.02%	propylparaben,	0.02%	edetate	disodium	and	1%	cidofovir	
1%	 Daily	for	5	consecutive	days	every	other	week	for	12	weeks.	
Koonsaeng	et	al.	2001	 Beeler	base	 1%	 5	months	of	intermittent	cycles	of	5	days	of	treatment	and	5	days	of	rest	Tristram,	Fiander	2005	 Unguentum	Merck	 1%	 Alternate	days	for	16	weeks	Stier	et	al.	2013	 Cream	base	–	an	emulsion	of	mineral	oil,	deionized	water,	acetyle	alcohol,	ceresin	wax,	beeswax	and	sodium	borate	
1%	 6	cycle	of	5	daily	applications	followed	by	9	rest	days	
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1.3.3 Cidofovir	and	HPV	The	anti-papillomavirus	activity	of	cidofovir	was	first	demonstrated	in	the	cottontail	rabbit	model	and	has	since	been	confirmed	in	patients	with	severe	recurrent	laryngeal	papillomatosis,	anogenital	disease	and	cervical	intraepithelial	neoplasia	(CIN)	(Andrei	et	
al.	1998;	Abdulkarim	et	al.	2002;	Johnson	&	Gangemi	1999;	Snoeck	et	al.	2001;	Grasso	et	
al.	2014;	Stragier	et	al.	2001;	Stier	et	al.	2010).	The	mechanism	of	action	of	cidofovir	in	HPV	associated	disease	is	not	defined.	Cidofovir	has	been	shown	to	have	higher	affinity	for	viral	DNA	polymerase	compared	to	human	DNA	polymerase;	this	results	in	its	preferential	incorporation	into	viral	DNA	in	viruses,	such	as	HSV,	which	encode	their	own	DNA	thereby	explaining	its	mechanism	of	action.		However,	HPV	does	not	encode	its	own	DNA	polymerase	and	therefore,	this	mechanism	of	action	cannot	be	attributed.	A	small	number	of	studies	exist	investigating	the	mechanism	of	action	of	cidofovir	in	HPV	associated	disease	in	vitro.	Analysis	of	these	studies	is	discussed	below	and	has	resulted	in	two	proposed	mechanisms	of	action	being	hypothesised.	
1.3.3.1 Altered	Drug	Metabolism	in	HPV	Infected	Cells	High	concentrations	of	cidofovir	(>1	uM)	inhibit	proliferation	of	normal	human	keratinocytes,	albeit	to	a	lesser	degree	than	in	HPV-transformed	keratinocytes.	However,	below	1	uM,	cidofovir	had	no	effect	on	normal	cells	whilst	inhibition	of	proliferation	still	occurred	in	the	HPV-transformed	cells	(Johnson,	Gangemi	1999).	These	findings	indicate	increased	sensitivity	to	cidofovir	in	HPV	transformed	cells.	The	differential	response	was	not	related	to	increased	uptake	of	the	drug	by	HPV-transformed	cells,	which	was	similar	in	all	cell	types	studied.	Instead,	the	results	indicate	that	HPV	transformed	cells	metabolized	CDV	differently.	There	was	an	increased	accumulation	of	the	biologically	active	metabolite,	HPMPCpp,	in	HPV-transformed	cells.	In	contrast,	in	normal	cells	the	end	product	of	cidofovir	metabolism,	HPMPCp-choline,	was	present	at	higher	levels.	This	suggests	that	the	presence	of	HPV	may	influence	metabolism	of	CDV.	In-vitro,	anti-proliferative	effects	were	seen	in	HPV	transformed	cell	lines	(HeLa,	SiHa)	and	immortalised	cell	lines	from	human	malignancies	that	were	HPV	negative	(breast,	colon,	lung,	skin)	but	not	in	human	primary	keratinocytes	(Andrei	et	al.	1998).		The	cellular	environment	that	leads	to	uncontrolled	proliferation	could	therefore	be	an	important	common	characteristic	shared	by	cells	sensitive	to	cidofovir.	In	order	to	proliferate,	cellular	machinery	involved	in	energy	metabolism	and	cell	cycle	progression	needs	to	be	activated.	Key	enzymes,	such	as	pyruvate	kinase,	are	crucial	in	cell	proliferation,	and	are	abundant	in	rapidly	proliferating	cells.	In	the	case	of	HPV	infection,	the	E7	oncoprotein	is	responsible	for	driving	cellular	proliferation	and	therefore	is	
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associated	with	the	presence	of	high	levels	of	pyruvate	kinase.	As	illustrated	in	Figure	1.14,	pyruvate	kinase	is	also	involved	in	the	metabolism	of	cidofovir	into	its	active	metabolite	–	CDVpp.	It	is	therefore	possible	that	the	increased	sensitivity	of	HPV	transformed	cells	to	cidofovir	is	not	directly	related	to	the	virus	itself	but	a	result	of	the	altered	cellular	environment	created	by	the	proliferating	cell.	Another	study	investigated	the	effects	of	cidofovir	on	the	HPV	negative	cervical	cancer	cell	line	C33A	and	two	derivative	lines	(Donne	et	al.	2009):	one	transfected	with	high-risk	HPV	16	E6	and	the	other	transfected	with	low-risk	HPV	6	E6.	A	marked	growth	inhibitory	effect	was	seen	in	the	high-risk	E6	expressing	cell	line	but	not	in	the	low-risk	E6	expressing	cells	line.	The	findings	of	this	study	indicate	that	despite	cidofovir’s	increased	activity	in	rapidly	dividing	cells	from	non-HPV	immortalized	cell	lines,	the	presence	of	high-risk	HPV	further	enhances	this	effect.	It	is	possible	that	the	presence	of	high-risk	HPV	enhances	the	effects	of	cidofovir	by	facilitating	its	ability	to	cause	DNA	damage	(see	below).	
1.3.3.2 Transforming	HPV	Infection	Permits	Genomic	DNA	Damage	by	Cidofovir	A	study	suggesting	that	the	action	of	cidofovir	in	HPV	transformed	cells	is	mediated	through	apoptosis	found	that	treatment	of	HPV	transformed	cells	with	cidofovir	resulted	in:	
• Induction	of	CPP32	(caspase-3)	protease	activity	
• Translocation	of	phosphatidylserine	(PS)	from	the	inner	part	of	the	plasma	membrane	to	the	outer	layer.	
• Disintegration	of	the	nuclear	matrix	protein	
• DNA	fragmentation	
• Increased	number	of	cells	in	apoptotic	phase	following	cell	cycle	analysis.	Further	to	this,	treatment	of	HPV	positive	cervical	carcinoma	cell	lines	with	cidofovir	has	been	shown	to:		 	
• Arrest	cells	in	the	S-phase	of	the	cell	cycle		
• Increase	levels	of	p53	and	pRb		
• Increase	levels	of	the	cyclin-dependent	kinase	inhibitor	p21/WAF-1		
• Induce	apoptosis	(Andrei	et	al.	2000;	Abdulkarim	et	al.	2002).	It	would	therefore	appear	that	treatment	with	cidofovir	is	able	to	overcome	some	of	the	cellular	sequelae	that	result	from	a	transforming	HPV	infection	(i.e.	reduced	p53)	The	viral	characteristics	of	a	transforming	HPV	infection	and	the	altered	cellular	environment	created	discussed	in	section	1.2.2	and	summarised	in	Figure	1.6	are	re-
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considered	at	this	stage.	In	normal	cells,	the	tumour	suppressor	protein	p53	responds	to	a	variety	of	stresses,	including	DNA	damage,	and	in	response	to	stress,	may	prevent	progression	through	the	cell	cycle.	P53	activity	regulates	multiple	genes,	including	genes	involved	in	the	induction	of	cell-cycle	arrest,	apoptosis,	senescence,	DNA	repair	and	altered	metabolism.	Specifically	p53	controls	the	G1/S	transition	at	the	G1	checkpoint	by	inducing	expression	of	cyclin	inhibitors	p16,	p21	and	p27,	which	block	the	activities	of	cyclin	dependent	kinase	complexes,	thus	promoting	cell	cycle	arrest.	In	HPV	transformed	cells,	these	cell	surveillance	mechanisms	are	diminished	as	a	result	of	the	de-regulated	expression	of	the	E6	and	E7	oncogenes.	HPV	E6	oncoprotein	results	in	the	ubiquitination	of	p53	through	its	association	with	the	ubiquitin	protein	ligase	E6AP	(E6	associated	protein)	disrupting	its	control	of	cell	cycle	progression.	HPV	E7	protein	binds	to	several	cellular	factors	including	the	retinoblastoma	(Rb)	family	of	proteins.	The	Rb	family	control	the	G1/S	phase	transition	by	regulating	the	activity	of	the	E2F	family	of	transcription	factors,	which	are	critical	regulators	of	G1/S	phase	transition.	The	Rb/E2F	complex	is	a	transcriptional	repressor	specific	to	G1.	The	binding	of	the	HPV	E7	protein	to	Rb	disrupts	the	Rb-E2F	complexes	and	leads	to	the	constitutive	expression	of	E2F-responsive	genes	resulting	in	cell	cycle	progression	(Kessis	et	al.	1993;	Duensing,	Münger	2004;	Andrei	et	al.	2015).	Reduced	functional	p53	is	a	characteristic	shared	by	many	non-HPV	related	tumour	cells	and	HPV	transformed	cells;	more	than	50%	of	human	tumours	contain	mutations	in	the	TP53	gene,	rendering	p53	inactive.	Aberrant	P53	specifically	could	therefore	be	linked	to	the	mechanism	of	action	of	cidofovir.	Gene	expression	changes	have	been	evaluated	following	cidofovir	treatment	in	different	cell	types	in	order	to	reveal	molecular	mechanisms	underlying	cidofovir’s	selectivity	for	tumour	cells	and	HPV	transformed	cells	(De	Schutter	et	al.	2013).	Response	to	cidofovir	in	HPV	transformed	cells	was	linked	to	expression	profiles	indicative	of	altered	response	to	DNA	damage,	DNA	replication	rate	as	well	as	incorporation	of	cidofovir	into	the	genome.	They	also	revealed	the	presence	of	micro-array	gene	expression	signatures	indicating	the	activation	of	DNA	double-stranded	break	repair	mechanism	in	normal	primary	human	keratinocytes	in	response	to	treatment	with	cidofovir.	It	is	therefore	possible	that	the	absence	of	functional	p53	in	HPV	transformed	cells	facilitates	the	incorporation	of	cidofovir	into	genomic	DNA	and	the	resultant	DNA	damage,	which	then	activates	alternative	apoptotic	pathways	leading	to	cell	death	(Figure	1.12).			
Chapter	1	 	 Background		
	HPV	Biology	in	VIN:	Viral	Biomarkers	to	Predict	Response	to	Treatment			 39	
	
Figure	1.12	Proposed	cellular	responses	to	cidofovir	in	normal	and	HPV	transformed	cells.	Top:	In	response	to	the	DNA	damage	caused	by	genomic	incorporation	of	cidofovir,	normal	cells	activate	DNA	damage	response	pathways	via	p53	leading	to	G1/S	cell	cycle	arrest.	DNA	repair	mechanisms	are	then	employed	by	the	cell	resulting	in	genomic	stabilization	and	cell	survival.	Bottom:	in	HPV	transformed	cells,	cell	surveillance	machinery,	including	p53	are	rendered	inactive	through	viral	oncoprotein	expression.	DNA	damage	caused	by	cidofovir	goes	undetected,	DNA	repair	mechanisms	are	not	activated	and	consequently	cell	death	ensues	via	apoptosis.	Need	to	include	explanation	of	how	CDV	causes	double	stranded	breaks		
1.3.4 Targeting	Cidofovir	Therapy	in	VIN	The	limited	research	available	indicates	that	not	all	patients	with	VIN	respond	to	treatment	with	cidofovir	(Tristram,	Fiander	2005).	In	vitro	studies	have	demonstrated	that	cidofovir	causes	selective	inhibition	of	proliferation	in	HPV	infected	cells	compared	with	HPV	negative	cell	lines	(Johnson,	Gangemi	1999;	Andrei	et	al.	1998).	Reports	have	also	shown	that	topical	treatment	causes	visible	reaction	in	the	skin	affected	by	VIN	whilst	conserving	the	normal,	surrounding	skin	and	that	those	patients	with	visible	reaction	are	those	women	more	likely	to	respond	(Tristram,	Fiander	2005).	It	is	plausible	therefore	that	knowledge	of	HPV	status	prior	to	treatment	with	cidofovir	could	be	used	to	identify	patients	more	likely	to	respond.	
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In	vitro	studies	have	also	demonstrated	increased	efficacy	of	cidofovir	in	cells	containing	a	high	risk	HPV	infection	(Donne	et	al.	2009).	As	described	in	section	1.4.2,	HPV	integration,	DNA	methylation	and	deregulated	oncogene	expression	are	all	viral	characteristics	associated	with	high-risk,	transforming	HPV	infection.	It	is	hypothesized	that	patients	in	whom	these	viral	characteristics	are	identified	will	be	more	likely	to	respond	to	treatment	with	cidofovir.
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1.4 Imiquimod:	
Imiquimod	(Aldara,	3M	Pharmaceuticals)	is	an	imidazoquinoline	amine	(Figure	1.13)	licensed	for	the	topical	treatment	of	external	genital	and	perianal	warts.	It	exhibits	antiviral	and	anti-tumour	effects	in	vivo	by	stimulation	of	the	innate	immune	response	through	induction	of	cytokines	and	the	cellular	arm	of	acquired	immunity	(Schön,	Schön	2007).	It	is	used	broadly	across	the	UK	for	the	treatment	of	genital	wart	and	is	priced	at	£48.60	for	a	12-sachet	pack.		
	
Figure	1.13	Molecular	structure	of	imiquimod.	1-(2-methylpropyl)-1	H	–imidazo	[4,5-c]quinolin-4-amine.	Molecular	formula:	C14H16N4.	Molecular	weight:	240.3	
1.4.1 Innate	Immune	System:	The	innate	immune	system	is	composed	of	mononuclear	phagocytes,	dendritic	cells,	the	complement	system	and	epithelial	barriers	(Alberts	et	al.	2002).	It	is	the	pre-programmed	immune	system	of	all	multicellular	organisms	that	quickly	detects	harmful	pathogens	the	body	may	encounter.	It	does	this	through	the	recognition	of	pathogen	associated	molecular	patterns	(PAMPs).	PAMPs	are	essential	microbial	products	and	include	molecules	such	as	lipopolysaccharides	and	peptidoglyans.	The	PAMPs	do	not	tend	to	be	specific	to	a	pathogen	but	are	generally	shared	by	groups	of	pathogens.	Single,	membrane	spanning,	toll-like	receptors	(TLRs)	on	the	cells	of	the	innate	immune	system	recognise	PAMPs.	Activation	of	TLRs	stimulates	the	innate	immune	system.	Activation	of	TLRs	in	monocytes	such	as	dendritic	cells,	results	in	phagocytosis	of	the	stimulant	of	its	receptor.	The	cell	then	combines	peptides	of	the	microbe	with	major	histocompatibility	complexes	forming	peptide/MHC	that	it	then	presents	on	its	surface.	Antigen	presentation	in	turn	leads	to	stimulation	of	T-lymphocytes.	Dendritic	cells	(and	macrophages)	are	also	involved	in	cytokine	production.	Cytokines	are	the	communication	proteins	involved	in	the	inflammatory	response	and	include	immunomodulating	agents	such	as	interleukins,	
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tumour	necrosis	factor	and	interferon.	The	production	of	these	cytokines	stimulates	the	differentiation	of	naïve	T	cells	and	promote	an	amplified	positive		autocrine	feedback	process	enhancing	immunity	to	the	point	that	microbial	invasion	is	resolved	(Alberts	et	al.	2014;	Stanley	2002).	
1.4.2 Mechanism	of	Action	of	Imiquimod:	Imiquimod	is	an	immunomodulator	through	its	binding	and	activation	of	toll-like	receptor	7	(TLR7).	TLR7	is	found	on	plasmacytoid	dendritic	cells	and	macrophages	when	activated,	enhances	the	innate	immune	system	by	stimulating	the	synthesis	of	pro-inflammatory	Th1	cytokines	(IL-12)	and	interferon	α	(IFNα).	This	in	turn	enhances	a	CD4+T	cell-mediated	response	and	leads	to	cytolytic	activity	against	viral	targets	(Stanley	2002;	Edwards	1998)	through	the	activation	of	CD8+	T	cells	natural	killer	cells,	macrophages	and	B-lymphocytes	(Miller	1999;	Stanley	2002;	Edwards	1998).	
1.4.3 Imiquimod	and	VIN:	
1.4.3.1 Efficacy	The	role	of	imiquimod	in	the	treatment	of	VIN	has	been	researched	more	extensively	than	Cidofovir.	Imiquimod	is	used	across	the	UK	as	an	off-license	treatment	for	VIN,	with	varying	success.	A	review	of	17	studies	investigating	the	efficacy	of	imiquimod	in	the	treatment	of	VIN	reported	complete	response	rates	ranging	from	26%	to	100%,	partial	response	rates	ranging	from	0%-60%	and	non-response	rates	from	0%	-69%	(Iavazzo	et	
al.	2008).	A	review	of	the	literature	to	date	reveals	complete	response	rates	ranging	from	20.0%-100.0%	(Table	1.4).	Analysing	the	literature	is	challenging	due	to:	variation	in	treatment	regimes	and	follow-up	periods	between	studies;	small	patient	numbers;	variable	inclusion/exclusion	criteria	and	varied	study	design.	The	two	studies	reporting	100.0%	complete	response	rates	are	from	case	reports	on	only	a	few	patients	(Davis	et	al.	2000;	McQuillan,	Morgan	2007).	One	randomized	controlled,	double	blind,	clinical	trial	of	52	patients	using	5%	Imiquimod	versus	placebo	has	been	performed	(van	Seters	et	al.	2008).	It	reported	complete	histological	response	as	significantly	higher	in	the	imiquimod	group	compared	to	the	placebo	group	(P<0.001),	with	complete	histological	response	in	9/26	(34.6%)	patients	in	the	treatment	arm.	A	further	five	(19.2%)	patients	experienced	a	significant	reduction	in	lesion	size	(>75%).	No	patients	in	the	placebo	arm	had	a	complete	histological	response.	One	study	compared	the	efficacy	of	imiquimod	5%	with	surgical	excision	in	the	treatment	of	VIN	(Frega	et	al.	2013).	This	study	had	the	added	advantage	of	5-year	follow-up	data;	
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one	of	the	longest	follow-up	periods	reported	in	this	area.	Thirty-two	patients	were	treated	with	imiquimod	and	38	patients	were	treated	with	surgical	excision.	In	the	imiquimod	arm,	13/32	(40.6%)	patients	had	a	complete	response	to	the	first	cycle	of	treatment	and	a	further	two	patients	had	complete	response	following	a	second	course	of	treatment.	Eight	patients	had	a	partial	response	followed	by	surgical	excision	and	nine	patients	failed	to	respond.	Of	the	complete	responders,	5/15	(33.3%)	developed	recurrence;	mean	time	to	recurrence	was	25.6±19	months.	In	the	surgical	arm,	21/38	(55.3%)	of	patients	had	no	recurrence	in	the	5-year	follow	up	period	and	17/38	(44.7%)	did.	Mean	time	to	recurrence	was	29±26	months.	At	the	end	of	the	5-year	follow	up	period,	10/32	(31.3%),	imiquimod	patients	remained	disease	free	and	so	did	21/38	(55.3%)	surgically	managed	patients.	This	study	found	the	complete	response	rate	to	surgical	excision	to	be	significantly	higher	than	the	response	rate	following	treatment	with	imiquimod	(p=0.04),	but	observed	that	recurrence	rates	following	treatment	were	significantly	lower	following	treatment	with	imiquimod	(p=0.009).	A	study	reported	by	Gentile	et	al.	(Gentile	et	al.	2014)	compared	efficacy	and	recurrence	rates	between	patients	treated	with	either	excisional	surgery	alone	or	excisional	surgery	followed	by	a	16-week	course	of	topical	imiquimod.	Patients	were	followed	up	for	5	years.	In	patients	treated	with	surgery	alone,	21/38	(55.2%)	had	a	complete	response,	and	17/38	(44.8%)	had	a	recurrence	(mean	time	to	recurrence	29±26	months).	In	patients	treated	with	combined	surgery	and	imiquimod,	17/33	(51.6%)	had	a	complete	response	with	16/33	(48.4%)	patients	experiencing	a	recurrence	(mean	time	to	recurrence	31±30months).	They	concluded	that	there	was	no	added	benefit	in	combining	imiquimod	with	surgical	excision	in	the	management	of	VIN.	However,	it	could	also	be	hypothesised,	based	on	the	response/recurrence	rates	reported	by	other	studies	of	imiquimod	therapy	alone,	that	current	optimal	management	of	VIN	may	be	achieved	using	surgery	as	an	adjunct	to	initial	imiquimod	therapy	in	patients	with	a	partial	response	or	repeated	recurrent	episodes.		
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Table	1-4	Summary	of	studies	investigating	use	of	imiquimod	in	treatment	of	VIN	
Study	 n=	
Complete	
response	
n=(%)	
Partial	
response	
(any)	
n=(%)	
Recurrence	
in	complete	
responders	
n=(%)	
Follow-up	 Notes	
Diaz-Arrastia	et	al.	2001	 8	 4/8	(50.0)	 2/8	(20.0)	 2/4(50%)	 Mean	33	months	 	Jayne	et	al.	2002	 13	 8/13	(61.5)	 4/13	(30.8)	 Not	reported	 5.5	months	 	Todd	et	al.	2002	 15	 3/15	(20.0)	 1/15	(6.7)	 Not	reported	 5	months	 Local	side	effects	limited	treatment	application	so	that	7	patients	only	applied	the	cream	once	a	week,	6	patients	applied	in	twice	a	week	and	only	2	patients	adhered	to	the	treatment	protocol	of	three	times	a	week.	Davis	et	al.	2000	 4	 4/4	(100.0)	 0/4	(0.0)	 2/4	(50.0%)	 12	months	 In	the	2	cases	of	recurrence,	one	cases	has	a	recurrence	in	the	perianal	region	and	another	had	a	recurrence	in	a	region	outside	of	the	previously	treated	field.	Van	Seters	et	al.	2002	 15	 4/15	(26.6)	 9/15	(60.0)	 0	 Not	reported	 	Marchitelli	et	al.	2004	 8	 7/8	(87.5)	 1/8	(12.5)	 0	 Range	10-30	months	 	Wendling	et	al.	2004	 12	 3/12	(25.0)	 4/12	(33.3)	 0	 Mean	9.7	months	 	Mathiesen	et	al.	2004	 32	 17/21	(81.0%)	 2/21(10.0%)	 Not	reported	 Not	reported	 14/21	patients	had	to	reduce	the	frequency	of	cream	applications	due	to	side	
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effects.	McQuillan,	Morgan	2007	 1	 1/1	(100.0%)	 N/A	 Not	reported	 Not	reported	 	Le	et	al.	2007	 39	 21/33	(63.6%)	 9/33	(27.3%)	 8/21(38.1%)	 Mean	16	months	 	van	Seters	et	al.	2008;	Terlou	et	al.	2011	 26	 9/26	(34.6%)	 12/26	(46.2%)	 0	 12	months	 7	year	follow	up	data	presented	by	linked	study	Terlou	et	al	of	24/26	patients.	1/9	(11.1%)	complete	responders	developed	recurrence.	Frega	et	al.	2013	 40	 10/32	(31.0%)	 10/32	(31.3%)	 5/15	(33.3%)	 5	years	 	Westermann	et	al.	2013	 62	 47/62	(75.8%)	 14/62	 17/47	(36.2%)	 Median	21	months	 	
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1.4.3.2 Treatment	Regime	Imiquimod	is	supplied	in	the	form	of	5%	cream.	The	European	Medicines	Agency’s	(EMA)	licenced	treatment	regime	for	genital	warts	is	three	applications	per	week	until	resolution	of	the	lesions	for	a	maximum	of	16	weeks	per	episode	(European	Medicines	Agency,	Aldara	2008).	The	optimal	treatment	regime	for	VIN	specifically,	is	yet	to	be	determined.	There	has	been	significant	variability	in	methods	of	administration	reported	in	studies	to	date.	Additional	clinical	trials	will	be	needed	if	this	treatment	option	proves	useful	in	the	treatment	of	VIN.	
1.4.3.3 Recurrence	Rates	Recurrence	rates	of	VIN	following	treatment	with	imiquimod	are	difficult	to	determine	accurately	due	to	the	varied	nature	of	the	studies	reported	in	the	literature.	A	review	of	the	literature	is	illustrated	in	Table	1.4,	and	shows	recurrence	rates	range	from	0%	-	50%	with	a	range	of	follow-up	period	of	9	months	–	7	years.	The	longest	follow-up	period	(7	years)	following	treatment	of	VIN	with	imiquimod	is	reported	by	Terlou	et	al.	2011	on	the	initial	RCT	performed	by	Van	Seters	et	al.	2008	discussed	above.	In	this	study,	patients	were	randomized	to	treatment	with	imiquimod	or	placebo.	Nine	of	twenty-six	patients	(34.6%)	had	a	complete	response	to	treatment	of	whom,	1/9	(11.1%)	experienced	a	recurrence	in	the	7-year	follow-up	period.	A	study	published	by	Wallbillich	et	al.	2012	compared	disease	recurrence	rates	between	different	treatment	modalities	including	surgical	excision	and	laser	ablation	and	found	imiquimod	to	have	the	lowest	recurrence	rates	at	13.6%	(laser	ablation	41.9%	and	excision	26.4%).		
1.4.3.4 Side	Effects	The	imiquimod	(Aldara)	product	information	approved	by	the	European	Medicines	Agency	(European	Medicines	Agency,	Aldara	2008)	regarding	side	effects	states	that	local	side	effects	in	response	to	treatment	with	imiquimod	are	very	common	(>1	in	10)	and	include:	erythema,	ulceration,	swelling,	burning,	pain	and	itching.	These	local	effects	are	usually	mild	and	tolerable	but	in	some	instances	require	a	reduction	in	treatment	intensity.	Headaches	are	commonly	(>1	in	10)	reported	and	flu-like	symptoms	as	well	as	joint	and	muscle	pains	are	uncommonly	(<1	in	100)	reported.	Very	rarely	(<1	in	10,000)	women	have	reported	severe	and	painful	skin	reactions	making	passing	urine	very	difficult.	The	largest	single	study	of	imiquimod	treatment	in	VIN	to	date,	a	retrospective	study	of	62	women	conducted	by	Westermann	et	al.	2013,	found	that	30/62	(48.4%)	
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reported	local	adverse	effects	(mainly	burning	and	itching),	22/62	(35.5%)	reported	local	and	systemic	(flu-like	symptoms)	and	2/62	(3.2%)	reported	exclusive	systemic	symptoms.	Interestingly,	complete	response	to	treatment	was	significantly	higher	among	women	who	reported	adverse	events	than	among	those	who	did	not	(p=0.049).	
1.4.4 Imiquimod	and	HPV:	HPV	related	disease	is	more	common	among	patients	with	immunodeficiency	(e.g.	organ	transplant,	HIV	and	diabetes)	(Doorbar	2006;	Palefsky	2006).	The	high	prevalence	of	HPV	infection	can	be	partly	attributed	to	its	ability	to	cause	minimal	inflammation	in	the	host.	HPV	has	been	shown	to	alter	transcriptional	activity	of	IFNβ	and	NFkβ	pathways	which	results	in	the	decreased	ability	of	keratinocytes	to	produce	the	necessary	cytokines	and	chemokines	to	activate	adaptive	immunity	(Muñoz,	Jacquard	2008;	Huang,	McCance	2002;	Ronco	et	al.	1998).	It	has	been	found	that	in	comparison	with	other	opportunistic	infections,	HPV	stimulates	less	local	inflammation	with	lower	antigen	levels	detectable	by	the	innate	immune	system	(Doorbar	2006;	Huang,	McCance	2002;	van	der	Burg,	Palefsky	2009).	This	evasion	of	host	immunity	is	essential	for	the	survival	of	the	virus,	which	requires	full	keratinocyte	differentiation	in	order	to	produce	new	viral	particles.	Treatment	of	HPV	related	disease	with	immune	modifying	agents	designed	to	enhance	innate	immunity	such	as	imiquimod	is	therefore	an	obvious	course	to	follow.	Imiquimod	has	demonstrated	efficacy	in	various	HPV	associated	diseases	including	cutaneous	warts,	genital	warts	and	intraepithelial	conditions	of	the	anogenital	tracts.	Imiquimod	has	been	shown	to	significantly	reduce	viral	load	as	well	as	HPV	E7	and	L1	mRNA	expression	(Tyring	et	al.	1998;	Arany	et	al.	1999;	Stanley	2002).	It	also	has	the	ability	to	generate	and	maintain	effective	HPV-specific	immunity	as	suggested	by	low	wart	recurrence	rates.	Evidence	that	HPV	clearance	is	driven	by	imiquimod	and	that	this	is	important	in	VIN	disease	resolution	comes	from	a	trial	by	van	Seters	et	al.	2008	(van	Seters,	van	Beurden	et	
al.	2008).	There	were	25	HPV	positive	patients	in	each	treatment	arm	(imiquimod	and	placebo)	of	this	study.	After	20	weeks	of	treatment,	15/25	(60%)	patients	and	2/25	(8%)	patients	were	HPV	negative	in	the	imiquimod	arm	and	placebo	arm	respectively	(p=<0.001).	There	was	a	strong	association	between	HPV	clearance	and	disease	clearance	(p=<0.001);	of	the	14	lesions	in	the	study	that	regressed,	13/14	were	cleared	of	an	original	HPV	infection	and	the	other	was	HPV	negative	at	baseline.	This	data,	along	with	knowledge	of	the	mechanism	of	action	of	imiquimod,	gives	rise	to	the	hypothesis	that	HPV	could	act	as	a	predictive	biomarker	to	response	to	treatment	with	imiquimod	in	patients	with	VIN.	
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In-vitro	investigations	have	demonstrated	that	when	integrated	and	episomal	forms	of	HPV	coexist,	expression	of	viral	E2	from	the	episomes	results	in	repression	of	transcription	of	E6	and	E7	from	the	integrated	HPV	and	it	is	only	when	there	is	complete	loss	of	episomal	HPV	that	E6	and	E7	expression	becomes	fully	deregulated.	Episome	loss	is	associated	with	expression	of	antiviral	response	genes	induced	by	the	type	I	interferon	(IFN)	pathway.	This	has	been	confirmed	by	studies	using	exogenous	IFN,	which	resulted	in	clearance	of	episomes.	Interestingly,	the	consequence	of	this	was	up-regulation	of	oncogene	expression	from	previously	latent	HPV	infection	(due	to	the	loss	of	the	episomal	E2)	(Herdman	et	al.	2006;	Pett	et	al.	2006).	Clinical	studies	have	shown	that	treatment	of	HPV	tissue	with	imiquimod	causes	an	increase	in	the	production	mRNA	for	IFN-α	at	the	application	site.	IFN-α	and	IFN-β	are	both	type	I	IFN’s	signalling	through	the	IFN-α	receptor,	it	is	likely	that	treatment	with	Imiquimod	may	cause	episome	clearance	in	the	same	manner	as	exogenous	IFN-β	(Stanley	2002).	If	is	the	case,	then	apparent	clinical	response	could	well	be	followed	by	emergence	of	a	more	aggressive	lesion	with	enhanced	expression	of	viral	oncogenes.	This	important	parameter	will	be	assessed	within	the	clinical	trial	(RT3	VIN)	that	is	linked	to	this	study.	
1.4.5 Targeting	Imiquimod	Therapy	in	VIN	Not	all	patients	with	VIN	respond	to	treatment	with	imiquimod;	non-response	rates	are	reported	between	0%	-	69%	(Iavazzo	et	al.	2008).	Imiquimod	also	carries	a	significant	side	effect	profile	and	can	be	difficult	to	tolerate.	A	means	of	targeting	therapy	to	those	patients	in	whom	a	response	is	more	likely	is	an	attractive	prospect,	and	could	avoid	unnecessary	side	effects	in	patients	in	whom	an	alternative	approach	would	be	better.	Cases	that	are	driven	by	HPV	have	been	shown	to	respond	better	to	treatment	with	imiquimod	than	cases	that	are	HPV	negative	(van	Seters,	van	Beurdenet	al.	2008).	It	is	therefore	possible	that	identification	of	patients	with	HPV	driven	disease	could	also	identify	patients	more	likely	to	respond	to	therapy.		It	is	also	the	case	that	not	all	cases	of	HPV	positive	VIN	respond	to	treatment	with	imiquimod	(10/25	(40%)	HPV	positive	cases	failed	to	respond	to	treatment	in	the	van	Seters	study	mentioned	above).	Three	explanations	have	been	proposed	as	to	why	some	patients	fail	to	respond	to	treatment	with	imiquimod	(Stanley	2002):	1. Persistent	disease	may	result	in	tolerance	to	viral	infection.	2. Presence	of	signalling	defects	in	the	T	cells.	3. Antigen	loads	being	too	low	for	effective	priming.	Points	1	and	3	above	are	of	particular	interest	to	this	thesis.	The	mechanism	of	action	of	imiquimod	is	linked	to	the	direct	stimulation	of	the	innate	immune	system	and	specifically	
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to	the	target	infection.	Therefore,	a	requirement	of	successful	imiquimod	treatment	would	be	a	degree	of	host	response	to	the	HPV	infection	in	the	first	instance.	The	likelihood	of	treatment	failure	is	potentially	higher	in	patients	in	whom	the	HPV	infection	is	more	successfully	evading	host	immunity	and	who	are	therefore	lacking	the	directed	immune	response	(van	Seters,	Beckmann	et	al.	2008).	Successful	evasion	of	host	immunity	increases	the	likelihood	of	persistent	HPV	infection,	which	in	turn	increases	the	likelihood	of	developing	a	transforming	infection.	Therefore	viral	markers	of	persistent/transforming	HPV	infection	could	potentially	identify	those	patients	in	whom	treatment	with	imiquimod	is	destined	to	fail.		As	described	in	section	1.2.2,	the	presence	of	viral	integration,	increased	viral	DNA	methylation	and	de-regulated	E6/E7	gene	expression	are	all	associated	with	persistent	transforming	infections.	By	creating	a	physical	‘profile’	of	the	HPV	infection	upon	diagnosis,	it	might	be	possible	to	predict	patients	in	whom	treatment	is	more	likely	to	be	successful.
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1.5 Biomarkers	
A	biological	marker	(biomarker)	is	a	characteristic	than	can	be	objectively	measured	such	as	DNA,	RNA,	protein,	protein	modification	or	metabolite	that	reflects	the	biological	state	of	interest.	Biomarkers	can	be	used	to	indicate	normal	biological	processes,	pathogenic	processes	or	pharmacological	responses	to	therapeutic	interventions	and	are	being	increasingly	used	in	day-to-day	medical	practice.	Biomarkers	may	be	used	in	a	variety	of	settings,	including:	
• Diagnostic–	indicating	the	probability	that	a	disease	is	present	
• Prognostic	–	indicating	how	disease	may	develop	in	individual	cases,	regardless	of	treatment	
• Predictive	–	indicating	the	probable	effect	of	an	intervention	on	the	disease	
1.5.1 Predictive	Biomarker	Development	The	aim	of	the	biomarker	investigation	in	this	thesis	was	to	determine	whether	HPV	characteristics	have	potential	to	identify	patients	whose	VIN	is	more	likely	to	respond	to	topical	treatment	of	VIN	3	with	cidofovir	or	imiquimod.	Cancer	Research	UK	has	published	guidelines	in	the	form	of	a	‘roadmap’	to	aid	in	development	of	predictive	biomarkers.	This	roadmap	breaks	down	biomarker	development	into	three	broad	sections	starting	with	establishing	the	rationale	for	developing	the	biomarker.	Questions	to	be	asked	at	this	stage	include:	
• Is	there	an	unmet	clinical	need	for	the	biomarker?	
• Does	the	work	primarily	focus	on	the	discovery/development	of	a	biomarker	for	application	to	clinical	material?	
• Is	there	a	sample	collection	available	for	retrospective	biomarker-outcome	correlation?	If	the	answer	to	the	above	questions	is	‘yes’	then	progress	can	be	made	through	several	stages	of	‘biomarker	discovery’	and	‘assay	development’	before	the	final	stages	of	‘biomarker	qualification’	are	addressed.	Figure	1.14	illustrates	the	CRUK	prognostic/predictive	biomarker	roadmap.			
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1.6 Study	aims	and	Hypotheses	
This	study	had	two	broad	aims:	firstly,	to	investigate	HPV	biology	in	VIN	and,	secondly,	to	assess	HPV	characteristics	as	potential	predictive	biomarkers	to	direct	treatment	of	VIN	with	cidofovir	and	imiquimod.	HPV	pathogenesis	in	VIN	is	in	largely	presumed	to	be	similar	to	HPV	pathogenesis	in	CIN.	Investigation	of	HPV	biology	in	VIN	is	important	in	view	of	the	lack	of	evidence	to	support	this	assumption.	This	study	is	the	largest	investigation	of	multiple	aspects	of	HPV	biology	in	VIN	to	date.	Based	on	the	literature	described,	several	hypotheses	were	generated	(Figure	1.15).	The	results	and	discussion	of	this	part	of	the	investigation	are	detailed	in	chapter	5.	The	second	aim	of	this	study	was	to	investigate	HPV	characteristics	as	potential	predictive	biomarkers	in	the	treatment	of	VIN	with	cidofovir	and	imiquimod.	This	thesis	describes	translational	work	associated	with	the	RT3	VIN	clinical	trial	(chapter	3).	This	phase	II	trial	confirmed	early	reports	in	the	literature	that	approximately	50%	of	patients	treated	with	either	cidofovir	or	imiquimod	respond	and	also	found	no	correlation	between	clinical	markers	(smoking	status,	disease	episode	and	disease	focality)	and	response	to	treatment.	These	findings	satisfied	the	‘unmet	clinical	need’	requirement	in	the	rationale	for	developing	a	biomarker	laid	out	in	the	CRUK	biomarker	development	roadmap	(Figure	1.14).	Regarding	the	two	remaining	questions	asked	in	the	rationale	for	biomarker	development	in	the	roadmap,	this	work	was	focused	primarily	on	the	discovery	and	development	of	a	biomarker	for	application	to	clinical	material.	The	RT3	VIN	cohort	provided	a	sample	collection	for	retrospective	biomarker-clinical	outcome	correlation	studies.	Based	on	what	was	known	about	the	pharmacology	of	the	two	drugs	being	studied,	several	hypotheses	were	generated	(Figure	1.16).	The	results	of	this	part	of	the	investigation	are	detailed	in	chapter	6.	The	following	chapter	describes	the	methods	used	to	carry	out	this	work.	Chapter	3	provides	a	summary	of	the	RT3	VIN	clinical	trial	(the	trial	with	which,	this	translational	work	was	associated),	which	is	followed	by	two	results	chapters	with	their	relevant	discussions:	‘HPV	biology	in	VIN’	(Chapter	4)	and	‘viral	characteristics	as	predictive	biomarkers	in	response	to	treatment’	(chapter	5).	A	short	conclusion	of	the	work	overall	can	be	found	at	the	end.				.	
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Figure	1.16	Study	Aim	2	and	Associated	Hypotheses
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2 Methods	
2.1 Study	Population	The	biopsies	used	for	this	study	were	collected	from	patients	in	the	RT3	VIN	clinical	trial;	for	detailed	trial	information	see	chapter	3.	In	summary,	patients	with	histologically	confirmed	VIN	3	were	recruited	for	treatment	with	one	of	two	novel	topical	treatments	(imiquimod	and	cidofovir)	in	a	phase	II	setting	with	curative	aims	over	a	maximum	course	of	24	weeks.	HPV	biopsies	were	taken	prior	to	treatment	(‘baseline’)	and	6	weeks	following	the	completion	of	treatment	(‘post-treatment’).	In	some	cases,	patients	consented	to	have	an	additional	biopsy	taken	at	6	weeks	into	treatment	(‘6	week’).	The	trial	was	run	across	32	centres	in	the	UK.	HPV	biopsies	were	initially	collected	in	ThinPrep	Liquid	Based	Cytology	(LBC)	media	(Hologic®,	Bedford,	MA,	USA)	for	transportation	and	then	stored	at	-20°C	prior	to	processing.	Later,	in	order	to	improve	RNA	quality,	all	samples	were	stored	at	-80°C	prior	to	extraction	and	samples	from	the	main	recruiting	centre	were	collected	and	stored	in	RNAlater®	storage	media	(Life	Technologies	Ltd,	Paisley,	UK).	Laboratory	researchers	were	blinded	to	clinical	outcomes	until	all	scientific	assays	were	complete	to	prevent	biased	data	interpretation.	
2.2 DNA	and	RNA	Extraction	A	modified	version	of	the	Qiagen	RNeasy®	Fibrous	Tissue	Mini	Kit	and	Qiagen®	DNA	Mini	kit	(Qiagen,	Hilden,	Germany)	was	used.	The	RNeasy	Fibrous	Tissue	Mini	Kit	was	chosen	because	the	tissue	of	the	vulva,	particularly	when	VIN	3	disease	is	present,	can	be	quite	fibrous.	Additionally,	fixation	of	the	tissue	in	LBC	media	resulted	in	more	physically	robust	samples.	Tissue	samples	were	first	lysed	and	homogenised	(TissueRuptor®,	Qiagen,	Hilden,	Germany)	for	20secs	in	360	μl	Buffer	RLT	solution	before	being	treated	with	728	μl	of	proteinase	K	solution	(708	μl	of	RNAse	free	water	and	20	μl	of	proteinase	K).	The	mixture	was	centrifuged	at	13,000rpm	for	3	minutes	to	create	a	pellet	of	debris;	650	μl	of	the	supernatant	was	removed	for	RNA	extraction.	The	remaining	350	μl	and	the	pellet	were	re-suspended	and	incubated	at	56	°C	for	16	hours	in	preparation	for	DNA	extraction	the	following	day.	The	650	μl	supernatant	was	mixed	by	repeat	pipetting	with	325	μl	of	ethanol	and	then	centrifuged	at	13,000	rpm	for	15	secs	through	the	provided	RNeasy	spin	column,	where	the	RNA	binds	to	a	silica	membrane.	Potential	contaminants	were	washed	away	with	one	350	μl	buffer	RW1	wash	followed	by	15	secs	centrifuge	at	13,000	rpm,	and	two	500	μl	buffer	RPE	washes;	the	first	followed	by	a	15	sec	centrifuge	at	13,000	rpm	and	the	second	followed	by	a	2	min	centrifuge	at	13,000	rpm.	The	remaining	RNA	was	eluted	using	100	μl	RNase-free	water.		
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The	suspension	previously	left	to	incubate	at	56	°C	was	used	for	DNA	extraction.	350	μl	of	Buffer	AL	was	added	to	the	suspension	and	mixed	by	pulse	vortex	for	15	secs	then	left	to	incubate	at	70	°C	for	10	mins	and	centrifuged	at	13,000	rpm	for	15	secs.	This	was	followed	by	the	addition	of	350	μl	of	100%	ethanol,	a	mix	by	pulse	vortex	for	15	secs	and	15	secs	in	the	centrifuge	at	13,000	rpm	to	precipitate	the	DNA.	The	mixture	was	then	added	to	the	spin	column	and	residual	contaminants	were	washed	away	using	2	wash	buffers,	AW1	and	AW2.		Initially	500	μl	of	AW1	was	added	to	the	column	and	centrifuged	at	13,000	rpm	for	1	minute,	then,	500	μl	of	AW2	was	added	and	centrifuged	at	13,000	rpm	for	3	minutes.	Purified	DNA	was	eluted	from	the	QIAmp	Mini	spin	column	in	a	concentrated	form	in	200	μl	of	AE	buffer.	
2.3 Nucleic	Acid	Quantification	Analysis	DNA	and	RNA	elutions	were	quantified	using	a	NanoDrop-1000	spectrophotometer	(FisherScientific	UK	Ltd,	Loughborough,	UK)	2	μl	of	DNA	or	RNA	was	tested	against	a	‘blank’	of	the	appropriate	elution	buffer	(AE	buffer	in	the	case	of	DNA	and	RNase	free	water	in	the	case	of	RNA).	Sample	purity	was	also	assessed	as	the	presence	of	impurities	negatively	affects	the	reliability	of	the	quantification.	The	ratio	of	absorbance	at	260	nm	and	280	nm	assesses	purity	and	a	ratio	of	~1.8	was	accepted	as	‘pure’	for	the	DNA	and	a	ratio	of	~2.0	was	regarded	as	‘pure’	for	the	RNA	sample.		These	figures	are	taken	from	guidelines	provided	by	the	NanoDrop	manufacturers.		
2.4 HPV	Testing	Four	different	HPV	detection/genotyping	assays	targeting	different	regions	of	the	virus	were	used	during	this	study.	Figure	2.1	is	a	representation	of	the	HPV	genome	with	the	regions	specific	to	each	assay	highlighted.	The	concentration	of	sample	DNA	was	standardised	in	all	HPV	detection/genotyping	assays	to	10	ng/μl,	except	for	the	PapilloCheck®	assay	which	requires	2	μl	of	sample	DNA.			
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Figure	2.1HPV	detection	assay	target	regions	in	the	HPV	genome.	Demonstrating	that	all	four	HPV	detection	methods	target	different	regions	of	the	HPV	genome.	
2.4.1 Greiner	PapilloCheck®	HPV	Genotyping	All	HPV	samples	received	from	the	RT3	VIN	trial	underwent	the	Greiner	PapilloCheck®(Greiner	Bio-one	GmbH,	Frickenhausen,	Germany)	assay	for	HPV	genotyping	as	per	manufacturer’s	instructions.	It	simultaneously	tests	for	24	different	HPV	genotypes	(HPV	6,	11,	40,	42,	43,	44,	16,	18,	31,	33,	35,	39,	45,	51,	52,	53,	56,	58,	59,	66,	68,	70,	73	and	82)	through	the	detection	of	a	350bp	fragment	of	the	E1	gene.	PCR	is	used	to	amplify	the	target	sequence	of	the	E1	gene	using	a	subset	of	fluorescently	labelled	HPV	specific	primers.	The	assay	incorporates	several	control	steps	including	the	amplification	of	the	human	gene,	ADAT1	(Adenosine	deaminase	1)	to	avoid	false	negatives	due	to	sample	inadequacy.	Amplification	products	hybridise	to	HPV-specific	probes	attached	to	a	DNA	chip	as	well	as	built	in	controls	to	check	for	adequate	amplification	and	hybridisation.	Un-hybridised	DNA	is	removed	in	later	wash	steps.	The	DNA	chip	is	then	scanned	and	analysed	using	CheckScanner	and	CheckReport	software	generating	a	data	output	indicating	samples	that	failed	or	passed	internal	controls	and	any	identified	genotypes	in	the	samples	that	passed	internal	controls.	Positive	(DNA	from	HPV16	positive	CaSki	cells)	and	negative	(H2O)	controls	were	included	on	each	chip.	
2.4.1.1 Quality	Assurance	For	the	purpose	of	quality	assurance,	25%	of	samples	were	repeated	in	duplicate	from	the	point	of	PCR	set-up	to	test	for	inter-run	variation.	98%	of	results	were	concordant.	In	cases	of	discrepant	results,	the	first	result	was	used	due	to	the	potential	for	DNA	degradation	to	be	caused	by	any	subsequent	freeze-thaw	cycles.		
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PCR$
HPV$16$E7$
PCR$
DiaMex$Technology$
PapilloCheck®$
HPV$16$Genome$
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2.4.2 HPV	16	E6	PCR	The	HPV	16	E6	PCR	assay	amplified	a	161	bp	region	of	the	E6	gene	of	HPV	16	using	the	primers	described	by	Collins	et	al.	(Collins	et	al.	2009).	All	PCR	primers	used	for	detection	of	different	fragments	of	HPV	are	listed	in	Table	2.1.	This	assay	was	run	on	all	samples	to	identify	those	that	were	HPV	16	positive.	This	method	of	HPV	16	detection	was	chosen	due	to	its	benefits	in	terms	of	cost,	ease	of	technique,	quick	generation	of	results	and	most	importantly	because	the	E6	gene	is	highly	conserved	in	HPV	infection	independent	of	the	physical	state	of	the	virus	and	therefore	reduces	the	likelihood	of	false	negatives.	Detection	of	HPV	16	was	the	primary	focus	due	to	data	from	existing	literature	indicating	it	to	be	the	most	prevalent	genotype	in	VIN	(de	Sanjose	et	al.	2013).		The	PCR	mastermix	was	setup	in	a	final	volume	of	20	μl	including	template	DNA	at	10	ng/μl,	10x	PCR	buffer,	forward	and	reverse	primers	at	10	μM,	MgCl2	at	15	mM,	dNTP	at	2	mM,	Taq	polymerase	at	1	U	and	4.8	μl	of	H2O.		The	Thermocycling	(Applied	Biosystems®	GeneAmp®	PCR	system	9700)	conditions	used	were:	initial	denaturation	of	94	°C	for	3	minutes;	a	touchdown	primer	annealing	stage	of	10	cycles	of	94	°C	for	30	secs,	65	°C	(decreased	by	1	°C	increments	every	cycle	to	55	°C)	and	72	°C	for	1	minute;	an	amplification	stage	of	30	cycles	of	94	°C	for	30	secs,	55	°C	for	30	secs	and	72	°C	for	1	minute	followed	by	a	final	extension	of	72	°C	for	10	minutes.	
2.4.2.1 Quality	Assurance	The	assay	was	repeated	on	20%	of	samples	from	the	point	of	PCR	set	up	for	the	purpose	of	inter-run	quality	control.	100%	of	samples	generated	the	same	result	on	both	occasions.	In	addition	each	run	included	a	positive	control	(CaSki)	and	a	negative	control	(H2O).	
2.4.3 HPV	Genotyping	using	the	Optiplex	HPV	Testing	Kit	All	RT3	VIN	baseline	samples	that	tested	negative	for	any	HPV	genotype	using	either	the	HPV	16	E6	PCR	assay	or	the	PapilloCheck®	assay	were	sent	to	the	Scottish	Human	Papillomavirus	Reference	Laboratory	in	Edinburgh	for	further	testing	using	the	Optiplex	HPV	testing	kit	(DiaMexGmbH,	Heidelberg,	Germany).	This	assay	was	chosen	because	it	amplifies	a	region	of	the	L1	gene	of	HPV,	generating	amplimers	ranging	from	145	bp	to	148	bp.	The	kit	is	a	multiplex	assay	using	polymerase	chain	reaction	to	test	for	the	presence	of	24	different	genotypes	(HPV	6,	11,	42,	43,	44,	70,	16,	18,	26,	31,	33,	35,	39,	45,	51,	52,	53,	56,	58,	59,	68,	73	and	82).	The	test	utilises	Luminex	technology,	which	is	based	on	a	suspension	of	polystyrene	beads	that	are	labelled	with	various	ratios	of	two	spectrally	distinct	red	fluorophores.	Each	of	the	beads	in	the	suspension	is	coupled	to	a	specific	oligonucleotide	probe.	The	target	sequences	are	indirectly	labelled	with	a	third	fluorophore.	The	bead	sets	can	be	differentiated	and	the	bound	fluorescence	can	be	quantified	using	the	Luminex	analyser	(Luminex®,	Austin,	USA).	
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2.4.3.1 Optiplex	Method	in	Summary	The	assay	was	performed	according	to	the	manufacturer’s	instructions.	Sample	DNA	at	10	ng/μl	was	subjected	to	PCR	amplification	using	biotinylated	primers	provided	in	the	Optiplex	kit.	Quantifast	Multiplex	Mastermix	(Qiagen,	Hilden,	Germany)	was	used	for	the	reaction	to	reduce	the	need	for	optimisation	of	reaction	cycling	conditions.	At	the	PCR	stage,	the	DiaMex	kit	incorporates	an	internal	control	for	sample	adequacy	in	the	form	of	primers	for	the	amplification	of	a	fragment	of	the	humanβ-Globin	gene.	The	PCR	product	is	then	added	to	the	Luminex	bead	mix	containing	the	24	different	HPV	genotype	bead	populations	and	the	β-Globin	bead	population.	An	additional	control	bead	population	is	present	to	ensure	that	correct	hybridization	conditions	were	applied	to	the	reaction.	Following	thermal	denaturation	and	the	hybridization	of	the	target	sequences	to	the	bead-bound	probes,	labelling	of	the	hybridised	biotinylated	PCR	products	is	achieved	by	addition	of	R-Phycoerythin	labelled	Streptavadin.	Finally,	the	Luminex	instrument	analyses	the	reported	fluorescence	signal	of	at	least	70	beads	of	each	individual	bead	set	per	well.	The	fluorescence	intensity	is	used	to	evaluate	the	output	data	using	pre-defined	‘cut-off’	values	for	the	median	fluorescence	intensity	(MFI).	
2.4.3.2 Quality	Assurance	Positive	(CaSki)	and	negative	(H2O)	controls	were	used	with	each	run.	The	assay	incorporates	internal	controls	including	the	amplification	of	the	human	gene	β-Globin	and	hybridization	controls.	
2.4.4 HPV	Type-Specific	E7	PCR	In	order	to	further	investigate	the	baseline	RT3	VIN	cohort	for	HPV	prevalence,	all	samples	that	generated	a	negative	result	from	PapilloCheck®,	HPV	16	E6	PCR	and	Luminex,	were	put	through	a	HPV	type-specific	PCR	targeting	the	E7	region	of	the	virus	for	genotypes	HPV	16,	18,	31,	33,	35	and	51.	This	was	done	in	attempt	to	reduce	the	risk	of	false	negative	results	as	a	result	of	the	previous	assay	target	regions	being	potentially	disrupted	in	non-HPV	16	genotypes.		These	genotypes	were	selected	based	on	their	relative	high	prevalence	in	HPV	related	disease	(de	Sanjose	et	al.	2013).	Primers	were	taken	from	Walboomers	et	
al.	1999	and	are	specified	in	Table	2	1.	Primer-specific	20	μl	mastermixes	were	made	up	using	5	μl	of	template	DNA	at	10	ng/μl,	2	μl	of	10x	concentration	PCR	buffer	(Invitrogen),	2	μl	of	forward	and	reverse	primers	at	10	μM,	2	μl	of	MgCl2	at	15	mM,	2	μl	of	dNTP’s	at	2	mM,	0.2	μl	of	Taq	polymerase	at	5	U/μl	and	water	to	make	up	the	final	volume	(4.8	μl).	The	thermocycling	conditions	(Applied	Biosystems®GeneAmp®	PCR	system	9700)	were	initial	denaturation	of	5	min	at	94	°C,	followed	by	40	cycles	of	94	°C	for	1	min,	55	°C	for	2	min	and	72	°C	for	1.5	min,	with	a	final	extension	of	72	°C	for	10min.	
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2.5 HPV	Disruption	Assay	An	assay	was	developed	that	combined	the	E2	tiling	PCR	assay	originally	described	by	Collins	et	al.	2009	with	a	novel	two-fragment	E1	tiling	PCR.	The	two	tiling	PCRs	were	run	separately	and	the	results	combined	for	final	interpretation.	The	assay	aimed	to	detect	the	presence	of	small,	breakdown	fragments	of	two	of	the	larger	HPV	genes:	E1	and	E2	(1954	and	1097	bp	respectively).	Figure	2.2	illustrates	the	combined	HPV	disruption	assay.		
	
Figure	2.2	Combined	E1/E2	gene	tiling	PCR.	Assay	used	to	detect	the	presence	of	viral	disruption	as	a	surrogate	marker	for	the	presence	of	viral	integration.	Dark	grey	boxes	are	E1	gene	fragments;	light	grey	boxes	are	E2	gene	fragments.	bp	=	base	pair.	Bottom	line	represents	base	pair	number.		This	method	was	chosen	because	it	is	highly	reproducible,	easy	to	run	(reducing	the	impact	of	human	error)	and	relatively	inexpensive.		
2.5.1 The	E1	Tiling	PCR	
A	primer	was	designed	for	two	fragments	of	the	E1	gene	to	determine	the	presence	of	intact	
HPV	16	E1	using	primer	blast	software	(http://www.ncbi.nlm.nih.gov/tools/primer-blast/).	
PCRs	were	performed	comprising	5	μl	of	DNA	at	10	ng/μl,	2.5	μl	of	PCR	buffer	with	15	mM	
MgCl2	(10x)	(Invitrogen™),	1	μl	of	primers	at	10	μM,	2.5μl	of	2	mM	dNTP,	0.125	μl	of	1	U	
Taq	Polymerase	and	12.875	μl	of	distilled	water	to	a	final	volume	of	25	μl.	Details	of	primers	
can	be	found	in	Table	2.1.	
The	initial	denaturation	step	was	95	°C	for	15	minutes	followed	by	an	amplification	step	of	30	
cycles	consisting	of	30	seconds	at	94	°C,	30	seconds	at	59	°C	and	180	seconds	at	72	°C.	This	was	
followed	with	a	final	extension	of	1	min	at	72	°C	for	7	minutes.	
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2.5.2 The	E2	Tiling	PCR	This	assay	consisted	of	five	tiling	PCRs	using	primers	previously	described	by	Collins	et	al.	2009.	The	reaction	used	5	μl	of	DNA	at	10	ng/μl,	2	μl	of	10x	concentration	PCR	buffer	(Invitrogen),	2μl	of	primers	at	10	μM	(Table	2.1),	2	μl	of	dNTP	at	2	mM,	2	μl	of	MgCl2	at	15	mM,	0.2	μl	of	Taq	Polymerase	at	5	U/μl	and	filtered	water	to	a	final	volume	of	20	μl	(4.8	μl).	Cycling	conditions	were	initial	denaturation	of	94°C	for	3	minutes	followed	by	a	touchdown	annealing	stage	(10	cycles	of	94	°C	for	30	seconds,	65	°C	decreasing	by	1	°C	every	cycle	for	30	seconds,	and	72	°C	for	1	minute),	followed	by	30	cycles	of	94	°C	30	seconds,	55	°C	for	30	seconds	and	72	°C	for	1	minute.	The	last	cycle	was	followed	by	a	10	minute	extension	at	72	°C.	
2.5.2.1 Data	Interpretation	A	sample	was	considered	to	have	intact	HPV	when	all	fragments	of	the	E1	and	E2	gene	were	present.	If	one	or	more	fragments	were	absent,	the	sample	was	considered	disrupted	(and	therefore	likely	to	have	HPV	integration).	A	significant	limitation	of	this	assay	is	its	inability	to	identify	those	samples	with	‘mixed’	HPV	infection	i.e.	those	cases	whereby	HPV	is	present	in	both	episomal	and	integrated	form	in	which	case	the	more	abundant	HPV	form	would	be	represented	by	the	assay.	An	additional	limitation	of	this	assay	is	its	inability	to	detect	the	presence	of	viral	disruption	in	regions	of	the	virus	other	than	E1	and	
E2.	
2.5.2.2 Quality	Assurance	For	the	E1	tiling	PCR	61%	of	baseline	RT3	VIN	samples	were	run	in	duplicate	at	separate	points	in	time	with	93.8%	concordance.	30%	of	all	E2	fragments	were	repeated	with	the	following	concordance:	E2-1	fragment	95.1%,	E2-2	fragment	95.1%,	E2-3	fragment	92.6%,	
E2-4	fragment	95.1%	and	E2-5	fragment	94.8%.	Where	there	was	a	discrepancy	between	repeats,	the	result	from	the	first	run	was	used	(due	to	the	potential	impact	of	time	and	multiple	freeze-thaw	cycles	on	the	DNA).	Positive	(CaSki)	and	negative	(H2O)	controls	were	included	in	each	run.	Runs	were	only	analysed	if	the	controls	gave	appropriate	results.						
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Table	2-1	PCR	primers	used	for	HPV	detection	assays	
	Note:	all	primer	sequences	are	given	in	5’-3’	orientation.		
2.6 HPV	DNA	Methylation	Analysis	Bisulfite	conversion	of	HPV	DNA	followed	by	PCR	and	pyrosequencing	was	used	for	the	analysis	of	HPV	DNA	methylation.	Bisulfite	conversion	is	widely	used	for	methylation	
!
Primer&Type& HPV&16&E6&Primer&sequence& Product&size&HPV!16!E6!Forward!primer!HPV!16!E6!Reverse!primer! GAACAGCAATACAACAAACC!GATCTGCAACAAGACATACA! ! 161!bp!
Primer&Type& HPV&16&E7&Primers&sequence& Product&size&HPV!16!E7!forward!primer&HPV!16!E7!reverse!primer!
&
GATGAAATAGATGGTCCAGC&GCTTTGTACGCACAACCGAAGC& !100bp!HPV!18!E7!forward!primer&HPV!18!E7!reverse!primer& AAGAAAACGATGAAATAGATGGA!GGCTTCACACTTACAACACA! !!100!bp!!HPV!31!E7!forward!primer!HPV!31!E7$reverse!primer! GGGCTCATTTGGAATCGTGTG!AACCATTGCATCCCGTCCCC!! !100!bp!HPV!33!E7!forward!primer!HPV!33!E7!reverse!primer! TGAGGATGAAGGCTTGGACC!TGACACATAAACGAACTGTG!! !100!bp!HPV!35!E7!forward!primer!HPV!35!E7!reverse!primer! CTATTGACGGTCCAGCT!TACACACAGACGTAGTGTCG!! !100!bp!HPV!51!E7!forward!primer!HPV!51!E7!reverse!primer! TACGTGTTACAGAATTGAAG!AACCAGGCTTAGTTCGCCCATT!! !100!bp!
Primer&Type! HPV&16&E2&Primers&sequence Product&size!HPV!16!E2>1!forward!HPV!16!E2>1!reverse! AGGACGTGGTCCAGATTAAG!TCAAACTGCACTTCCACTGT! !418!bp!HPV!16!E2>2!forward!HPV!16!E2>2!reverse! TAACTGCACCAACAGGATGT!GCCAAGTGCTGCCTAATAAT!! !340!bp!HPV!16!E2>3!forward!HPV!16!E2>3!reverse! ATCTGTGTTTAGCAGCAACG!TAAATGCAGTGAGGATTGGA!! !223!bp!HPV!16!E2>4!forward!HPV!16!E2>4!reverse! ACAGTGCTCCAATCCTCACT!TCACGTTGCCATTCACTATC!! !243!bp!HPV!16!E2>5!forward!HPV!16!E2>5!reverse! GGCATTGGACAGGACATAAT!CAAAAGCACACAAAGCAAAG!! !206!bp!
Primer&Type! HPV&16&E1&Primers&sequence Product&size!HPV!16!E1>1!forward!HPV!16!E1>1!reverse! CTAGGAATTGTGTGCCCATCTG!CTTTCTATCCATTCTGGCGTGTCT!! !1069!bp!HPV!16!E1>2!forward!HPV!16!E1>2!reverse! GATAGAGCCTCCAAAATTGCGT!ACGTTGGCAAAGAGTCTCCATC!! !995!bp!
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analysis	and	relies	on	the	ability	of	sodium	bisulfite	to	deaminate	unmethylated	cytosines	to	produce	uracil	whilst	leaving	methylated	cytosines	unchanged	(Figure	2.3).	In	subsequent	PCR	amplification,	ATP	is	incorporated	opposite	the	uracil	base.	Sequencing	of	the	PCR	product	then	allows	differentiation	between	products	derived	from	templates	containing	the	original	methylated	and	unmethylated	cytosines.			
		
	
	
	
	
	
	
	
	
	
	
Figure	2.3	Bisulfite	conversion.	'A'	shows	the	result	of	sodium	bisulfite	conversion	of	unmethylated	cytosine	to	uracil	through	deamination	and	'B'	illustrates	maintenance	of	cytosine	due	to	methylation			Bisulfite	conversion	and	PCR	were	followed	by	pyrosequencing	(Figure	2.4).	Pyrosequencing	involves	the	photon-based	detection	of	released	inorganic	phosphate	(PPi)	during	nucleotide	incorporation.	This	method	was	chosen	because	it	allows	for	quantitative	analysis	of	the	methylation	status	of	multiple	CpG	sites	within	relatively	short	reads.	Initially,	the	DNA	segment	is	amplified	by	PCR	using	a	biotinylated	primer.	The	biotinylated	strand	is	then	isolated	and	hybridized	with	the	sequencing	primer.	The	hybridized	primer	is	then	incubated	with	DNA	polymerase,	ATP	sulfurylase,	luciferase	and	apyrase	and	the	substrates	adenosine	5’phosphosulphate(APS)	and	luciferin.	As	the	dNTPs	are	added	to	the	reaction,	incorporation	is	catalaysed	by	DNA	polymerase	(if	complimentary	to	the	base	template),	which,	is	accompanied	by	the	release	of	pyrophosphate	(PPi)	in	a	quantity	that	is	equimolar	to	the	amount	of	incorporated	
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nucleotide.	The	ATP	sulfurylase	then	converts	the	PPi	to	ATP	in	the	presence	of	APS,	which	then	drives	the	luciferase-mediated	conversion	of	luciferin	to	oxyluciferin,	which	generates	visible	light	proportional	to	the	amount	of	ATP.		 										The	light	produced	is	detected	by	a	charged	couples	device	(CCD)	camera	and	is	seen	as	a	peak	in	the	raw	data	output,	the	height	of	which	is	proportional	to	the	number	of	nucleotides	incorporated.	The	purpose	of	the	apyrase	in	the	reaction	is	to	degrade	unincorporated	nucleotides	and	ATP	prior	to	the	addition	of	another	nucleotide.	
2.6.1 Bisulfite	Conversion	The	EZ	DNA	Methylation	Kit	(Zymo	Research	Corporation,	CA,	USA)	was	used	for	sodium	bisulfite	conversion.	Kit	reagents	were	prepared	according	to	manufacturer’s	instructions.	Briefly,	500	ng	of	DNA	was	made	up	to	a	final	volume	of	32.5	μl	with	distilled	H2O.	M-dilution	Buffer	(7.5	μl)	was	added	to	each	reaction	and	then	incubated	at	42	°C	for	30	minutes.	97.5	μl	of	pre-prepared	CT	Conversion	Reagent	was	added	to	each	reaction	and	incubated	overnight	at	50	°C	(12-16	hours).	Negative	controls	were	included	in	each	bisulfite	treatment	stage	whereby	the	CT	conversion	reagent	was	replaced	with	sterile	H2O.	Samples	were	then	cooled	on	ice	for	10	minutes	and	loaded	into	Zymo-Spin	columns	containing	400	μl	of	M-Binding	Buffer,	mixed	by	inversion	and	centrifuged	at	13,000	rpm	for	30	seconds.	Two	consecutive	wash	steps	were	undertaken	where	100	μl	of	M-Wash	
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Figure	2-4	Schematic	representation	of	pyrosequencing	reaction.	APS=5'phosphosulphate,	ATP=Adenosine	triphosphate,	PPi=inorganic	pyrophosphate,	dNTP=Deoxynucleotide	triphosphate.	
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Buffer	was	added	to	each	column	and	centrifuged	in	the	same	manner	described	previously.	DNA	was	eluted	into	10	μl	of	M-Elution	Buffer.		
2.6.2 PCR	The	bisulfite	converted	sample	DNA	was	diluted	1:10;	CaSki	HPV	positive	cell	line	DNA	was	used	as	a	positive	control	for	the	PCR	and	was	diluted	1:100;	molecular	grade	water	(Sigma)	was	used	as	a	negative.	ZymoTaq	hot	start	DNA	polymerase	premix	was	used	for	the	PCR	reaction	(Zymo	Research	Corporation,	CA,	USA).	Three	PCR	primers	were	used;	two	(E2	and	L1/L2)	targeting	viral	genes	and	one	targeting	the	promoter	region	of	the	virus.	Mastermixes	and	PCR	conditions	are	shown	in	Table	2.2	and	Table	2.3).																		
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Table	2-2	Mastermix	setup	for	Pyrosequencing	PC	 	 		 					
	
	
Table	2-3	PCR	Thermocycling	conditions	for	pyrosequencing	PCR	 												
	 Temp	(˚C)	 Time	(secs)	 Cycles	
Initial	Denaturation	 95	 600	 1	
Denaturation	 95	 30	 		40		
Primer	Annealing	
48	(E2)	 	45	54	(L1/L2)	51	(Promoter)	
Extension	 72	 30	
Final	Extension	 72	 600	 1	
	 Primer	
E2	 L1/L2	 Promoter	
Reagent	 Concentration	 Volume	required	for	1	x	50	µl						
reaction	(µl)	Zymotaq	premix	 -	 25	 25	 25	Forward	primer	 5	µM	 2	 2	 2	Reverse	primer	 5	µM	 2	 2	 2	H2O	 -	 17	 16	 16		MgCl2	 25	mM	 2	 3	 3	Template	DNA	 -	 2	 2	 2	
Chapter	2	 	 HPV	biology	in	VIN	3		
	HPV	Biology	in	VIN:	Viral	Biomarkers	to	Predict	Response	to	Treatment			 68	
2.6.3 Pyrosequencing	Reaction	The	majority	of	equipment	and	reagents	required	for	pyrosequencing	were	supplied	by	Qiagen	(Qiagen,	Hilden,	Germany)	including	the:	
• PyroMark	Q96	ID	instrument	
• PyroMark	CpG	Software	v1.0.11	
• PSQ96	Reagent	cartridges	
• PSQ	Reaction	plates	
• PyroMark	Vacuum	Prep	Workstation	
• PyroMark	Gold	Q96	Reagents	
• PyroMark	Buffer	solutions.	The	streptavidin	Sepharose	beads	were	supplied	by	GE	Healthcare	Life	Sciences	(Buckinghamshire,	UK).	PCR	products	were	diluted	by	adding	13	μl	of	water	to	27	μl	of	PCR	product.	The	PyroMark	Vacuum	Prep	Workstation	was	prepared	by	filling	the	4	trays	with	the	appropriate	solution	(tray	1	=	70%	ethanol,	tray	2	=	denaturation	buffer,	tray	3	=	1:10	diluted	wash	buffer	and	tray	4	=	de-ionised	water).	Pyrosequencing	was	performed	using	a	biotin	labelled	primer.	PCR	products	were	initially	immobilised	by	adding	1.75	μl	of	streptavidin	sepharose	bead	suspension	and	38.25	μl	of	PyroMark	Binding	buffer	to	each	reaction.	The	samples	were	then	placed	on	a	heated	shaking	plate	for	5	minutes	at	22	°C	(1,400	rpm).	Sequencing	primers	were	made	up	by	diluting	1.5	μl	of	10	μM	sequencing	primer	with	43.5	μl	of	PyroMark	Annealing	Buffer	per	reaction.	This	was	then	dispensed	into	each	well	of	a	PSQ	reaction	plate,	which	was	in	turn	placed	on	the	‘PSQ	plate’	compartment	on	the	workstation.	The	PCR	product	was	removed	from	the	shaking	plate	and	placed	on	the	‘PCR	plate’	compartment	of	the	workstation.	The	vacuum	tool	was	activated	within	30	seconds	of	the	PCR	product	being	removed	from	the	shaking	plate	and	used	to	capture	the	PCR	products	(immobilised	with	sepharose	beads)	by	lowering	it	into	the	PCR	plate.		The	vacuum	tool	was	then	placed	into	each	of	the	trays	in	the	correct	order	for	5	seconds	(tray	1-4).	Finally	the	vacuum	switch	was	closed	and	the	tool	lowered	into	the	PSQ	reaction	plate	(containing	the	sequencing	primer)	and	agitated	in	order	to	release	the	captured	PCR	products.	The	result	of	these	steps	was	denatured,	single	stranded	PCR	products.	The	PSQ	plate,	containing	the	beads	and	sequencing	primers,	was	heated	at	80	°C	for	2	minutes	and	then	cooled	to	room	temperature.	Enzyme	and	substrate	from	the	PyroMark	Gold	Q96	Reagent	kit	were	reconstituted	with	the	manufacturer’s	specified	volume	of	water	10	minutes	prior	to	use.	The	PSQ96	Reagent	
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Cartridge	was	loaded	using	the	volumes	specified	by	the	pyrosequencing	software	taking	care	to	ensure	the	appropriate	solution	went	into	the	appropriate	well.	The	cartridge	was	then	loaded	into	the	PyroMark	Q96	ID	instrument	and	the	run	was	initiated.	The	software	analysed	the	data	on	run	completion,	automatically	generating	a	pyrogram	for	each	pyrosequencing	reaction.	Following	run	completion,	the	workstation,	vacuum	tool	and	cartridge	were	cleaned	as	per	the	manufacturer’s	guidelines.	
2.6.4 Primer	Sequences	For	each	pyrosequencing	assay,	the	primer	sequences,	regions	amplified	and	dispensation	order	for	sequencing	are	listed	in	Table	2.4.
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Table	2-4	Primer	sequences,	regions	amplified	and	CpGs	sequenced	for	the	pyrosequencing	
assays.	
	
E2	
Forward	primer	 GTGAAATTATTAGGTAGTATTTGG	 
Reverse	primer	 *BTN-CAACAACTTAATAATATAACAAAAA	 
Sequencing	primer	 GTGAAATTATTAGGTAGTA 
Dispensation	order	 ATTGCTATGATTCTGTCAGTCGATTATATAATGTCAGTCGTTTGGTGATCGAGAA	
TATAGTATCGATATTATGTCGA 
Amplified	DNA	 148	bp	(nt	3378-3525	of	**NC001526.1)	 
Sequenced	CpGs	 ***nt	3411,	3414,	3416,	3432,	3435,	3447	(targeting	E2	binding	sites	3	and	4) 
Reference	 Dr	T	Liloglou,	University	of	Liverpool,	personal	communication	(Dec	7th	2010) 
Promoter	
Forward	primer	 GTAAAATTGTATATGGGTGT	 
Reverse	primer	 BTN-TAAAATATCTACTTTTATACTAACC	 
Sequencing	primer	 TAATTTATGTATAAAATTAAGG	 
Dispensation	order	 AGTCGTCGATCGTAATCGTGTATCGTAATCGTA	 
Amplified	DNA	 156	bp	(nt	7832-83	of	NC001526.1)	 
Sequenced	CpGs	 nt	31,	37,	43,	52,	58	 
Reference	 Dr	T	Liloglou,	University	of	Liverpool,	personal	communication	(Dec	7th	2010)	 
	 L1/L2	
Forward	primer	 BTN-TTATTGTTGATGTAGGTGATTT		
Reverse	primer	 CCCAATAACCTCACTAAACAACC		
Sequencing	primer	 TAACCTCACTAAACAACCAA		
Dispensation	order	 GCAAAAACAATCTAAAAAAATGATAATAAATCGATTATCGATACGATTTACGATAC		
Amplified	DNA	 118	bp	(nt	5551-5668	of	NC001526.1)		
Sequenced	CpGs	 nt	5615,	5609,	5606,	5600		
Reference	 (Bryant,	Tristram	et	al.	2014)	
Chapter	2	 	 HPV	biology	in	VIN	3		
	HPV	Biology	in	VIN:	Viral	Biomarkers	to	Predict	Response	to	Treatment			 71	
*BTN	refers	to	the	position	of	a	biotin	label.	**NC001526.1	is	the	HPV	16	reference	sequence.	The	dispensation	order	is	the	order	in	which,	nucleotides	were	dispensed.	***nt	=	nucleotide.	Primer	sequences	are	listed	in	5’-3’	orientation.	All	primers	used	were	HPLC	purified.	
2.6.5 Data	Analysis	and	Quality	Assurance	Each	sample	was	repeated	in	duplicate	within	a	run	in	order	to	improve	data	reliability	and	to	achieve	a	‘pass’	result	for	as	many	samples	as	possible.	The	pyrosequencing	software	runs	internal	control	checks	and	the	output	report	defines	each	sample	run	as	either	a	‘pass’	(blue),	a	‘check’	(yellow)	requiring	human	analysis	in	order	to	determine	acceptability	of	data,	or	‘fail’	(red).	All	failed	runs	were	excluded	from	analyses.	‘Check’	runs	were	included	following	manual	analysis	if	the	generated	histogram	matched	the	expected	pre-defined	histogram.		A	standard	deviation	was	calculated	for	each	sample	with	duplicate	runs	for	each	CpG	site	analysed.	This	data	was	used	to	demonstrate	the	intra-run	reproducibility	of	the	assay	and	also	to	further	improve	the	quality	of	the	data;	samples	were	excluded	from	further	analysis	if	this	value	was	beyond	3	standard	deviations	of	the	mean	standard	deviation	calculated	for	all	CpG	sites	for	each	region	(Table	2.5).		
Table	2-5	Quality	control	analysis	for	methylation	data.	
		
2.7 Quantitative	Real-Time	Reverse	Transcriptase	PCR	(qRT-PCR)	Quantitative	real-time,	reverse	transcriptase	PCR	was	used	for	gene	expression	analysis.	Two	human	genes,	HPRT	and	TBP	and	five	HPV	genes,	E2,	E4,	E5E6	and	E7,	were	assessed	
Mean%SD%for%each%CpG%site SD%of%the%mean
E2#CpG1 1.56 1.71
E2#CpG2 0.84 1.15
E2#CpG3 0.92 1.03
E2#CpG4 1.06 1.17
E2#CpG5 1.09 1.39
E2#CpG6 1.37 1.9
L1L2#CpG1 1.39 1.98
L1L2#CpG2 2.49 7.44
L1L2#CpG3 2.04 3.15
L1L2#CpG4 1.56 2.28
Promoter#CpG1 0.32 0.72
Promoter#CpG2 0.37 0.79
Promoter#CpG3 0.51 1.03
Promoter#CpG4 0.64 0.87
Promoter#CpG5 0.43 1.27
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in	all	RT3	VIN	baseline	samples.	The	HPV	genes	were	selected	based	on	their	role	in	the	pathogenesis	of	HPV	associated	disease	and	their	role	as	potential	biomarkers	in	treatment	with	the	trial	medications	(cidofovir	and	imiquimod).		
2.7.1 Reverse	Transcription	(cDNA	Synthesis)	Reverse	transcription	was	performed	using	random	primers,	and	the	SuperScript®	III	Reverse	Transcriptase	(RT)	kit	(Invitrogen,	Paisley,	UK).	Reagents	for	the	first	stage	of	the	RT	reaction	included	1	μl	of	random	primers	at	200	ng/μl,	1	μl	of	dNTP’s	at	10	mM,	0.5	μg	of	RNA	(DNase	treated)	and	RNase	free	water	to	make	up	the	final	volume	of	13	μl.	The	mix	was	incubated	at	65	°C	for	5	minutes	and	then	kept	on	ice	for	at	least	1	minute.	This	was	followed	by	the	addition	of	1	μl	of	Dithiothreitol	(DTT)	at	0.1M,	4	μl	of	FS	buffer	at	5	x	concentration,	1	μl	of	RNase	OUT	and	1	μl	SuperScript®	III	RT	(1	μl)	to	the	mixture	and	mixed	by	repeat	pipetting	to	complete	the	RT	reaction.	The	mixture	was	incubated	at	25	°C	for	5	minutes,	50	°C	for	60	minutes	and	then	inactivated	at	70	°C	for	15	minutes.	In	order	to	assess	amplification	due	to	undigested	genomic	DNA,	which	could	affect	the	accuracy	of	results	later	in	the	experiment,	all	reaction	were	performed	in	triplicate,	2	reactions	with	complete	RT	reaction	and	1	reaction	in	which	the	SuperScript®	III	RT	was	replaced	by	H2O.	
2.7.2 Quantitative	Real	Time	Reverse	Transcriptase	(qRT-PCR)	Reaction	Protocol	qRT-PCR	was	performed	using	the	LightCycler	carousel-based	qPCR	system,	LightCycler®	DNA	Master	SYBR	Green	I	reagent	kits	and	LightCycler®	reaction	capillary	tubes	(Roche	Applied	Science,	Mannheim,	Germany).	Initially	the	FS	mix	was	made	by	adding	10	μl	of	reagent	1a	to	a	full	vial	of	defrosted	reagent	1b	(kept	at	4	°C	and	never	re-frozen).	Primer	sequences	are	described	in	Table	2.6.	The	qRT-PCR	mastermixes	(Table	2.7)	were	prepared	in	a	cooling	block.	18	μl	of	the	mastermix	was	then	dispensed	into	the	appropriate	number	of	glass	capillary	tubes	and	2	μl	of	the	appropriate	cDNA	added.	The	capillaries	were	briefly	centrifuged	(2,000	rpm	for	5	seconds)	to	ensure	the	sample	was	collected	in	the	stem	of	the	tube.	Each	run	included	a	water	negative	control	and	a	triplicate	repeat	of	1:100	diluted	CaSki	cDNA.	RT	negative	controls	were	included	for	each	sample.	Capillaries	were	loaded	into	the	LightCycler®	and	subjected	to	the	appropriate	reaction	conditions,	the	conditions	differed	in	terms	of	the	primer	annealing	temperature	for	each	primer	set	but	otherwise	were	constant	(Table	2.8).	
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Table	2-6	D
escription	of	prim
ers	used	for	RT-qPCR	
bp	=	base	pair,	nt	=	nucleotide,	NC001526.1	–	HPV	16	genbank	reference	sequence.	
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Table	2-7	qRT-PCR	mastermixes		
	
	
	
	
	
	
	
	
	
	
	
Table	2-8	PCR	Thermocycling	conditions	used	for	qRTPCR		
	
	
	 	 Volume	per	Primer	Pair	(μl)	
Reagent	 Concentration	 HPV	
E2/E6/E4	
HPRT	
HPV	E5	 HPV	E7	 TBP	
Forward	Primer	 5	μM	 2	 2	 2	 2	
Reverse	Primer	 5	μM	 2	 2	 2	 2	
FS	Mix	 -	 2	 2	 2	 2	
MgCl2	 25mM	 1.6	 1.2	 2	 2.4	
Water	 -	 10.4	 10.8	 10	 9.6	
Template	cDNA	
(1:10	dilution	cDNA,	1:100	
dilution	for	Caski	positive	
control	cDNA)	
2	 2	 2	 2	
	 Temp	(°C)	 Time	(secs)	 Cycles	
Initial	Denaturation	 95	 600	 1	
Denaturation	 95	 10	
60	
Primer	Annealing	
58	(E2,E4)	
60	(E5,	E6,	HPRT,	TBP)	
62	(E7)	
	
	
	
	
60	(E6/HPRT/TBP2)	
62	(E7)	
5	
Extension	 72	 5	
	 Temp	(°C)	 Rate	of	Change	(°C/sec)	 Cycles	
Melting	Curve	 65-95	 0.1	 1	
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2.7.3 Data	Analysis	and	Quality	Assurance	CT	(threshold	cycle)	values	were	exported	from	the	LightCycler	software.	All	data	analysis	was	done	using	qBase+	software	(Biogazelle	NV,	Zwijnaarde,	Belgium)	and	expression	levels	were	calculated	relative	to	the	average	for	the	specific	gene	in	question	across	the	entire	cohort.	Samples	were	excluded	from	analysis	if	they	generated	a	non-specific	PCR	product	or	if	the	crossing	point	threshold	of	the	RT	negative	control	was	within	5	points	of	the	RT	positive	reaction.	Relative	quantification	was	performed	using	the	two	human	reference	genes	(HPRT	and	TBP)	using	the	PCR	efficiency	corrected	equation	described	by	Vandesompele	et	al.	2002.		Crossing	point	values	for	E2	and	E6	expression	for	each	sample	were	used	to	calculate	the	
E2:E6	expression	ratio.	This	ratio	was	then	utilised	in	an	exploratory	capacity	to	represent	cases	with	regulated	(E2>E6)	expression	and	deregulated	(E6>E2)	expression.	This	was	done	on	the	basis	that	expression	of	E6	in	the	cohort	studied	was	relatively	constant	but	the	expression	of	E2	varied	significantly.	With	the	understanding	that	E2	regulates	the	expression	of	E6,	relatively	low	or	absent	E2	expression	could	represent	deregulated	oncogene	expression	and	relatively	high	E2	expression	could	represent	regulated	oncogene	expression.		The	qBase+	software	incorporates	internal	quality	controls,	which	were	strictly	adhered	to.	To	further	improve	data	reliability	all	RT	positive	reactions	were	repeated	in	duplicate	within	a	run.	All	samples	that	generated	data	indicative	of	inadequate	RT	reaction	were	excluded	from	analysis.						
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Chapter	3	
	Results		RT3	VIN	(A	Randomised	Trial	into	Topical	Treatment	of	Vulval	Intraepithelial	Neoplasia)
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3 RT3	VIN–	A	randomised	Trial	of	Topical	Treatment	in	Vulval	Intraepithelial	Neoplasia	
3.1 Introduction	
This	chapter	details	the	methods	and	clinical	results	from	the	phase	II	clinical	trial	that	the	work	described	in	this	thesis	contributed	to.	The	RT3	VIN	trial	(Tristram	et	al,	2014),	aimed	to	investigate	the	safety	and	efficacy	of	topical	treatment	of	VIN	with	cidofovir	and	imiquimod	(Appendix2).	This	trial	was	funded	by	Cancer	Research	UK	(CRUK/06/024).	All	patients	provided	written	informed	consent	prior	to	randomization.		Appropriate	regulatory	approvals	were	obtained	from	the	UK	Medicines	and	Healthcare	products	Regulatory	Agency	(21323/0020/001-0001),	the	Office	for	Research	Ethics	Committees	Northern	Ireland	(08/NIR03/82)	and	NHS	Research	and	Development	departments	at	participating	sites.	The	RT3VIN	trial	was	sponsored	by	Cardiff	University	and	coordinated	by	the	Wales	Cancer	Trials	Unit	(WCTU)	at	Cardiff	University.	This	trial	is	registered	with	International	Standard	Randomized	Controlled	Trial	Number	34420460. I	was	a	member	of	the	trial	management	group,	and	contributed	to	patient	recruitment	and	follow-up	.The	work	described	in	this	thesis	comprised	the	majority	of	the	HPV	testing	and	analysis	conducted	for	the	trial.	The	clinical	trial	design	and	methods	are	first	outlined	followed	by	the	results.	Specifically,	this	chapter	describes	response	rates	to	treatment	with	both	cidofovir	and	imiquimod	and	the	relevant	safety	data.	It	also	details	correlations	between	clinical	outcome	and	certain	characteristics	of	the	patient	and	disease,	performed	to	determine	whether	they	demonstrate	potential	as	clinical	markers	to	predict	response	to	treatment.	Results	of	the	HPV	testing	in	relation	to	clinical	outcome	are	discussed	in	later	chapters.	
3.2 Methods	
3.2.1 Trial	Design	To	assess	the	activity,	safety	and	feasibility	of	treatment	of	VIN	3	with	topical	cidofovir	and	5%	 concentration	 imiquimod,	 a	 phase	 II	 randomised	 controlled	 trial	was	 designed.	 UK-wide,	 multi-centre	 recruitment	 was	 established	 and	 in	 total,	 32	 centres	 were	 involved.	Ethical	 approval	 was	 obtained	 from	 the	 Research	 Ethics	 Committees	 Northern	 Ireland	(08/NIR03/82).	 Regulatory	 approval	 was	 also	 obtained	 from	 the	 Medicines	 and	Healthcare	 Products	 Regulatory	 Agency	 (MHRA)	 under	 the	 Medicines	 for	 Human	 Use	(Clinical	 Trials)	 Regulations	 2004	 S.I	 2004/1031	 (reference	 number	 21323/0020/001-
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0001).	 	 Approval	 was	 also	 obtained	 from	 Research	 and	 Development	 at	 each	 of	 the	 32	participating	 hospitals.	 	 The	 RT3VIN	 trial	 was	 sponsored	 by	 Cardiff	 University	 and	 co-ordinated	 by	 the	Wales	 Cancer	 Trials	 Unit	 (WCTU)	 at	 Cardiff	 University.	 This	 trial	 was	registered	with	International	Standard	Randomised	Controlled	Trial	Number	34420460.	The	primary	endpoint	for	the	trial	was	histologically	confirmed	complete	response	by	6	weeks	from	termination	of	treatment.	Secondary	endpoints	included	treatment	toxicity	as	well	as	treatment	compliance.	
3.2.2 Patient	Recruitment	and	Randomisation	All	patients	were	required	to	provide	informed	consent	in	order	to	participate	in	the	trial.	
Table	3-1	describes	the	criteria	used	for	patient	inclusion	and	exclusion.	The	WCTU	carried	out	randomisation.	Patients	were	allocated	to	a	treatment	arm	at	a	1:1	ratio	and	stratified	by	hospital,	unifocal	or	multi-focal	disease	and	first-episode	or	recurrent	disease.	
3.2.3 Trial	Schema	Once	written	consent	was	obtained	and	eligibility	criteria	checked,	a	series	of	baseline	assessments	were	conducted	prior	to	the	commencement	of	treatment	including	a	medical	history,	assessment	of	toxicities,	clinical	assessment	of	lesions	and	urinanalysis	to	check	kidney	function.	Urinanalysis	was	undertaken	due	to	the	potential	nephrotoxicity	of	cidofovir.	A	4mm	punch	biopsy	stored	in	ThinPrep	media	for	HPV	testing	was	also	taken.	Patients	then	commenced	a	course	of	treatment	with	the	assigned	trial	medication	for	a	maximum	of	24	weeks.	Patients	were	seen	every	6	weeks	during	treatment	at	which	time	treatment	concordance	was	checked,	clinical	assessment	of	lesions	was	performed,	toxicities	were	assessed,	and	urinanalysis	was	undertaken.	Six	weeks	after	completion	of	treatment,	another	two	4mm	punch	biopsies	were	taken,	one	for	histology	and	one	for	HPV	testing,	clinical	assessment	of	the	lesions,	kidney	function	tests,	haemoglobin	and	white	blood	cell	count	tests	were	also	performed.	Patients	who	showed	a	complete	response	to	their	originally	allocated	treatment	were	then	assessed	at	6	monthly	intervals	for	a	further	2	years,	at	which	time	assessment	of	toxicities,	clinical	examination	+/-	biopsy	took	place	(Figure	3.1).	All	histology	samples	were	examined	and	reported	on	by	the	histopathology	department	at	the	relevant	participating	site	for	each	patient.				
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Table	3-1	RT3	VIN	inclusion/exclusion	criteria	
	
Inclusion	Criteria	 Exclusion	Criteria	
• Female	>16	years		
• Biopsy	proven	VIN	3	(including	visible	peri-anal	disease	not	extending	into	the	anal	canal),	biopsy	to	have	been	taken	within	the	previous	three	months		
• At	least	one	lesion	that	could	be	accurately	measured	(using	RECIST	criteria)	in	at	least	one	dimension	with	longest	diameter	≥	20mm	or	two	perpendicular	dimension	that	when	multiplied	together	came	to	greater	than	120mm2		
• Using	a	reliable	method	of	contraception	if	of	childbearing	age	(excluding	condoms)		
• Written	informed	consent	to	participate	in	trial	(Participant	Information	Sheet	and	Consent	Form	2)	
• Any	patient	with	impaired	renal	function	(defined	as	serum	creatinine>	133	μmol/l	or	>	1.5	mg/dl)		
• Any	patient	with	current	anogenital	carcinoma	or	any	patient	who,	in	the	PIs	opinion,	is	at	a	high	risk	of	developing	invasive	disease	(patients	in	whom	invasive	disease	or	micro-invasive	disease	is	suspected	should	have	adequate	biopsies	to	exclude	this	prior	to	entry)		
• Pregnant,	breast	feeding	or	trying	to	conceive		
• Active	treatment	for	VIN	within	the	previous	four	weeks		
• Known	allergy	to	either	of	the	topical	treatments	or	any	components	in	either	the	imiquimod	or	cidofovir	gel		
• Unable	to	comply	with	protocol	treatment		
• Previous	failure	of	imiquimod	or	cidofovir	following	treatment	three	times	a	week	for	a	minimum	of	12	weeks.	
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Figure	3.1	RT3	VIN	trial	schema
Biopsy proven VIN 3
•  Trial eligibility
•  Consent
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3.2.4 HPV	Biopsies	Biopsies	for	HPV	testing	were	taken	before	the	start	of	treatment	and	6	weeks	following	cessation	of	treatment.	In	some	cases,	patients	consented	to	have	an	additional	biopsy	taken	at	6	weeks	into	the	course	of	treatment	for	translational	research.	The	4mm	punch	biopsies	were	taken	from	the	site	of	disease	adjacent	to	the	biopsy	taken	for	histology	and,	in	the	majority	of	cases	(n=330),	were	placed	into	a	transportation	pot	containing	ThinPrep	media.	Upon	arrival	in	the	laboratory	sample	were	stored	at		-20	°C	prior	to	DNA	and	RNA	extraction.	Extracted	DNA	and	RNA	was	then	stored	at	-20	ready	for	further	testing.	Towards	the	end	of	the	trial	the	sample	collection	protocol	was	amended	and	collection	media	was	changed	to	RNAlater	with	pre	and	post	extraction	storage	at	-80	°C,	four	samples	included	in	this	work	were	subject	to	this	protocol.	
3.3 Results	
180	patients	were	recruited	and	randomised	from	a	total	of	32	UK	based	centres.		
3.3.1 Patient	Demographics	Data	was	collected	from	all	180	cases	for	demographic	analysis	including	age,	smoking	status	and	immunocompromise.		The	mean	age	of	patients	in	this	cohort	was	47.2	years	(range	20-81	years)	(Figure	3.2).		Current	smoking	was	reported	by	106/180	(58.8%)	patients,	42/180	(23.3%)	patients	were	previous	smokers	and	32/180	(17.7%)	had	never	smoked	(Figure	3.3).	A	history	of	immunocompromise	was	recorded	in	9/180,	four	of	these	patients	were	HIV	positive	and	the	five	remaining	patients	had	another	form	of	immunocompromise.		
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Figure	3.2	RT3	VIN	study	cohort	age	distribution	(n=180)	
	
	
	
Figure	3.3	RT3	VIN	study	cohort	smoking	status	(n=180)			
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3.3.2 Clinical	Characteristics	of	VIN	3	Data	was	collected	on	clinical	characteristics	of	the	disease	for	all	180	patients	recruited	and	comprised	unifocal	or	multi-focal	lesions,	first	episode	or	recurrent	episode	and	additional	anogenital	site	(single	site/multiple	site).	Unifocal	disease	was	present	in	89/180	(49.4%)	of	patients;	91/180	(50.6%)	patients	had	multi-focal	disease.	First	presentation	episodes	were	seen	in	98/180	(54.4%)	and	recurrent	presentations	were	seen	in	82/180	(45.6%).		
3.3.3 Response	to	treatment		Of	the	180	patients,	89	were	randomised	to	treatment	with	cidofovir	and	91	patients	were	randomised	to	treatment	with	imiquimod.	Patient	demographic	factors	and	clinical	disease	characteristics	were	equally	distributed	between	the	two	treatment	arms	as	demonstrated	in	Table	3-2.	The	flow	chart	in	Figure	3.5	demonstrates	the	clinical	outcome	of	the	two	arms	of	the	trial.	Clinical	outcome	data	was	available	for	72	patients	treated	with	cidofovir	(three	patients	were	lost	to	follow	up,	12	patients	withdrew	from	the	study	and	no	post-treatment	biopsy	was	available	for	two	patients)	and	69	patients	treated	with	imiquimod	(five	patients	were	lost	to	follow	up,	15	patients	withdrew	from	the	study	and	no	post	treatment	biopsy	was	available	for	two	patients).	In	the	per	protocol	analysis,	a	complete	response	was	reported	in	41	of	72	(56.9%,	90%	CIs:	46.6-66.9)	women	treated	with	cidofovir	and	42	out	of	69	(60.9%,	90%	CIs:	50.3-70.7)	women	treated	with	imiquimod.	Figure	3.4	shows	photographs	of	disease	prior	to	treatment	with	cidofovir	(a),	during	treatment	(B)	and	having	healed	following	treatment	(c).	It	is	of	note	that	a	history	of	smoking	(present	or	previous)	was	reported	by	the	majority	of	patients	participating	in	the	trial	(148/180	82.2%).	This	is	significantly	higher	than	the	17%	average	smoking	rates	for	the	UK,	female	population	reported	for	2014		(www.ash.org.uk).	It	is	likely	that	smoking	plays	a	role	in	the	aetiology	of	VIN.	Data	was	not	collected	on	change	in	smoking	status	over	the	course	of	the	trial	to	correlate	with	response/resolution	of	VIN.	This	would	be	a	worthy	line	of	investigation	in	the	future.					
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	A	
	B	
	C	
Figure	3.4	Photographic	images	of	treatment	with	cidofovir.	A	=	VIN	prior	to	treatment,	B	=	disease	during	treatment,	C	=	healed	tissue	(disease-free)	following	treatment.		
Chapter	3	 	 RT3	VIN		
	HPV	Biology	in	VIN:	Viral	Biomarkers	to	Predict	Response	to	Treatment			 85	
		
	Table	3-2	Baseline	characteristics	by	treatment	arm	in	RT3	VIN		
																		 	
Baseline	characteristic	
Cidofovir	Arm	 Imiquimod	Arm	
n=	 %	 n=	 %	
No.	Patients	 89	 49.4	 91	 50.6	
Median	age	(range)	in	years	 48	(26-74)	 46	(20-81)	
Focality	 								Unifocal	
Multifocal	
44	
45	
49.4	
50.6	
45	
46	
49.5	
50.5	
Recurrent	disease	 Yes	
No	
42	
47	
47.2	
52.8	
40	
51	
44	
56	
Immunocompromise	 Yes	
No	
3	
86	
3.4	
96.6	
6	
85	
6.6	
93.4	
Smoking	status	 Current	
Previous	
Never	
50	
24	
15	
56.2	
27	
16.9	
56	
18	
17	
61.5	
19.8	
18.7	
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Figure	3.5	Flow	chart	depicting	the	outcome	of	180	patients	recruited	into	the	RT3	VIN	trial	
as	per	protocol	analysis.	Final	analysis	possible	for	72	patients	treated	with	cidofovir	and	for	69	patients	treated	with	imiquimod.	Histological	presence	of	VIN	was	determined	by	a	vulval	punch	biopsy	of	the	previously	affected	area,	6	weeks	following	the	termination	of	treatment.								
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3.3.4 Clinical	markers	predictive	of	response	Relationships	were	investigated	between	clinical	characteristics	and	response	to	treatment	to	determine	if	a	correlation	was	present	indicating	the	potential	of	a	clinical	measure	as	a	predictive	marker	of	response.	No	correlation	was	found	between	focality	of	disease,	episode	type	or	smoking	status	and	response	to	treatment	in	either	treatment	arm	(Table	3.3).	
3.3.5 Adverse	events	Adverse	events	were	recorded	as	per	the	National	Cancer	Institute	Common	Terminology	Criteria	for	Adverse	Events	version	3.0	(NCI	CTCAE	v.3.0).	Overall,	adverse	events	were	commonly	reported	in	both	groups.	Adverse	events	of	grade	2	(moderate)	or	above	were	less	common	in	the	cidofovir	arm	than	the	imiquimod	arm	(72.6%	(61/84)	vs.	86.9%	(73/84)	respectively)	p=0.021.	Within	the	adverse	event	reports,	most	events	were	grade	2.	Grade	3	(severe)	toxicities	were	reported	in	31/84	(36.9%)	of	patients	in	the	cidofovir	arm	and	39.84	(46.4%)	in	the	imiquimod	arm.	There	were	no	deaths	during	the	course	of	the	trial.	
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Table	3-3	Clinical	characteristics	and	smoking	status	correlation	with	treatment	outcome		
								
	 Cidofovir	arm	 Imiquimod	arm	
n	(%)	 n	(%)	
Patients	randomised	 89	 91	
Per	protocol	population	 72	(80.9)	 69	(75.8)	
Unifocal/multifocal	 VIN	absent	
(n)	
VIN	present	
(n)	
p-value	 VIN	absent	
(n)	
VIN	present	
(n)	
p-value	
Unifocal	
Multifocal	
24	
17	
13	
18	
0.163	
Χ2=1.95	
20	
22	
13	
14	
0.966	
Χ2=0.00	
First/recurrent	disease	 VIN	absent	
(n)	
VIN	present	
(n)	
p-value	 VIN	absent	
(n)	
VIN	present	
(n)	
p-value	
First	
Recurrent	
22	
19	
17	
14	
0.921	
Χ2=0.01	
24	
18	
13	
14	
0.465	
Χ2=0.53	
Smoking	status	 VIN	absent	
(n)	
VIN	present	
(n)	
p-value	 VIN	absent	
(n)	
VIN	present	
(n)	
p-value	
Current	smoker	
Previous	or	non-smoker	
24	
17	
15	
16	
0.392	
Χ2=0.73	
23	
19	
16	
11	
0.713	
Χ2=0.14	
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3.4 Conclusion	
The	clinical	response	data	in	the	RT3	VIN	trial	has	demonstrated	adequate	efficacy	and	safety	of	both	cidofovir	and	imiquimod	as	potential	alternatives	to	surgery	in	women	with	VIN.	This	data	warrants	further	clinical	research	in	the	context	of	a	phase	III	trial.	No	patient	demographic	variable	or	disease	characteristics	demonstrated	roles	as	potential	biomarkers.	The	clinical	response	rates	of	approximately	50%	in	both	of	the	treatment	arms	justifies	further	investigation	of	predictive	biomarkers	in	order	to	better	target	therapy	in	the	future.	Viral	factors	would	be	an	obvious	parameter	for	investigation.						
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4 HPV	biology	in	VIN	3	
4.1 Introduction	
The	aim	of	this	work	was	to	contribute	to	worldwide	research	improving	the	understanding	of	HPV	driven	disease,	aiding	in	the	development	of	health	policies	and	novel	therapies	in	the	future.	A	growing	body	of	research,	investigating	HPV	in	VIN	exists	but	this	study	represents	the	largest,	high-grade	disease,	single-study	cohort	to	date	investigating	multiple	aspects	of	HPV	biology.	The	specific	aims	of	this	chapter	were	to	determine	HPV	genotype	specific	prevalence	in	VIN	3;	to	investigate	viral	characteristics	(gene	expression,	HPV	disruption	and	HPV	methylation)	in	VIN	3;	to	establish	relationships	between	viral	characteristics	and	to	investigate	HPV	methylation	and	integration	as	mechanisms	leading	to	deregulated	oncogene	expression.	Investigation	into	the	biomarker	potential	of	these	viral	characteristics	in	the	treatment	of	VIN	is	presented	in	the	chapter	5.		
4.2 HPV	Prevalence	in	VIN	3	
Two	methodologies	were	chosen	to	investigate	HPV	prevalence	in	VIN	3.	Firstly,	an	HPV	16	type-specific	E6	PCR	(HPV	16	E6	PCR)	was	used	to	identify	cases	of	HPV	16,	as	this	is	well	documented	as	the	most	prevalent	genotype	in	VIN.	In	addition,	the	Greiner	PapilloCheck®	assay	was	used	to	determine	non-HPV	16	genotype	prevalence.	Biopsies	for	analysis	were	from	167	patients	with	histologically	confirmed	VIN	3	participating	in	the	RT3	VIN	clinical	trial,	as	described	in	chapter	3.	HPV	16	was	detected	in	135/167	(80.8%)	cases	using	HPV	16	E6	PCR,	(Figure	4.1	is	an	example	gel	image).	The	PapilloCheck®	assay	identified	an	additional	18	HR	HPV	positive	cases.		HPV	33	was	the	second	most	prevalent	genotype,	detected	in	10/167	cases;	followed	by	HPV	genotypes	18,	44/55	(low	risk)	and	70,	each	detected	in	3/167	cases.	The	majority	of	HPV	positive	cases	contained	a	single	HPV	genotype	124/136	(91.2%)	whereas	multiple	genotypes	were	only	detected	in	12/136	(8.8%)	cases	(11	of	which	included	HPV	16).	The	non-HPV	16-genotype	prevalence	and	distribution	amongst	cases	of	single	and	multiple	genotype	infections	is	shown	in	(Figure	4.2).	There	were	three	cases	(1.8%)	in	the	cohort	that	only	tested	positive	for	a	low-risk	HPV	genotype.	Importantly,	it	was	also	noted	that	HPV	16	was	only	detected	in	110/167	(65.9%)	cases	by	the	PapilloCheck®	assay	(25	cases	less	than	the	HPV	16	E6	PCR).		
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Figure	4.1	HPV	16	E6	PCR	electrophoresis	gel	image.	A	100	bp	ladder	was	used	(centre	of	the	gel).	The	HPV	16	E6	fragment	is	161	bp	N=negative	control	(H2O)	and	P=positive	control	(CaSki).				
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Figure	4.2	Non	HPV	16	genotype	prevalence	in	VIN	3	-	PapilloCheck®	data.	Showing	the	number	of	cases	of	each	genotype	detected	in	a	cohort	of	167	cases	of	histologically	confirmed	VIN	3.	HPV	44/55,	42,	and	6	are	low-risk	genotypes,	all	remaining	genotypes	are	high-risk.	Green	areas	of	columns	represent	genotype	prevalence	in	cases	testing	positive	for	multiple	HPV	genotypes	and	blue	areas	represent	genotype	prevalence	in	cases	testing	positive	for	a	single	genotype.	12	cases	testing	positive	for	multiple	genotypes	were	identified	in	the	cohort,	11	of	which	contained	HPV	16.	Nb	for	HPV	44/55,	the	PapilloCheck®	assay	is	unable	to	differentiate	between	HPV	44	and	HPV	55	therefore	this	result	indicates	the	presence	of	either	genotype.		
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4.2.1 PCR	Target	Region	Disruption	Leads	to	False	Negative	HPV	Results	Comparison	of	the	HPV	16	prevalence	data	generated	by	the	PapilloCheck®	assay	and	the	HPV	16	E6	PCR	highlighted	a	disparity.	The	HPV	16	E6	PCR	detected	25	more	cases	of	HPV	16	than	the	PapilloCheck®	assay.	Quality	assurance	analysis	of	each	assay	revealed	good	reproducibility.	Twenty-five	per	cent	of	cases	were	randomly	selected	for	duplicate	testing	using	the	PapilloCheck®	assay	and	generated	data	that	was	98%	concordant;	and	20%	of	cases	were	randomly	selected	for	the	HPV	16	E6	PCR	generating	100%	concordant	results	(see	methods,	chapter	2).	Additionally,	the	human	ADAT-1	gene	was	successfully	amplified	in	all	cases	(this	provides	a	positive	control	for	DNA	integrity	within	the	PapilloCheck®	assay).	It	was	hypothesised	that	disruption	in	the	HPV	E1	open	reading	frame	(the	PCR	target	region	of	the	PapilloCheck®	assay)	would	be	present	in	the	25	discordant	cases,	confirming	them	to	be	false	negative	results.	A	two-fragment	HPV	16	specific	E1	tiling	PCR	was	designed	to	identify	disruption	in	the	PCR	target	region	and	test	this	hypothesis	(chapter	2).	The	E1	region	was	deemed	intact	if	both	fragments	were	amplified,	and	disrupted	if	one	or	no	fragments	were	amplified.	
4.2.1.1 HPV	16	E1	Tiling	PCR	Data	
E1	disruption	was	detected	in	77/136	(56.6%)	HPV	16	positive	cases	identified	by	PapilloCheck®	and	HPV	16	E6	PCR	combined.	In	all	25	cases	where	HPV	16	was	detected	by	the	type-specific	E6	PCR	but	not	by	the	PapilloCheck®	assay,	disruption	of	the	E1	region	was	present.	This	finding	confirmed	that	disruption	in	the	E1	region	of	the	virus	in	VIN	3	is	a	common	event	and	an	important	cause	of	false	negative	results	from	the	PapilloCheck®	assay.	It	is	notable	that	E1	disruption	did	not	always	prevent	the	PapilloCheck	assay	from	detecting	the	virus.	In	21	cases,	PapilloCheck®	detected	the	presence	of	HPV	16	despite	E1	disruption;	in	20	of	these	cases,	the	HPV	16	E6	PCR	assay	also	generated	a	positive	result	and	in	one	it	generated	a	negative	result	(thought	to	be	a	false	positive	HPV	16	result	from	PapilloCheck®,	discussed	later).	In	all	cases	where	both	PapilloCheck®	and	HPV	16	E6	PCR	were	HPV	16	negative	(n=31),	neither	E1	fragment	was	amplified	(Table	4.1).				
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Table	4–1	E1	disruption	data	in	RT3	VIN	baseline	cohort	
*E1	disruption	was	defined	as	absence	of	one	or	more	fragments	of	the	E1	tiling	PCR;	**E1	intact	defined	as	the	presence	of	both	tiling	fragments	of	E1	tiling	PCR.	
	
	
	
	
	
HPV	16	test	results	 n=	 E1	intact	(%)**	 E1	disrupted	(%)*	
PapilloCheck®	+ve	and	HPV	16	E6	PCR	+ve	 110	 90	(81.8)	 20	(18.2)	
PapilloCheck®	+ve	and	HPV	16	E6	PCR	-ve	 1	 0	 1	(100)	
PapilloCheck®	-ve	and	HPV	16	E6	PCR	+ve	 25	 0	 25	(100)	
PapilloCheck®	-ve	and	HPV	16	E6	PCR	-ve	 31	 0	 31	(100)	
Total	 167	 90	 77	
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4.2.2 Further	analysis	of	HPV	negative	results	Combined	data	generated	from	the	PapilloCheck®	assay	and	the	HPV	16	E6	PCR	gave	an	overall	(all	genotypes)	HPV	prevalence	rate	of	153/167	(91.6%).	Results	of	the	E1	analysis	demonstrated	a	false	negative	rate	of	14.9%	for	the	detection	of	HPV	16	specifically	using	PapilloCheck®.	It	was	hypothesised	that	non-HPV	16	genotypes	could	also	go	undetected	by	the	PapilloCheck®	assay	as	a	result	of	viral	disruption.	Two	additional	HPV	detection	assays,	targeting	different	regions	of	the	virus	were	sequentially	run	on	the	HPV	negative	samples	to	try	to	minimise	the	number	of	false	negative	results.	The	DiaMex	HPV	typing	kit	utilising	Luminex	technology	targeting	the	L1	region	was	run	on	the	initial	14	HPV	negative	samples	followed	by	an	HPV	E7	PCR	for	genotypes	16,	18,	31,	33,	35	and	51	on	any	negative	samples	thereafter.		Figure	4.3	summarises	the	method	used	to	minimise	false	negative	results.	Results	are	detailed	below.
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Figure	4-3Summary	of	results	and	protocols	used	for	HPV	testing	of	the	RT3	VIN	baseline	cohort	(n=167).	Results	include	high	risk	and	low	risk	genotypes	when	tested	for.	Final	HPV	prevalence	=	164/167	(98.2%)	
Chapter	4	 	 HPV	biology	in	VIN	3		
	HPV	Biology	in	VIN:	Viral	Biomarkers	to	Predict	Response	to	Treatment			 98	
4.2.2.1 DiaMex	HPV	genotyping	data	Samples	testing	HPV	negative	following	PapilloCheck®	and	HPV	16	E6	PCR	(n=14)	were	sent	to	the	Scottish	Human	Papillomavirus	Virus	Reference	laboratory	in	Edinburgh	for	further	testing	using	the	DiaMex	HPV	typing	kit.	This	assay	targets	the	L1	region	of	the	virus	and	can	identify	multiple	genotypes	(HPV	6,	11,	42,	43,	44,	70,	16,	18,	26,	31,	33,	35,	39,	45,	51,	52,	53,	56,	58,	59,	66,	68,	73	and	82)	(see	methods	chapter	2).	It	was	chosen	at	this	stage	to	ensure	that	remaining	DNA	was	utilised	efficiently,	conserving	as	much	as	was	possible	for	downstream	analyses.	Ten	additional	samples	were	sent	for	analysis	that	had	already	generated	a	positive	HPV	result	with	either	the	PapilloCheck®	and/or	the	HPV	16	E6	PCR	assay.		The	DiaMex	assay	detected	HPV	in	10/14	(71.4%)	of	the	previously	HPV	negative	samples.	This	included	two	cases	of	HPV	16,	three	cases	of	HPV	33,	one	case	of	HPV	51,	one	case	of	HPV	73	and	three	cases	of	mixed	infection	(two	of	which	contained	HPV	16	and	33	and	the	other	contained	HPV	42	and	51),	(Table	4.2).	Of	the	ten	control	samples	that	were	sent,	eight	generated	results	that	were	concordant	with	previous	genotyping.	Two	cases	(samples	23	and	24	in	Table	4.2)	generated	disparate	results.	Both	these	samples	tested	HPV	16	positive	with	PapilloCheck®	and	HPV	16	E6	PCR.	However,	DiaMex	identified	Sample	23	as	HPV	42	positive.	This	could	be	explained	by	the	presence	of	HPV	16	integration	disrupting	the	L1	region	with	conserved	E1	and	HPV	42	integration	disrupting	
E1	with	conserved	L1.	Sample	24	generated	a	positive	HPV	16	result	with	all	three	assays	but	only	the	DiaMex	assay	detected	the	presence	of	HPV	42,	similarly	this	could	be	explained	by	HPV	42	integration	disrupting	the	E1	region	with	conserved	L1.
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Table	4–2	HPV	genotyping	data	using	the	DiaMex	assay		
	
*Results	obtained	from	a	total	of	24	samples	sent	for	DiaMex	HPV	testing	from	the	RT3	VIN	cohort.	Samples	1-14	tested	HPV	negative	by	PapilloCheck®	and	HPV	16	E6	PCR;	samples	15-24	tested	HPV	positive	and	were	sent	as	positive	controls.	**,	***	Samples	23	and	24	generated	disparate	results	likely	due	to	disruption	in	assay	target	regions.		
RT3	VIN	
Sample*	
PapilloCheck®	 HPV	16	E6	PCR	 DiaMex	HPV	result	
Sample	1	 Negative	 Negative	 16	
Sample	2	 Negative	 Negative	 16	
Sample	3	 Negative	 Negative	 33	
Sample	4	 Negative	 Negative	 33	
Sample	5	 Negative	 Negative	 33	
Sample	6	 Negative	 Negative	 51	
Sample	7	 Negative	 Negative	 73	
Sample	8	 Negative	 Negative	 16,33	
Sample	9	 Negative	 Negative	 16,33	
Sample	10	 Negative	 Negative	 42,51	
Sample	11	 Negative	 Negative	 Negative	
Sample	12	 Negative	 Negative	 Negative	
Sample	13	 Negative	 Negative	 Negative	
Sample	14	 Negative	 Negative	 Negative	
Sample	15	 42	 Negative	 42	
Sample	16	 42	 Negative	 42	
Sample	17	 16	 16	 16	
Sample	18	 16	 16	 16	
Sample	19	 16	 16	 16	
Sample	20	 16	 16	 16	
Sample	21	 16	 16	 16	
Sample	22	 16	 16	 16	
Sample	23**	 16	 16	 42	
Sample	24***	 16	 16	 16,42	
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4.2.2.2 HPV	E7	type	specific	PCR	for	genotypes	16,	18,	31,	33,	35	and	51	To	this	point,	4/167	(2.4%)	cases	consistently	tested	HPV	negative.	It	was	possible	that	viral	disruption	affecting	multiple	viral	regions	was	still	preventing	HPV	being	detected.	Type-specific	PCRs	targeting	the	well-conserved	E7	region	of	the	virus,	using	primers	described	by	Walboomers	et	al,	1999	for	HPV	genotypes	16,	18,	31,	33,	35	were	applied	to	these	samples.	HPV	33	was	detected	in	one	of	the	four	samples,	the	remaining	3	samples	(3/167,	1.8%)	continued	to	test	HPV	negative.	
4.2.3 Overall	HPV	Genotype	specific	prevalence	Combined	data	from	the	four	assays	applied	to	the	cohort	indicated	an	overall	HPV	prevalence	of	164/167	(98.2%).	HPV	16	was	the	most	common	genotype,	present	in	140/164	(85.4%)	cases.	A	single	genotype	was	detected	in	150/164	(91.5%)	cases	and	multiple	genotypes	were	detected	in	14/164	(8.54%)	cases.	Of	the	cases	with	single	genotypes,	128/150	(85.3%)	were	HPV	16,	HPV	33	was	the	second	most	prevalent	genotype	with	12/150	(8%)	infections	(Figure	4.4).	Of	the	14	cases	of	multiple	genotypes,	all	but	two	cases	included	HPV	16;	HPV	33	was	the	next	most	prevalent,	present	in	4/14	in	conjunction	with	HPV	16.	There	were	three	cases	of	HPV	positivity	in	the	cohort	that	could	only	be	attributed	to	a	low-risk	genotype:	two	cases	of	HPV	42	and	one	cases	of	HPV	44/55	(PapilloCheck®).		
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Figure	4.4	Non-HPV	16	genotype	prevalence	in	single	infections	in	RT3	VIN	baseline	cohort.	Segments	on	bars	represent	the	number	of	cases	detected	by	each	assay.	HPV	44/55	are	grouped	as	the	PapilloCheck®	assay	is	unable	to	distinguish	these	genotypes	and	therefore	a	positive	result	could	indicate	the	presence	of	either	genotype.	HPV	genotypes	42	and	44/55	represent	low-risk	HPV	genotypes,	the	remaining	genotypes	are	high-risk.
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4.2.4 Summary	of	Findings	
• The	majority	of	cases	of	VIN	3	in	the	RT3	VIN	cohort	tested	positive	for	the	presence	of	HPV	(164/167,	98.2%)	
• HPV	16	was	the	most	prevalent	genotype,	detected	in	140/164	(85.4%)	cases	
• HPV	33	was	the	second	most	prevalent	detected	in	16/164	(9.8%)	cases	
• A	single	genotype	was	detected	in	the	majority	of	cases	150/164	(91.5%)	
• In	3/164	(1.8%)	cases,	only	a	low-risk	genotype	was	identified		 	
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4.3 HPV	Integration	in	VIN	3	HPV	16	positive	cases	detected	by	either	PapilloCheck®	or	HPV	16	E6	PCR	were	investigated	for	the	presence	of	HPV	integration	(n=136).	HPV	16	positive	cases	identified	by	these	assays	were	selected,	as	these	assays	were	those	applied	to	all	cases	in	the	cohort.	A	novel	test	combining	a	two-fragment,	tiling	E1	PCR	and	a	commonly	used	five-fragment	
E2	tiling	PCR	(Collins	et	al.	2009)	was	used	to	detect	the	presence	of	viral	disruption.	Addition	of	the	E1	tiling	PCR	was	made	on	the	premise	that	integration	does	not	always	affect	the	E2	region	of	the	virus	(Bryant,	Onions	et	al.	2014).	A	sample	was	considered	to	contain	intact	HPV	if	all	seven	PCR	fragments	were	amplified;	if	≥	1	fragment	failed	to	amplify,	the	sample	was	deemed	to	contain	disrupted	HPV.	Cases	of	viral	disruption	were	judged	to	represent	cases	of	viral	integration.	
4.3.1 Prevalence	of	HPV	Integration	in	VIN	3	Of	the	136	cases	tested,	71	(52.2%)	failed	to	amplify	all	seven	E1/E2	fragments	indicating	the	presence	of	viral	integration.	Intact	virus	was	present	in	65/136	(47.8%)	cases	(Table	4.3).	Figure	4.5	and	Figure	4.6	show	example	gel	images.	
E6	PCR	was	performed	on	all	samples	to	confirm	HPV	DNA	adequacy	and	was	present	in	all	cases	except	case	number	1	in	Table	4.3.	Case	number	1	was	identified	as	HPV	16	positive	using	PapilloCheck®	genotyping	(E1	targeting)	but	did	not	amplify	E6,	E1	or	E2	and	is	therefore	likely	to	represent	a	false	positive	PapilloCheck®	result.	In	cases	with	viral	disruption	present,	12/71	had	disruption	in	the	E1	region	and	intact	E2.	Hence	assessment	of	E1	disruption,	increased	the	number	of	cases	of	presumed	viral	integration	detected	from	59/136	(43.4%)	to	71/136	(52.5%),	an	almost	10%	increase	in	rate	of	detection	(Table	4.4).	No	discernible	pattern	of	HPV	integration	was	apparent	in	terms	of	the	location	of	HPV	disruption	within	the	E1/E2	regions.
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Table	4–3	HPV	disruption	in	the	RT3	VIN	baseline	cohort.	
	
E1-1	and	E1-2	refer	to	the	two	tiling	fragments	of	the	E1	gene	PCR	and	E2-1	to	E2-5	refers	to	the	five	tiling	fragments	of	the	E2	gene	PCR.	Any	case	with	at	least	one	fragment	absent	(‘0’	in	the	table,	highlighted	red)	was	regarded	as	containing	integrated	HPV.	A	number	‘1’	(highlighted	green)	indicates	successful	amplification	of	the	fragment	in	question.	Case	number	1*	represents	a	case	that	repeatedly	tested	positive	for	HPV	16	using	the	PapilloCheck®	but	failed	to	amplify	or	any	of	the	E1	or	fragments.	It	is	likely	that	this	is	a	false	positive	PapilloCheck	result.
HPV$DNA$control HPV$DNA$control
Case$number E6$result E181 E182 E281 E282 E283 E284 E285 Case$number E6$result E181 E182 E281 E282 E283 E284 E285
case%1* 0 0 0 0 0 0 0 0 case%69 1 1 0 1 1 1 1 1
case%2 1 0 0 0 0 0 0 0 case%70 1 0 1 1 1 1 1 1
case%3 1 0 0 0 0 0 0 0 case%71 1 0 1 1 1 1 1 1
case%4 1 0 0 0 0 0 0 0 case%72 1 1 1 1 1 1 1 1
case%5 1 0 0 0 0 0 0 0 case%73 1 1 1 1 1 1 1 1
case%6 1 0 0 0 0 0 0 0 case%74 1 1 1 1 1 1 1 1
case%7 1 0 0 0 0 0 0 0 case%75 1 1 1 1 1 1 1 1
case%8 1 0 0 0 0 0 0 0 case%76 1 1 1 1 1 1 1 1
case%9 1 1 0 0 0 0 0 0 case%77 1 1 1 1 1 1 1 1
case%10 1 1 0 0 0 0 0 0 case%78 1 1 1 1 1 1 1 1
case%11 1 1 0 0 0 0 0 0 case%79 1 1 1 1 1 1 1 1
case%12 1 1 0 0 0 0 0 0 case%80 1 1 1 1 1 1 1 1
case%13 1 1 0 0 0 0 0 0 case%81 1 1 1 1 1 1 1 1
case%14 1 1 0 0 0 0 0 0 case%82 1 1 1 1 1 1 1 1
case%15 1 1 0 0 0 0 0 0 case%83 1 1 1 1 1 1 1 1
case%16 1 1 0 0 0 0 0 0 case%84 1 1 1 1 1 1 1 1
case%17 1 1 0 0 0 0 0 0 case%85 1 1 1 1 1 1 1 1
case%18 1 1 0 0 0 0 0 0 case%86 1 1 1 1 1 1 1 1
case%19 1 1 0 0 0 0 0 0 case%87 1 1 1 1 1 1 1 1
case%20 1 1 0 0 0 0 0 0 case%88 1 1 1 1 1 1 1 1
case%21 1 1 0 0 0 0 0 0 case%89 1 1 1 1 1 1 1 1
case%22 1 1 1 0 0 0 0 0 case%90 1 1 1 1 1 1 1 1
case%23 1 1 1 0 0 0 0 0 case%91 1 1 1 1 1 1 1 1
case%24 1 1 1 0 0 0 0 0 case%92 1 1 1 1 1 1 1 1
case%25 1 1 1 0 0 0 0 0 case%93 1 1 1 1 1 1 1 1
case%26 1 1 1 1 0 0 0 0 case%94 1 1 1 1 1 1 1 1
case%27 1 1 1 1 0 0 0 0 case%95 1 1 1 1 1 1 1 1
case%28 1 1 1 1 0 0 0 0 case%96 1 1 1 1 1 1 1 1
case%29 1 1 0 0 1 0 0 0 case%97 1 1 1 1 1 1 1 1
case%30 1 1 1 1 1 0 0 0 case%98 1 1 1 1 1 1 1 1
case%31 1 1 1 1 1 0 0 0 case%99 1 1 1 1 1 1 1 1
case%32 1 1 1 0 0 0 1 0 case%100 1 1 1 1 1 1 1 1
case%33 1 0 0 1 1 1 1 0 case%101 1 1 1 1 1 1 1 1
case%34 1 0 0 1 1 1 1 0 case%102 1 1 1 1 1 1 1 1
case%35 1 1 0 1 1 1 1 0 case%103 1 1 1 1 1 1 1 1
case%36 1 1 1 1 1 1 1 0 case%104 1 1 1 1 1 1 1 1
case%37 1 1 1 1 1 1 1 0 case%105 1 1 1 1 1 1 1 1
case%38 1 1 1 1 1 1 1 0 case%106 1 1 1 1 1 1 1 1
case%39 1 1 1 1 1 1 1 0 case%107 1 1 1 1 1 1 1 1
case%40 1 1 1 1 1 1 1 0 case%108 1 1 1 1 1 1 1 1
case%41 1 1 1 1 1 1 1 0 case%109 1 1 1 1 1 1 1 1
case%42 1 1 1 1 1 1 1 0 case%110 1 1 1 1 1 1 1 1
case%43 1 1 1 1 1 1 1 0 case%111 1 1 1 1 1 1 1 1
case%44 1 1 1 1 1 1 1 0 case%112 1 1 1 1 1 1 1 1
case%45 1 1 1 1 1 1 1 0 case%113 1 1 1 1 1 1 1 1
case%46 1 1 1 1 1 1 1 0 case%114 1 1 1 1 1 1 1 1
case%47 1 0 0 0 0 0 0 1 case%115 1 1 1 1 1 1 1 1
case%48 1 0 0 0 0 0 0 1 case%116 1 1 1 1 1 1 1 1
case%49 1 0 0 0 0 1 0 1 case%117 1 1 1 1 1 1 1 1
case%50 1 1 0 0 0 1 0 1 case%118 1 1 1 1 1 1 1 1
case%51 1 1 0 1 1 1 0 1 case%119 1 1 1 1 1 1 1 1
case%52 1 1 0 0 0 0 1 1 case%120 1 1 1 1 1 1 1 1
case%53 1 1 1 1 0 0 1 1 case%121 1 1 1 1 1 1 1 1
case%54 1 0 0 0 0 1 1 1 case%122 1 1 1 1 1 1 1 1
case%55 1 1 1 0 0 1 1 1 case%123 1 1 1 1 1 1 1 1
case%56 1 1 1 0 0 1 1 1 case%124 1 1 1 1 1 1 1 1
case%57 1 0 0 0 1 1 1 1 case%125 1 1 1 1 1 1 1 1
case%58 1 1 0 0 1 1 1 1 case%126 1 1 1 1 1 1 1 1
case%59 1 1 1 0 1 1 1 1 case%127 1 1 1 1 1 1 1 1
case%60 1 0 0 1 1 1 1 1 case%128 1 1 1 1 1 1 1 1
case%61 1 0 0 1 1 1 1 1 case%129 1 1 1 1 1 1 1 1
case%62 1 0 0 1 1 1 1 1 case%130 1 1 1 1 1 1 1 1
case%63 1 0 0 1 1 1 1 1 case%131 1 1 1 1 1 1 1 1
case%64 1 0 0 1 1 1 1 1 case%132 1 1 1 1 1 1 1 1
case%65 1 0 0 1 1 1 1 1 case%133 1 1 1 1 1 1 1 1
case%66 1 1 0 1 1 1 1 1 case%134 1 1 1 1 1 1 1 1
case%67 1 1 0 1 1 1 1 1 case%135 1 1 1 1 1 1 1 1
case%68 1 1 0 1 1 1 1 1 case%136 1 1 1 1 1 1 1 1
Fragment Fragment
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Figure	4.5	Example	E2	tiling	PCR	gel	image.	Results	for	cases	96,	115,	57,	40,	and	10	are	shown.	Cases	marked	with	*	indicate	samples	not	part	of	the	study.	N=negative	control	(H20),	P=positive	control	(CaSki)	
	
Figure	4.6	Example	E1	tiling	PCR	gel	image.		The	first	fragment	band	generated	for	each	sample	represents	the	E1-1	fragment,	the	second	represents	the	E1-2	fragment	and	the	third	represents	the	full-length	fragment	that	was	not	included	in	this	analysis.	Results	for	cases	6,	33,36,51,25,101,	65,7,99,125	and	131	are	shown.	Cases	marked	with	an	*	represent	samples	that	were	part	of	this	study.	
Table	4–4	Comparison	of	E1	and	E2	tiling	result	
E2#–#full#length#primer# E211#primer#
E212#primer# E213#primer#
E2–4#primer# E215#primer#
96# 57#115# *#*# *# P#N#*#10#*#40#
96#96#
96# 96#
96#
115#
115#
115#
115#
115#
57# 57#
57# 57#
57# *#
*#
*#
*#*#
*#*#*#
*a#*#*#
*#*#
*#
*#*#
40#
40#40#
40#
40#
10#
10#
10#
10#
10#
*#
*# *#
*#
*#*#
*#
*# *#
N#
N# N#
N#
N#
P#P#
P#P#
P#
51# 25# 101#33#6# *#98#36#
125#*#99#7#65# P#N#131#
	 E2	result	 	
E2	intact	 E2	disrupted	 Total	
E1	result	
E1	intact	 65	 25	 90	
E1	disrupted	 12	 34	 46	
	 Total	 77	 59	 136	
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4.3.2 Viral	Integration,	Patient	Age,	Smoking	Status	and	Disease	Episode	It	was	hypothesised	that	viral	integration	would	be	more	common	with	increased	age,	positive	smoking	history	and	recurrent	disease.	A	Bonferroni	correction	was	applied	to	account	for	multiple	comparisons;	a	p-value	of	<0.01	was	considered	significant.	The	median	patient	age	for	cases	identified	as	containing	integrated	HPV	(absence	≥	one	E1/E2	tiling	fragments)	was	47	years	and	with	intact	HPV	was	45	years;	this	difference	was	not	significant	(U	=	1,823,	z	=	-2.11	and	p	=	0.05).	A	positive	smoking	history	was	found	in	57/71	(80.3%)	and	55/65	(84.6%)	of	women	with	integrated	virus	and	intact	virus	respectively.		This	finding	was	not	statistically	significant	(χ2	=	0.439,	p=0.508).	Finally,	no	statistically	significant	relationship	was	identified	between	viral	integration	and	disease	episode	with	viral	integration	being	present	in	32/63	cases	of	recurrent	disease	and	39/73	cases	of	first	episode	disease,	(χ2	=	0.094,	p	=	0.759).	
4.3.3 Summary	of	Findings	
• HPV	integration	defined	by	the	absence	of	≥1	E1/E2	PCR	tiling	fragments	was	present	in	71/136	(52.2%)	HPV	16	positive	cases	of	VIN	3	
• Adding	an	E1	tiling	PCR	to	the	more	commonly	used	E2	assay	increased	detection	of	integrated	HPV	by	9.1%	
• No	statistically	significant	relationships	were	identified	between	smoking	status,	age	or	recurrent	disease	and	HPV	integration		 			
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4.4 HPV	DNA	Methylation	in	VIN	3	HPV	DNA	methylation	levels	were	investigated	using	pyrosequencing	in	all	HPV	16	positive	cases	identified	by	PapilloCheck®	and/or	HPV	16	E6	PCR	(n=136).	Three	regions	of	the	virus	were	of	interest:	the	E2	region,	the	L1/L2	overlapping	region,	and	the	promoter	region.	The	E2	and	L1/L2	regions	were	chosen	due	to	reports	in	the	literature	of	their	methylation	being	potential	biomarkers	of	high-grade	disease	(Mirabello,	Schiffman	
et	al.	2012).	The	promoter	region	was	investigated	due	to	promoter	methylation	being	a	potential	alternative	mechanism	leading	to	deregulated	oncogene	expression.	Six	CpG	sites	were	analysed	in	the	E2	region,	four	in	the	L1/L2	region	and	five	sites	in	the	promoter	region.	Analysable	data	was	available	for	a	different	number	of	cases	for	each	region	(E2	=	82,	L1/L2	=	93	and	promoter	=	122).	This	was	a	result	of	quality	control	checks	applied	to	the	data	and	impacted	more	on	the	E2	and	L1/L2	regions	due	to	the	increased	likelihood	of	disruption	in	these	PCR	target	regions;	this	is	discussed	further	in	the	discussion	of	this	chapter.	
4.4.1 Regional	HPV	DNA	Methylation	For	each	case,	the	methylation	level	at	each	region	(E2,	L1/L2	and	promoter)	was	calculated	by	taking	the	mean	value	generated	from	the	CpG	sites	within	the	region	in	question.	A	minimum	of	two	valid	CpG	readings	for	each	region	was	required	following	the	application	of	quality	assurance	checks	(see	methods	chapter	2).	To	determine	if	methylation	at	each	region	varied	significantly	between	cases	within	the	cohort,	a	one-sample	T-test	was	used.	Kolmogorov-Smirnov	(KS)	and	Shapiro-Wilk	(SW)	statistics	were	used	to	see	if	the	data	was	normally	distributed.	Despite	not	following	normal	distribution	for	any	of	the	analysed	regions	(E2	methylation	KS=0.35,	p=<0.000	and	SW=0.68,	p=<0.000;	L1L2	methylation	KS=0.33,	p=<0.000	and	SW=0.72,	p=<0.01;	promoter	methylation	KS=0.42,	p=<0.002	and	SW=0.29,	p=<0.02),	the	one-sample	t-test	was	still	used	due	to	its	robustness	at	coping	with	breaches	in	required	assumptions	(Markowski,	Markowski	2012).	A	Bonferroni	correction	to	account	for	multiple	comparisons	was	applied	and	a	p-value	of	<	0.01	was	considered	significant.	Methylation	at	each	region	was	found	to	be	variable	in	the	cohort	with	the	E2	and	L1/L2	exhibiting	the	most	variation	and	the	promoter	region,	the	least.	For	the	E2	region	(n	=	82)	mean	methylation	was	27.2%	±	35.8%	(p	=	<0.000),	for	the	L1/L2	region	(n	=	93),	mean	methylation	was	37.5%	±	34.9%	(p	=	<0.000)	and	for	the	promoter	region	(n	=	122),	mean	methylation	was	3.9%	±	13.44%	(p	=	<0.002),	(Figure	4.7).		
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Figure	4.7.Variation	of	regional	HPV	methylation	in	the	RT3	VIN	cohort.	The	mean	value	was	calculated	for	each	region	from	all	CpG	sites	tested.	Error	bars	represent	the	mean	and	standard	deviation.	E2	mean	=	26.3%±35.6,	L1L2mean	=	28.0%±32.1,	promoter	mean	=	3.1±11.6.			 	
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4.4.2 Inter-regional	Methylation	Sixty-one	cases	generated	data	for	all	three	tested	HPV	regions	and	were	therefore	suitable	for	investigating	differences	in	inter-regional	HPV	DNA	methylation.	The	median	level	of	methylation	was	4.2%	for	the	E2	region,	6.2%	for	the	L1/L2	region	and	0.16%	for	the	promoter	region.	In	order	to	determine	if	the	methylation	level	varied	significantly	between	regions,	a	Friedman’s	two-way	analysis	of	variance	was	used	to	compare	the	mean	rank	at	each	region.	There	was	a	statistically	significant	difference	in	methylation	between	the	three	regions	χ2(2)=92.96,	p=<0.001.	Post	hoc	analysis	with	Wilcoxon	signed-rank	tests	were	conducted	with	a	Bonferroni	correction	applied,	resulting	in	a	significant	level	set	at	p	<	0.016.	Statistically	significant	differences	in	methylation	existed	between	all	three	regions:	between	the	E2	and	L1/L2	region	Ζ	=	-3.519,	p	=	<0.001,	between	the	E2	and	promoter	region	Ζ=	-7.404,	p	=	<0.001	and	between	the	L1/L2	and	promoter	regions	Ζ	=	-8.101,	p	=	<0.001.	Methylation	was	typically	higher	in	the	E2	and	L1/L2	region	and	lower	at	the	promoter	region	(Figure	4.8).	It	was	also	hypothesised	that	trends	would	exist	in	the	methylation	levels	of	the	different	regions	i.e.	as	methylation	of	the	E2	region	increased	so	would	methylation	of	the	L1/L2	region.	Pearson’s	correlation	coefficient	was	used	to	investigate	this.	A	strong	positive	correlation	was	shown	between	methylation	of	the	L1/L2	region	and	the	E2	region	as	illustrated	in	Figure	4.9	(Pearson	Correlation	=	0.97,	p=<0.000).A	weakly	positive	correlation	was	found	between	E2	methylation	and	promoter	region	methylation	(Pearson’s	correlation	=	0.42,	p=<0.000)	and	L1L2	methylation	and	promoter	region	methylation	respectively	(Pearson’s	Correlation	=	0.32,	p=<0.002).					
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Figure	4.8	Case-by-case	analysis	of	inter-regional	variation	of	HPV	DNA	methylation.	Mean	methylation	for	each	case	was	calculated	from	all	CpG	sites	within	the	region	in	question.	Points	are	linked	to	aid	visualisation	of	trends	within	samples.	Methylation	of	the	E2	and	L1/L2	regions	was	generally	similar	in	samples	whereas	promoter	region	methylation	was	lower.	Friedman’s	two	way	analysis	of	variation	found	the	differences	in	mean	rank	of	methylation	between	the	three	regions	to	be	statistically	significant	p=<0.000.				
Promoter	Mean	L1L2	Mean	E2	
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Figure	4.9	Relationships	between	HPV	DNA	methylation	at	different	regions.	Image	A	=	E2	and	
L1L2	methylation,	image	B	=	E2	and	promoter	methylation	and	image	C	=	L1L2	and	promoter	methylation.	Methylation	measured	using	pyrosequencing	and	recorded	as	mean	percentage.	N=61.	
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4.4.3 Intra-Regional	HPV	DNA	Methylation	It	was	hypothesised	that	variation	would	exist	between	the	methylation	levels	at	each	CpG	site	within	a	region.	The	graphs	in	Figure	4.10,	Figure	4.11	and	Figure	4.12	show	conserved	patterns	of	methylation	at	each	region.	Mean	methylation	levels	with	corresponding	range	and	standard	deviations,	at	each	CpG	site,	within	each	region	are	shown	in	Table	4.5.	To	determine	if	this	intra-regional	variation	was	significant,	a	Friedman’s	two-way	analysis	of	variance	was	used	to	compare	the	mean	ranks	for	each	CpG	site	for	each	region.	Statistically	significant	differences	in	methylation	levels	existed	between	the	CpG	sites	at	the	E2	region	(χ2	(2)	=	177.65,	p=<0.001),	the	L1/L2	region	(χ2	(2)	=	148.48,	p=<0.001)	and	the	promoter	region	(χ2	(2)=	49.6,	p=<0.001).	Post	hoc	analysis	with	Wilcoxon	signed-rank	tests	were	conducted	with	a	Bonferroni	correction	applied,	resulting	in	a	significant	level	set	at	p	<	0.003.	Results	described	in	Table	4.6	show	that	the	differences	in	methylation	levels	between	adjacent	CpG	sites	in	the	E2	and	L2/L2	region	were	significant.	For	the	promoter	region,	the	differences	in	methylation	between	CpG3	and	CpG4	and	also	between	CpG4	and	CpG5	were	significant.			
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Figure	4.10	Pattern	of	E2	intra-regional	methylation	n=68.	Nucleotides	sequenced	as	follows:	E2	CpG1	=	NT	3411,	CpG2	=	NT	3414,	CpG3	=	3416,	CpG4	=	3432,	CpG5	=	3447,	CpG6	=	3447.	Points	are	linked	to	aid	visualisation	of	trends	within	samples.			
	
	
	
	
	
	
	
	
	
	
	
Figure	4.11	Pattern	on	promoter	intra-regional	methylation	n=114.	Sequenced	nucleotides	as	follows:	CpG1	=	31,	CpG2	=	37,	CpG3	=	43,	CpG4	=	52,	CpG5	=	58.	Points	are	linked	to	aid	visualisation	of	trends	within	samples.			
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Figure	4.12Patterns	of	L1/L2	intra-regional	methylation	n=60.	Sequenced	nucleotides	as	follows:	CpG1	=	5615,	CpG2	=	5606,	CpG3	=	5609,	CpG4	=	5600.	Points	are	linked	to	aid	visualisation	of	trends	within	samples.		
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Methylation	at	CpG	sites	within	each	tested	viral	region:	E2,	promoter	and	L1/L2																									
*nt	=	nucleotide	position	in	sequence	NC	001526.1	(HPV	genbank	accession	number).	
	 E2	region	methylation(n=68)	 	
CpG	site	 Mean	(%)	 Min	(%)	 Max	(%)	 Std.	Dev	
E2	CpG1	(nt*	3411)	 23.25	 0.00	 92.37	 32.16	
E2	CpG2	(nt	3414)	 22.03	 0.00	 99.81	 34.80	
E2	CpG3	(nt	3416)	 18.31	 0.00	 83.00	 29.37	
E2	CpG4	(nt	3432)	 26.46	 0.00	 100.00	 35.36	
E2	CpG5	(nt	3435)	 22.70	 0.00	 99.57	 34.68	
E2	CpG6	(nt	3447)	 23.31	 0.00	 94.24	 32.28	
Promoter	region	methylation(n=114)	
CpG	site	 Mean	(%)	 Min	(%)	 Max	(%)	 Std.	Dev	
Promoter	CpG1	(nt	31)	 2.72	 0.00	 82.60	 11.41	
Promoter	CpG2	(nt	37)	 2.86	 0.00	 79.68	 11.47	
Promoter	CpG3	(nt	43)	 2.87	 0.00	 81.83	 11.94	
Promoter	CpG4	(nt	52)	 3.29	 0.00	 81.58	 12.01	
Promoter	CpG5	(nt	58)	 2.51	 0.00	 73.17	 10.71	
L1/L2	region	methylation(n=60)	
CpG	site	 Mean	(%)	 Min	(%)	 Max	(%)	 Std.	Dev	
L1/L2	CpG1	(nt	5615)	 32.77	 0.00	 85.25	 32.65	
L1/L2	CpG2	(nt	5606)	 46.08	 0.00	 92.05	 37.77	
L1/L2	CpG3	(nt	5609)	 40.82	 0.00	 97.19	 39.46	
L1/L2	CpG4	(nt	5600)	 52.06	 0.00	 100.00	 37.23	
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Table	4–5	Statistical	significance	of	difference	in	methylation	levels	between	intra-regional	
CpG	sites	
E2	Region		 CpG1–CpG2	 CpG2–CpG3	 CpG3–CpG4	 CpG4–CpG5	 CpG5–CpG6	
Ζ	statistic	 -3.070	 -4.677	 -6.942	 -6.610	 -2.094	
P	value	 0.002	 <0.001	 <0.001	 <0.001	 0.036	
L1/L2	region		 CpG1-CpG2	 CpG2-CpG3	 CpG3-CpG4	 	 	
Ζ	statistic	 -6.680	 -5.110	 -6.552	 	 	
P	value	 <0.001	 <0.001	 <0.001	 	 	
Promoter	region		 CpG1-CpG2	 CpG2-CpG3	 CpG3-CpG4	 CpG4-CpG5	 	
Ζ	statistic	 -1.292	 -0.158	 -4.359	 -5.857	 	
P	value	 0.196	 0.875	 <0.001	 <0.001	 	
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4.4.4 HPV	DNA	Methylation,	Patient	Age,	Smoking	and	Disease	Episode	Increased	levels	of	methylation	were	anticipated	in	older	patients,	those	with	a	smoking	history	and	those	with	recurrent	disease.	Bonferroni	correction	was	applied	to	account	for	multiple	comparisons	and	a	p-value	of	<0.01	was	considered	significant.	Pearson’s	rank	found	no	significant	correlation	between	increasing	age	and	increased	HPV	DNA	methylation	at	any	of	the	three	tested	regions	(E2	r=0.206	p=0.063,	L1/L2	r=0.236	p=0.022	and	promoter	r=0.022	p=0.81).	Median	methylation	level	in	smokers	versus	non-smokers	for	the	E2	region	were	4.33%	and	3.71%,	for	the	L1/L2	region	were	15.22%	and	29.76%	and	for	the	promoter	region	were	0.19%	and	0.19%.	Results	of	a	Mann-Whitney	U	test	did	not	find	differences	between	groups	at	any	region	to	be	significant.	Finally,	median	methylation	levels	in	patients	with	first	episode	versus	recurrent	disease	for	the	E2	region	were	27.48%	and	26.95%,	for	the	L1/L2	region	were	38.42%	and	36.46%	and	for	the	promoter	were	3.58%	and	4.20%.	A	Mann-Whitney	U	test	did	not	find	significant	differences	between	the	groups	at	any	region.		
4.4.5 Summary	of	Findings	
• HPV	DNA	methylation	in	VIN	3	varied	significantly:		
o Between	cases	for	each	tested	region	
o Between	the	three	tested	regions	
o Methylation	levels	were	generally	higher	at	the	E2	and	L1/L2	regions	than	the	promoter	region	
o Between	CpG	sites	within	regions	(with	patterns	of	methylation	found	at	each	region)		
• A	strong	positive	correlation	existed	between	E2	and	L1/L2	region	methylation	
• No	relationships	were	identified	between	HPV	DNA	methylation	and	patient	age,	smoking	status	and	disease	episode				
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4.5 	 HPV	Gene	Expression	Data		HPV	gene	expression	levels	were	estimated	in	the	136	HPV	16	positive	cases	detected	by	PapilloCheck®	and/or	HPV	16	E6	PCR	(n=136)	using	RT-qPCR.	Three	HPV	genes	were	analysed:	E2,	E6	and	E7	as	well	as	two	human	reference	genes:	HPRT	and	TBP.	Of	the	136	HPV	16	positive	cases,	two	cases	had	insufficient	RNA	to	perform	any	expression	analyses,	nine	had	insufficient	to	perform	the	E2	analysis	and	three	cases	for	the	E6	analysis.	The	data	was	analysed	in	two	ways.	In	the	first	instance,	crossing	point	data	was	analysed	using	Biogazelle	qBase+	software,	which	generates	gene	expression	levels	for	each	gene	relative	to	the	cohort	being	tested.	This	method	enabled	comparisons	in	gene	expression	to	be	made	between	samples.	Secondly,	direct	comparison	was	made	between	the	crossing	point	values	generated	by	the	LightCycler	software	for	the	E2	and	E6	gene	for	each	case.	This	method	meant	that	comparisons	could	be	made	between	the	expression	levels	of	each	gene	within	a	sample	and	permitted	exploratory	work	to	be	conducted	using	E2:E6	expression	ratio	to	identify	those	cases	with	and	without	deregulated	oncogene	expression.	Cases	with	E2>E6expression	were	judged	to	represent	cases	with	regulated	oncogene	expression,	and	cases	with	E6>E2	were	judged	to	represent	cases	with	deregulated	oncogene	expression.			
4.5.1 Variation	of	HPV	Gene	Expression	in	VIN	3	Calibrated,	normalised,	relative	quantities	(CNRQ)	of	expression	of	each	gene	were	generated	by	qBase+	software.	The	expression	value	was	normalised	to	the	two	stably	expressed	reference	genes	(TBP	and	HPRT)	and	then	made	relative,	to	the	minimum	value	generated	in	the	cohort,	for	the	particular	gene	in	question.	Samples	that	generated	a	non-specific	PCR	product	(NSP)	(determined	by	visual	inspection	of	the	melt	curve	generated	by	the	LightCycler)	were	not	put	through	analysis	using	the	qBase+	software.	These	samples	were	cases	in	which,	no	gene	expression	could	be	detected.	These	samples	were	included	in	downstream	statistical	analysis	using	SPSS	with	a	value	of	‘0’	(equal	to	the	minimum	value	generated	for	the	gene	in	the	cohort).	This	was	done	to	prevent	inaccurate	analysis	of	gene	expression	by	qBase+	software	whilst	including	them	in	overall	analysis	to	ensure	that	data	was	not	biased	towards	those	samples	with	intact	HPV.	Following	quality	control	measures,	115	samples	were	available	for	E2	gene	expression	analysis,	120	cases	for	E6	and	119	cases	for	E7.		The	range	of	E2	gene	expression	was	CNRQ	0.00	–	3.68,	with	a	mean	CNRQ	of	1.88	±	1.30.		The	range	of	E6	expression	was	0.00	-	2.19	with	a	mean	CNRQ	of	1.01	±	0.48	and	the	range	of	E7	expression	was	0.00	–	2.32	with	a	mean	CNRQ	of	1.2	±	0.49	Table	4.7.	Figure	4.13	
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shows	the	variation	in	expression	of	each	gene	in	the	cohort	and	enables	visual	comparisons	to	be	made	between	expression	levels	of	each	gene.	The	range	of	both	HPRT	and	TBP	expression	was	CNRQ	0.00	–	0.83,	the	mean	HPRT	and	TBP	CNRQ	were	0.43	±	0.23	and	0.40	±	0.23	respectively.	Expression	of	each	HPV	gene	was	more	variable	than	the	expression	of	the	human	reference	genes,	with	E2	expression	demonstrating	the	most	variation.			 	
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Table	4–6	CNRQ	analysis	for	each	gene	
	
	
	
	
	
	
	
	
	
*Missing	values	include	those	samples	for	which	there	was	insufficient	RNA	to	run	the	assay	and	those	samples	that	failed	quality	assurance	parameters.	
  E2 E6 E7 HPRT TBP 
                Valid results n= 115 120 119 122 122 
Missing* 21 16 17 14 14 
Mean 1.88 1.01 1.20 0.43 0.40 
Median 2.40 1.02 1.23 0.47 0.36 
Std. Deviation 1.30 0.48 0.49 0.23 0.23 
Range 3.68 2.19 2.32 0.83 0.83 
Minimum 0.00 0.00 0.00 0.00 0.00 
Maximum 3.68 2.19 2.32 0.83 0.83 
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Figure	4-13	Variation	in	CNRQ	values	for	HPV	genes	and	two	human	reference	genes.	CNRQ	=	corrected,	normalised,	relative	quantity,	data	generated	using	qBase+	software	analysing	the	relative	quantity	of	each	gene	to	the	minimum	value	generated	in	the	cohort.	Mean	and	standard	deviation	for	each	gene	shown	Presence	of	variation	determined	by	visual	comparison	with	the	HPRT	and	TBP	human	reference	genes.		
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4.5.2 HPV	E2:E6	Gene	Expression	in	VIN	3	Direct	comparisons	of	the	crossing	point	values	generated	by	the	LightCycler	software	were	made	and	a	ratio	of	E2:E6	expression	generated.	Full	data	was	available	for	112	cases	in	total;	for	9	cases,	there	was	insufficient	DNA	to	run	the	assay,	2	cases	were	not	included	because	both	the	E2	and	the	E6	assay	generated	a	non-specific	product	and	13	samples	failed	quality	control.	This	exploratory	analysis	found	that	in	the	majority	of	cases	(83/112,	74.1%)	E6	expression	was	greater	than	E2indicating	the	presence	of	deregulated	gene	expression	and	in	29/112	(25.9%)	E2expression	was	greater	than	E6indicating	those	cases	with	regulated	oncogene	expression.			
4.5.3 HPV	Gene	Expression	and	Patient	Age,	Smoking	Status	and	Disease	Episode	It	was	hypothesised	that	age	and	recurrent	disease	would	correlate	with	decreasing	E2	expression.	For	this	section	of	analyses,	a	Bonferroni	correction	was	applied	to	account	for	multiple	comparisons,	and	a	p-value	of	<	0.008	was	considered	significant.		E2	expression	was	found	to	decrease	with	increasing	age	as	demonstrated	by	Pearson’s	correlation	coefficient	(x=-0.228,	p=0.014),	(Figure	4.14).	Similarly,	patients	with	E2>E6	(regulated	oncogene	expression)	were	on	average	younger	than	women	with	E6>E2	(deregulated	oncogene	expression)	with	a	mean	age	of	43	years	vs.	48	years.	However,	neither	of	these	findings	reached	statistical	significance	(p=0.014	and	0.057	respectively).		Regarding	disease	episode,	E2	expression	was	found	to	be	higher	in	patients	with	first	episode	disease	(CNRQ	2.65)	than	in	patients	with	recurrent	disease	(CNRQ	2.22);	however,	a	Mann-Whitney	U	test	did	not	find	this	difference	to	be	statistically	significant	(U	=	1332,	Z	=	-1.8,	p	=	0.072).	The	majority	of	cases	of	both	recurrent	and	first	episode	disease	had	greater	E6	expression	than	E2	expression	however;	it	was	statistically	significantly	more	likely	to	be	the	pattern	of	expression	in	recurrent	disease.	In	recurrent	disease	46/53	(86.8%)	cases	had	E6>E2	expression	and	7/53	(13.2%)	had	E2>E6;	in	first	episode	disease	37/59	(62.7%)	had	E6>E2	and	22/59	(37.3%)	had	E2>E6	(p=0.004)	See	Figure	4.15.	No	statistically	significant	difference	in	E2	expression	and	was	found	between	patients	with	and	without	a	history	of	smoking	(E2	CNRQ	2.39	and	E2	CNRQ	2.41	respectively,	p	=	0.681).		E6	expression	was	more	likely	to	be	greater	than	E2	expression	in	patients	with	and	without	a	history	of	smoking	(74.4%	and	72.2%	respectively),	(Figure	4.16).
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Figure	4.14	Relationship	between	E2	expression	(CNRQ)	and	patient	age	(years)	in	the	RT3	
VIN	baseline	cohort.	Multiple	values	at	CNRQ	0	represent	those	samples	generating	a	non-specific	PCR	product	and	therefore	exhibiting	no	gene	expression.	A	negative	correlation	was	identified	but	did	not	reach	statistical	significance	(p=0.014)	following	the	application	of	a	Bonferroni	correction	to	allow	for	multiple	comparisons	making	a	p-value	of	<0.008	significant.										
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Figure	4.15	Relationship	between	disease	episode	and	viral	gene	expression	pattern.	E6	expression	was	greater	than	E2	expression	in	86.8%	of	recurrent	disease	cases	and	62.7%	of	first	episode	disease	cases	(p=0.004).	
	
Figure	4.16	Relationship	between	smoking	status	and	viral	gene	expression	pattern.	
E6expression	was	higher	than	E2	expression	in	74.4%	of	patients	with	a	smoking	history	and	in	72.2%	of	patients	with	no	history	of	smoking.			
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4.5.4 Summary	of	Findings	
• Expression	of	each	HPV	gene	(E2,	E6	and	E7)	was	more	variable	in	VIN	3	than	the	human	reference	genes	HPRT	and	TBP	(broadly	accepted	to	be	stably	expressed)	
• The	majority	of	VIN	3	expressed	more	E6	than	E2	
• No	statistically	significant	relationship	between	patient	age	or	smoking	status	and	gene	expression	was	identified	
• E6>E2	expression	was	statistically	more	likely	to	be	the	pattern	of	gene	expression	in	cases	of	recurrent	disease	than	first-episode	disease			
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4.6 Relationship	Between	Viral	Characteristics	HPV	integration	(represented	by	absence	of	≥	1	E1/E2	tiling	PCR	fragments),	high	HPV	DNA	methylation	(determined	by	mean	of	E2	and	L1/L2	CpG	sites	>50%)	and	deregulated	oncogene	expression	(part	of	exploratory	analysis	represented	by	E6>E2	expression),	have	all	been	associated	with	transforming	HPV	infection.	Mean	methylation	with	a	cut-off,	of	>50%	for	the	E2	and	L1/L2	CpG	sites	was	used	to	represent	‘high’	methylation	for	three	reasons.	Firstly,	VIN	3	cases	appeared	to	either	be	highly	methylated	or	lowly	methylated	and	rarely	in	between;	secondly	E2	and	L1/L2	methylation	levels	were	strongly	correlated	with	one	another	and	varied	widely	whereas	promoter	methylation	was	almost	invariably	low	and	finally,	a	similar	cut-off	has	been	used	by	other	studies	(Bryant,	Onions	et	al.	2014).	The	first	aim	of	this	section	was	to	explore	relationships	between	these	characteristics.	The	second	aim	of	this	section	was	to	investigate	viral	characteristics	leading	to	deregulated	oncogene	expression	(E6>E2).		
4.6.1 Viral	Integration	and	HPV	Gene	Expression	 	HPV	was	more	likely	to	be	integrated	in	cases	of	E6>E2	(deregulated	oncogene	expression)	(49/83,	59%)	and	more	likely	to	be	intact	in	patients	with	E2>E6	(regulated	oncogene	expression)	(20/29,	69%)	(p	=	0.009),	(Figure	4.17).	Similarly,	the	median	expression	of	E2	was	lower	(CNRQ	0.0)	when	the	virus	was	integrated	and	higher	(CNRQ	2.8)	when	intact.	This	difference	reached	statistical	significance	(p	=	<0.0001)	with	a	Mann-Whitney	U	test	incorporating	a	Bonferroni	correction	(p=<0.01)	to	allow	for	multiple	comparisons.	No	statistical	significance	was	identified	between	the	expression	levels	of	E6	and	E7	in	cases	of	integrated	and	intact	virus	(CNRQ	1.02	vs.	0.96	and	CNRQ	1.12	vs.	1.3	respectively).										
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Figure	4.17	Relationship	between	HPV	gene	expression	profile	and	viral	integration.	Full	data	was	available	for	both	assays	for	112	cases.	Integration	status	was	determined	by	an	E1/E2	tiling	PCR.	HPV	gene	expression	profile	determine	by	ratio	of	expression	of	E2:E6.	E2>E6	used	to	represent	regulated	oncogene	expression	and	if	E6>E2	used	to	represent	deregulated	oncogene	expression.															
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4.6.2 Viral	Gene	Expression	and	Viral	DNA	Methylation	High	HPV	DNA	methylation	of	the	E2	and	L1/L2	regions	was	strongly	correlated	with	decreased	E2	gene	expression	using	Pearson’s	rank	(r	=	-0.679,	p	=	<0.0001	and	r	=	-0.511,	p	=	<0.0001	respectively),	(Figure	4.18	and	Figure	4.19).	No	correlation	was	found	between	promoter	region	methylation	and	E2	gene	expression.	Similarly,	mean	E2	methylation	was	higher	(36.4%)	in	cases	of	deregulated	oncogene	expression	compared	to	regulated	(12.04%)	cases	(p	=	0.008).	Likewise,	mean	L1/L2	methylation	was	higher	(46.3%)	in	cases	with	deregulated	oncogene	expression	compared	to	21.0%	in	cases	with	regulated	oncogene	expression	(p	=	0.004).	No	correlation	was	found	between	promoter	region	methylation	and	E2:E6	expression	(Table	4.8).		
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Figure	4.18	E2	methylation	and	E2	expression.	Increased	E2	DNA	methylation	strongly	correlated	with	reduced	E2	gene	expression	(p=<0.000).	E2	methylation	represents	the	mean	methylation	of	all	tested	CpG	sites.	E2	expression	is	generated	as	the	corrected	normalised	relative	quantity	within	the	study	cohort.	Line	of	best	fit	applied.		
	
Figure	4.19	L1/L2	methylation	and	E2	gene	expression.	Increased	L1/L2	DNA	methylation	strongly	correlated	with	reduced	E2	gene	expression	(p=<0.000).	L1/L2	methylation	represents	the	mean	methylation	of	all	tested	CpG	sites.	E2	expression	is	generated	as	the	corrected	normalised	relative	quantity	within	the	study	cohort.	Line	of	best	fit	applied.	
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Figure	4.20	Promoter	methylation	and	E2	gene	expression.	No	correlation	identified.	Promoter	methylation	represents	the	mean	methylation	of	all	tested	CpG	sites.	E2	expression	is	generated	as	the	corrected	normalised	relative	quantity	within	the	study	cohort.	Line	of	best	fit	applied.		Table	4–7HPV	gene	expression	and	DNA	methylation	
	
					 	
	
	
	
	
	
E2>E6	represents	cases	of	regulated	oncogene	expression	and	E6>E2	represents	cases	of	deregulated	oncogene	expression.	Significance	calculated	using	Mann	-	Whitney	U	test	incorporating	a	Bonferroni	correction	for	multiple	comparisons	making	a	p	value	of	<	0.03	significant.	
E2	methylation	
	 Mean	 Median	 Significance	
E2>E6	 12.04	 3.2	 P=0.008	
E6>E2	 36.4	 7.7	
L1/L2	methylation	
	 Mean	 Median	 Significance	
E2>E6	 21.0	 8.05	 P=0.004	
E6>E2	 46.3	 42.9	
Promoter	methylation	
	 Mean	 Median	 Significance	
E2>E6	 3.7	 0.4	 P=0.232	
E6>E2	 4.7	 0.18	
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4.6.3 Viral	Integration	and	HPV	DNA	Methylation	Methylation	of	the	E2	and	L1/L2	regions	was	higher	in	patients	with	integrated	virus.	For	the	E2	region,	median	methylation	was	80.6%	in	disrupted	cases	and	3.19%	in	intact	cases	(p	=	<0.0001).	For	the	L1/L2	region	median	methylation	was	75.9%	in	disrupted	cases	and	7.89%	in	intact	cases	(p=<0.0001).	Levels	of	methylation	at	the	viral	promoter	were	found	to	be	similarly	low	at	0.17%	and	0.28%	in	cases	of	integrated	and	intact	virus	respectively.	This	difference	was	not	statistically	significant	(p	=	0.25),	(Figure	4.21).		 				 														
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	Figure	4.21	Regional	HPV	DNA	methylation	in	cases	of	disrupted	and	intact	virus.	Whiskers	of	the	box	plot	represent	the	minimum	and	maximum	value	in	the	range.	Based	on	the	results	of	a	Mann	Whitney	U	test,	for	the	E2	region	and	the	L1/L2	region,	HPV	DNA	methylation	was	significantly	higher	in	cases	with	integrated	virus	than	in	cases	with	intact	virus	(p=<0.0005).	Methylation	of	the	promoter	region	was	found	to	be	similar	in	disrupted	and	intact	cases.										
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4.6.4 Relationships	Between	Viral	Disruption,	Methylation	and	Oncogene	Expression	Ninety-two	cases	had	data	available	for	all	three	viral	characteristics.	Correlations	between	all	three	characteristics	are	illustrated	in	Figure	4.22.	In	19/92	cases	(20.7%),	no	transforming	HPV	characteristics	were	detected.	Conversely,	in	73/92	(79.3%)	cases,	at	least	one	transforming	characteristic	was	present.	Deregulated	oncogene	expression	(E6>E2)	was	the	most	common	transforming	characteristic	present	in	the	cohort,	detected	in	66/92	(71.7%)	cases.	High	HPV	DNA	methylation	was	found	in	35/92	(38.0%)	and	viral	disruption	in	43/92	(46.7%)	cases.	All	three	transforming	characteristics	were	present	in	25/92	(27.2%)	cases.	In	all	35	cases	of	high	HPV	DNA	methylation	and	40/43	(93.2%)	cases	of	HPV	disruption,	at	least	one	(normally	both)	of	the	other	transforming	characteristics	was	also	detected.	Regarding	deregulated	oncogene	expression	(E6>E2),	the	majority	(42/66,	63.3%)	of	cases	showed	the	presence	of	≥1	other	transforming	characteristic,	however,	in	24/66	(36.7%)	cases,	no	other	transforming	characteristic	was	detected.		
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Figure	4.22	Correlations	between	HPV	gene	expression,	high	methylation	and	HPV	
disruption	in	92	cases	of	HPV	16	positive	VIN	3.	Among	the	92	cases,	there	were	66	cases	of	
E6>E2	expression,	43	cases	of	viral	integration	and	35	cases	of	high	HPV	DNA	methylation	in	total.	The	sum	of	all	proportions	in	each	circle	represents	these	values.	Sample	methylation	was	calculated	by	taking	the	mean	value	from	the	CpG	sites	in	the	E2	and	L1/L2	regions
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4.6.5 Mechanisms	of	Deregulated	Oncogene	Expression	Figure	4.23	demonstrates	the	presence	of	heterogeneous	HPV	biology	in	the	92	HPV	16	positive	cases	that	had	data	available	for	all	three	tested	viral	characteristics.	The	left-hand-side	of	the	figure	(highlighted	blue)	describes	the	physical	status	of	the	HPV	infection	in	the	66/92	cases	of	deregulated	oncogene	expression.	In	the	majority	of	cases	(42/66,	63.6%)	HPV	integration,	high	methylation	(>50%)	or	both	are	present.	In	25/66	(37.9%)	there	is	both	viral	integration	and	high	methylation.	In	11/66	(16.7%)	cases	there	is	viral	integration	without	increased	methylation	and	in	6/66	(9.1%)	cases;	there	is	increased	HPV	DNA	methylation	without	viral	integration.	This	finding	indicates	the	possibility	that	both	HPV	integration	and	HPV	DNA	methylation	lead	to	deregulated	oncogene	expression	independently	but	that	deregulated	oncogene	expression	is	increasingly	likely	when	these	characteristics	are	present	together.		In	24/66	(36.4%)	there	is	neither	high	HPV	DNA	methylation	nor	viral	integration.	This	finding	indicates	the	possibility	that	alternative	mechanisms	to	those	investigated	in	this	study	may	play	an	important	role	in	HPV	pathogenesis	in	VIN	(see	discussion).	The	right	side	of	the	figure	(highlighted	green)	represents	the	26/92	(28.3%)	cases	in	which	E2	expression	was	higher	than	E6	expression	(regulated	oncogene	expression).	In	the	majority	of	these	cases	(19/26,	73.1%)	HPV	was	intact	and	lowly	methylated,	in	7/26	(26.9%)	cases	the	virus	was	integrated,	three	of	which	were	also	highly	methylated.	It	is	of	note	that	the	location	of	viral	disruption	in	these	seven	cases	was	variable:	four	cases	failed	to	amplify	the	E2-5	fragment;	one	case	failed	to	amplify	fragments	E2-2	to	E2-5;	one	cases	failed	to	amplify	fragments	E2-3	to	E2-5	and	the	last	cases	failed	to	amplify	fragment	E1-2.											
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Figure	4.23	HPV	characteristics	in	92	cases	of	HPV	16	positive	VIN	3.	Exploratory	work	used	E6>E2	expression	ratio	to	represent	cases	of	deregulated	oncogene	expression	and	E2>E6	ratio	to	represent	regulated	oncogene	expression.	Viral	integration	was	determined	by	the	failure	of	amplification	of	≥1	fragments	of	an	E1/E2	tiling	PCR.	High	HPV	DNA	methylation	was	determined	by	a	mean	methylation	of	E2	and	L1/L2	CpG	sites	of	>50%.	Heterogeneous	HPV	biology	in	VIN	3	was	present.	Figure	shows	cross-sectional	evidence	of	multiple	mechanisms	potentially	causing	oncogene	expression;	viral	integration	and	methylation	together	as	well	as	each	independently	(A,	B	and	C).	*,	**	Evidence	also	indicating	in	a	minority	of	cases,	that	HPV	pathogenesis	is	occurring	in	the	absence	of	deregulated	oncogene	expression	
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4.6.6 Summary	of	Findings	
• HPV	disruption	correlated	with	deregulated	oncogene	expression	and	relatively	low	E2	gene	expression	in	the	cohort	overall	
• No	relationships	were	identified	between	HPV	disruption	and	E6	or	E7	gene	expression	
• High	E2	and	L1/L2	methylation	(>50%)	strongly	correlated	with	decreased	E2	gene	expression,	and	mean	methylation	was	higher	in	cases	of	deregulated	oncogene	expression	than	in	cases	of	regulated	oncogene	expression	
• Methylation	of	the	promoter	region	did	not	correlate	with	E2	gene	expression	or	deregulated	oncogene	expression	
• High	E2	and	L1/L2	DNA	methylation	strongly	correlated	with	viral	disruption	
• At	least	one	of	three	transforming	viral	characteristics	was	present	in	the	majority	(73/92,	79.3%)	of	cases	of	VIN	3,	and	27.2%	of	VIN	tested	positive	for	all	three.		
• Deregulated	oncogene	expression	was	present	independently	of	other	transforming	HPV	characteristics	in	24/66	(36.4%),	whereas	viral	disruption	and	high	HPV	DNA	methylation	almost	exclusively	occurred	in	combination	with	at	least	one	other	transforming	characteristic.		
• Evidence	exists	for	the	potential	presence	of	multiple	mechanisms	that	could	lead	to	deregulated	oncogene	expression.		
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4.7 Discussion	This	discussion	firstly	gives	an	overview	of	the	principal	findings	of	this	chapter	and	its	overall	strengths	and	limitations.	The	principal	findings	are	then	discussed	individually	in	more	detail.	
4.7.1 Principal	Findings	
• High	HPV	prevalence	in	VIN	3,	with	HPV	16	being	the	most	common	genotype	followed	by	HPV	33	
• Strong	correlations	among	viral	characteristics	associated	with	transforming	HPV	infection	(deregulated	oncogene	expression,	viral	integration	and	high	HPV	DNA	methylation)	
4.7.2 Overall	Study	Strengths	The	large	cohort	size	investigated	in	this	study	is	a	major	strength;	this	is	the	largest	cohort	of	VIN	3,	with	investigation	of	multiple	HPV	characteristics	to	date.	The	quality	of	the	tissue	samples	obtained	from	the	patients	is	another	strength.	The	tissue	samples	were	collected	as	4	mm	punch	biopsies	from	the	disease	affected	area	and	immediately	transferred	into	ThinPrep	storage	media	for	transportation	and	storage	at	-20	°C	prior	to	DNA	extraction.	The	DNA	obtained	from	the	samples	was	of	good	quality,	the	mean	concentration	was	89	ng/μl	(range:	3.8-337.9	ng/μl)	and	the	mean	purity	based	on	the	A260/A280	ratio	was	2.0	(range:	1.5-2.2)	(ThermoScientific,	NanoDrop	2008).	The	quality	of	the	DNA	investigated	has	contributed	to	the	reliability	of	the	data.		
4.7.3 Overall	Study	Limitations	It	is	possible	that	the	RT3	VIN	trial	recruited	a	biased	study	cohort.	This	trial	offered	women	access	to	novel	topical	therapies	that	could	obviate	the	need	for	excisional	surgery.	It	is	possible	therefore	that	recruitment	could	be	biased	towards	women	particularly	keen	to	avoid	surgical	excision	and	its	potential	risks	e.g.	scarring,	altered	anatomy	and	potential	psychosexual	morbidity.	It	could	be	argued	that	these	women	are	more	likely	to	be	younger	women	of	child-breading	age	and	therefore	women	in	whom	HPV	driven	disease	is	more	likely	(de	Sanjose	et	al.	2013).	Presently,	two	histological	classifications	of	VIN	exist:	usual	VIN	(uVIN),	which	is	associated	with	HPV	infection,	and	differentiated	VIN	(dVIN),	which	is	independent	of	HPV	and	driven	by	chronic	skin	conditions	such	as	lichen	sclerosus.	Even	when	disease	is	driven	by	lichen	sclerosus,	HPV	may	still	be	present	as	a	bystander	(de	Sanjose	et	al.	2013).	It	is	not	possible	to	definitively	distinguish	cases	of	HPV-driven	disease	and	non-
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HPV	driven	disease.	This	must	be	considered	when	conclusions	are	drawn;	the	physical	state	of	the	virus	is	likely	to	be	different	between	cases	driven	by	HPV	and	those	that	are	not.	Grouping	the	two	aetiologies	together	could	complicate	analyses	aiming	to	investigate	HPV	biology	in	HPV-driven	disease.	Incorporating	histological	classification	into	dVIN	and	uVIN	as	well	as	incorporating	use	of	P16	expression	(Riethdorf	et	al.	2004)	as	a	marker	of	HPV	driven	disease	could	be	advantageous	in	future	work	developing	understanding	of	HPV	biology	in	VIN	further.	Investigation	of	HPV	biology	in	this	study	was	limited	to	HPV	16	positive	cases.	HPV	16	was	the	most	prevalent	HPV	genotype	however;	the	HPV	biology	in	the	28	non-16	HPV	genotypes	remains	unknown.	It	is	possible	that	biological	variation	exists	between	genotypes	that	could	explain	why	certain	genotypes	are	more	prevalent	than	others.	Finally,	conclusions	drawn	from	analyses	of	relationships	between	viral	characteristics	are	limited	by	the	cross	sectional	nature	of	this	data.	Correlations	can	be	made	and	biological	explanations	can	be	suggested	but	ultimately,	no	firm	conclusions	can	be	made	regarding	causal	relationships.	
4.7.4 HPV	Prevalence	in	VIN	A	high	HPV	prevalence	was	found	in	this	cohort	of	histologically	confirmed	VIN	3(164/167,	98.2%).	In	agreement	with	the	published	literature,	HPV	16	was	the	most	common	genotype	detected	(140/164,	85.4%	cases),	the	second	most	common	genotype	was	HPV	33,	detected	in	16/164	(9.8%)	cases,	followed	by	HPV	42	and	18,	which	were	each	detected	in	4/164	cases	(2.4%).	In	most	HPV	positive	cases	(150/164,	91.5%),	a	single	genotype	was	detected	and	in	14/164	(8.5%)	cases,	multiple	genotypes	were	present.	High-risk	genotypes	were	identified	in	161/164	(96.9%)	HPV	positive	cases	and	low-risk	only	genotypes	were	detected	in	3/164	(3.1%)	(two	cases	of	HPV	42	and	one	case	of	HPV	44/55).		This	study	found	that	disruption	in	PCR	target	sequence	was	an	important	source	of	false	negative	HPV	results	obtained	using	the	E1	targeting,	PapilloCheck®	assay.	HPV	16	was	detected	in	110/167	(65.9%)	cases	using	PapilloCheck®	and	in	135/167	(80.8%)	cases	using	an	HPV	16	type-specific	PCR	that	targets	the	E6	viral	region.	Poor	sample	integrity	was	unlikely	to	be	the	cause	of	this	disparity,	as	all	167	cases	successfully	amplified	the	
ADAT-1	human	gene	during	PapilloCheck®	assay	quality	control	checks.	Additionally,	a	standardised	concentration	of	DNA	(5	ng/μl)	was	used	for	all	assays	to	ensure	that	variation	in	DNA	concentration	was	not	a	source	of	disparate	results.	Similarly,	the	risk	of	false	positive	results	was	minimised	by	using	positive	and	negative	controls	in	every	PCR	
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run	and	scrupulous	technique.	The	E1	ORF	was	disrupted	in	all	25	discordant	cases	and	loss	or	disruption	of	the	PCR	target	region	for	the	PapilloCheck®	assay	was	therefore	the	most	likely	explanation.	Following	this,	the	remaining	HPV	negative	cases	(n=14)	were	sequentially	tested	with	two	additional	assays	targeting	different	viral	regions	(L1	and	E7)	and	different	genotypes	in	order	to	minimise	the	number	of	false	negatives.	This	methodology	resulted	in	overall	HPV	prevalence	for	all	genotypes	increasing	from	77.8%	with	PapilloCheck®	data	alone	to	98.2%.	This	approach	was	by	no	means	infallible;	non-HPV	16	genotypes	with	viral	disruption	were	particularly	vulnerable	to	being	missed	and	HPV	prevalence	of	100%	cannot	be	excluded.	These	findings	are	similar	to	those	in	the	seminal	study	of	HPV	prevalence	in	cervical	cancer	published	by	Walboomers	et	al.	in	1999.	HPV	was	detected	in	nearly	all	cases	of	cervical	cancer	(99.7%,	n=921)	following	sequential	testing	of	HPV	negative	cases	with	assays	targeting	different	regions;	from	this	study,	the	principal	that	HPV	infection	is	necessary	for	the	development	cervical	cancer	was	established.		Walboomers	et	al.	also	found	that	in	cases	initially	identified	as	HPV	negative	(using	MY09/11,	L1	targeting	primers)	which	were	then	re-tested	(=55),	an	E7	type-specific	PCR	detected	HPV	in	38/55	(69.0%),	L1	consensus	primers	in	6/55	(10.9%)	and	E1	consensus	primers	in	14/55	(25.5%).	HPV	that	was	not	detected	using	E1/L1	but	was	detected	by	E7,	were	more	likely	to	be	non-HPV	16	genotypes,	particularly	HPV	18	and	31.	Additional	reports	in	the	literature	indicate	that	in	cases	of	high-grade	cervical	intraepithelial	neoplasia,	8.3%	of	HPV	16	and	27.9%	of	HPV	18	infections	are	missed	by	an	L1	targeting	assay	compared	to	an	E6/E7	targeting	assay;	a	finding	attributed	to	the	fact	that	viral	integration	is	reported	more	commonly	in	non-HPV	16	genotypes	(Pett	&	Coleman	2007;	Roberts	et	al.	2006;	Vinokurova	et	al.	2008).	Studies	have	also	demonstrated	that	the	cases	undetected	by	an	L1	targeting	assay	are	more	likely	to	be	cases	of	higher-grade	disease,	in	which	viral	integration	is	more	likely.	The	present	study	has	similarly	found	that	the	proportion	of	non-HPV	16	genotypes	was	higher	in	cases	with	viral	disruption,	but	contrary	to	cervical	disease,	HPV	33	was	the	second	most	prevalent	non-16	genotype.	Proportionally,	more	non-HPV	16	genotypes	were	identified	in	cases	initially	identified	as	HPV	negative	by	PapilloCheck®	(6/31,	19.4%)	than	in	the	initial	HPV	positive	cases	identified	(16/119,	13.4%).		This	study	has	found	that,	similar	to	CIN	and	cervical	cancer,	disruption	in	PCR	target	region	is	an	important	cause	of	false	negative	HPV	results	in	high	grade	VIN.	This	finding,	at	least	in	part,	provides	explanation	for	the	broad	range	of	HPV	prevalence	in	VIN	reported	in	the	literature	to	date	(30.8%	-	100%).	Aside	from	the	fact	that	the	histological	composition	of	the	cohorts	varied	amongst	these	studies,	the	majority	of	these	studies	
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used	only	an	L1	targeting	PCR	to	identify	cases	of	HPV	(see	table	1.2	in	background).	In	addition,	nearly	all	studies	in	a	meta-analysis	conducted	by	de	Vuyst	et	al.	2009,	which	reported	HPV	prevalence	of	85.3%	in	1061	cases	of	VIN,	used	single	region	L1	targeting	assays.		
4.7.4.1 HPV	Prevalence:	Strengths	
4.7.4.1.1 Quality	Assurance	(QA)	and	Reproducibility	All	HPV	detection/genotyping	assays	used	in	this	work	included	a	positive	(CaSki	cell	line	DNA)	and	a	negative	(H20)	control	for	which,	all	runs	had	to	generate	the	correct	result.	Additional	quality	assurance	checks	were	applied	by	the	Greiner	PapilloCheck®	assay	which	tested	DNA	integrity	in	all	samples	via	the	amplification	of	the	ADAT-1	gene;	all	samples	used	in	this	work	passed	this	QA	step.	The	inter-run	reproducibility	of	the	PapilloCheck®	and	HPV	16	E6	PCR	assays	was	tested	and	found	to	be	high.	The	PapilloCheck®	assay	was	repeated	in	25%	of	the	baseline	cohort	with	98%	concordance.		For	the	HPV	16	E6	PCR	assay,	20%	of	the	baseline	cohort	was	retested	with	100%	concordance	and	for	the	HPV	16	E1	PCR,	testing	was	repeated	in	61%	of	the	baseline	cohort	with	93.8%	concordance.		The	number	of	samples	repeated	was	higher	for	the	HPV	16	E1	PCR	as	this	was	a	new	assay	developed	for	this	study.	The	stringent	quality	control	measures	were	a	significant	strength	of	this	study.	
4.7.4.2 HPV	Prevalence:	Limitations	
4.7.4.2.1 Is	a	Negative	Result	Truly	a	Negative	Result	in	This	Cohort?	The	multiple	assays	used	by	this	study	could	still	have	failed	to	detect	certain	cases	of	disrupted	HPV.	HPV	16	was	the	genotype	most	exhaustively	tested	for,	and	would	have	been	identified	by	all	4	assays	used	should	their	specific	target	regions	be	intact	(E1,	L1,	E7	and	E6).	Non-HPV	16	genotypes	were	tested	for	by	three	of	the	assays:	PapilloCheck®,	DiaMex	and	HPV	E7	type	specific	PCR.	PapilloCheck®	tested	for	multiple,	commonly	reported	genotypes	but	targeted	the	E1	region,	well	documented	to	be	commonly	affected	by	viral	integration	(Cricca,	Venturoli	et	al.	2009b;	Wang	et	al.	2013;	Romanczuk	&	Howley	1992;	Bryant	et	al.	2014).	The	DiaMex	assay	also	tests	for	multiple	genotypes	but	specifically	targets	the	L1	region	of	the	virus;	high	levels	of	disruption	in	this	region	in	cervical	disease	have	been	reported.	For	example,	Wang	et	al.	in	2013	found	integration	events	in	64/113	(56.64%)	cases	of	CIN,	of	which,	73.52%	involved	the	L1	region	of	the	virus	(Wang	et	al.	2013).	HPV	E7	type-specific	PCR	was	only	able	to	detect	HPV	18,	31,	33,	35	and	51.	Retrospectively,	the	E6	and	E7	type	specific	PCRs	were	best	suited	to	accurately	determine	the	presence	of	HPV	being	almost	invariably	retained	viral	regions	due	to	their	
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expression	being	necessary	for	conversion	to,	and	maintenance	of,	the	transformed	state.	Limited	DNA	availability	prohibited	extensive	use	of	these	assays	and	HPV	16,	18,	31,	33,	35	and	51	were	the	genotypes	tested	for.	These	limitations	mean	that	the	potential	for	the	three	HPV	negative	samples	in	this	cohort	being	HPV	positive	should	be	considered.	It	cannot	be	ruled	out	that	the	true	HPV	prevalence	in	this	cohort	is	100%.	
4.7.4.2.2 Does	HPV	Prevalence	in	this	Cohort	Equate	to	HPV	Pathogenesis?	It	is	widely	accepted	that	there	are	four	stages	in	the	progression	of	HPV	related	disease:	HPV	acquisition,	HPV	persistence,	progression	of	persisting	infection	to	transforming	infection,	and	invasion	(World	Health	Organisation	International	Agency	for	Research	on	Cancer	2005).	The	data	presented	in	this	study	(and	in	most	studies)	assessed	HPV	status	at	a	single	point	in	time	and	although	a	histological	diagnosis	of	VIN	has	been	made,	it	cannot	be	said	with	certainty	that	the	two	are	not	independent	of	one	another.	Some	studies	have	tried	to	tackle	this	by	using	additional	tests	to	try	to	identify	those	cases	where	HPV	is	likely	to	be	the	driving	force	for	the	disease.	For	example	de	Sanjose	et	al.	2013	incorporated	a	p16INK4a	immunohistochemistry-staining	test;	based	on	evidence	that	p16INK4a	is	commonly	overexpressed	in	VIN	caused	by	HPV	infection.	Application	of	p16	immunohistochemistry	to	the	RT3	VIN	cohort	was	considered,	but	was	not	performed,	because	of	conflicting	evidence	in	the	literature	regarding	the	specificity	of	p16INK4a	over-expression	in	HPV	associated	disease;	several	studies	have	found	high	expression	in	non-HPV	associated	VIN	(Rufforny	et	al.	2005;	Hoevenaars	et	al.	2008;	O’Neil,	McCluggage	2006;	Ordi	et	al.	2009;	Riethdorf	et	al.	2004).	In	the	absence	of	a	definitive	method	available	to	determine	HPV	driven	disease	and	HPV	independent	disease	(despite	HPV	positivity),	this	study	investigated	three	physical	characteristics	of	the	virus	associated	with	cellular	transformation:	viral	integration,	viral	DNA	methylation	and	viral	gene	expression.	The	presence	of	one	or	more	of	these	characteristics	in	a	sample	can	help	identify	HPV	driven	cases	and	HPV	independent	cases	and	is	discussed	further	in	section	4.7.5.4.	
4.7.4.3 Broader	Implications	This	work	emphasises	the	importance	of	using	HPV	detection/genotyping	assays	that	target	well-conserved	regions	of	the	virus	(E6	and	E7)	to	accurately	determine	HPV	presence.	HPV	presence	is	more	likely	to	be	missed	in	disease	that	is	high-grade	and/or	caused	by	non-HPV	16	genotypes	due	to	the	increased	likelihood	of	HPV	integration	in	both	scenarios.	This	is	of	particular	importance	if	HPV	is	to	be	utilised	as	a	biomarker	in	disease	management.	For	example	at	the	time	of	this	study,	the	cervical	screening	programme	in	England	has	incorporated	the	addition	of	HPV	testing	to	triage	management	
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of	patients	with	low-grade	abnormal	cytology	found	in	cervical	smear	tests.	In	this	setting,	selection	of	the	HPV	test	to	be	used	is	of	paramount	importance,	in	order	to	minimise	the	risk	of	missing	high-grade	disease,	with	its	associated	integrated	HPV	infection	and	disrupted	DNA.	Precision	in	estimating	HPV	genotype	prevalence	in	all	HPV	related	disease	is	also	important	to	aid	HPV	vaccine	design	and	development,	in	addition	to	ensuring	accurate	assessment	of	clinical	benefit	and	cost	effectiveness.		It	is	also	possible	that	this	work	indicates	that	HPV	prevalence	in	VIN	(and	perhaps	vulval	cancer	where	viral	integration	is	even	more	likely)	is	under-represented	worldwide	due	to	extensive	use	of	assays	reliant	on	the	presence	of	intact	virus.	The	cohort	used	in	this	study	was	potentially	biased	towards	HPV	positive	cases	through	its	likely	appeal	to	younger	women,	particularly	keen	to	avoid	the	traditional	surgical	approaches	to	management.	However,	other	studies	reporting	100%	prevalence	do	exist	(Torre	et	al.	1992;	Nagano	et	al.	1996;	Logani	et	al.	2003;	Riethdorf	et	al.	2004;	Rufforny	et	al.	2005;	Srodon	et	al.	2006;	Skapa	et	al.	2007;	van	de	Nieuwenhof,	van	Kempen,	et	al.	2009;	Tachezy	et	al.	2011)	and	it	is	possible	that,	like	CIN	and	cervical	cancer,	HPV	may	be	necessary	in	the	causation	of	VIN	and	vulval	cancer	but	not	in	isolation.	It	is	possible	that	the	presence	of	lichen	sclerosus	(thought	to	drive	disease	in	a	proportion	of	cases	of	VIN)	is	one	reason	why	some	women	with	HPV	infection	develop	VIN	and	others	do	not.	This	is	potentially	supported	by	findings	of	high	HPV	prevalence	(48.9%)	in	48	cases	of	histologically	defined	dVIN	(de	Sanjose	et	al.	2013).	This	concept	is	developed	and	discussed	in	more	detail	in	the	sections	that	follow.	Finally,	the	cohort	could	have	been	biased	as	women	with	invasive	disease	were	excluded	and	lichen	sclerosus	dVIN	has	been	reported	more	commonly	in	associated	with	invasive	disease	(McCluggage	2009).	
4.7.4.4 Future	Work	It	would	be	of	interest	to	conduct	a	large	study	of	HPV	prevalence	VIN.	It	would	be	useful	to	carry	out	histological	assessment	to	define	samples	as	usual	(thought	to	be	HPV	dependent)	or	differentiated	(thought	to	be	HPV	independent);	undertake	HPV	testing	using	an	assay,	such	as	Hybrid	Capture	2	that	targets	the	full	HPV	genome	(that	would	limit	false	negative	results	obtained	through	PCR	target	disruption);	and	apply	P16	analysis	to	determine	those	cases	in	which	HPV	driven	disease	is	present.	Such	a	study	could	greatly	improve	understanding	of	HPV	biology	in	VIN.		Finally,	the	limitation	of	HPV	detection/genotyping	tests	targeting	non-conserved	viral	regions	should	be	acknowledged	and	their	appropriate	use	in	HPV	research	carefully	considered.	It	is	important	to	note	that	the	PapilloCheck®	assay	has	clinical	validation	for	use	within	the	cervical	screening	program	(Hesselink	et	al.	2014).	From	a	clinical	perspective,	accurate	detection	of	every	
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HPV	positive	cases	is	not	always	what	is	important,	but	recognition	of	those	cases	causing	disease,	is.	The	validity	of	the	PapilloCheck®	assay	in	this	context	may	reflect	this;	nonetheless,	its	95.8%	(Hesselink	et	al.	2014)	sensitivity	could	be	a	result	of	failure	to	detect	cases	with	disruption	in	the	E1	region.		
4.7.5 HPV	Characteristics	in	VIN	
4.7.5.1 HPV	Integration	This	study	constitutes	the	largest	study	of	HPV	integration	in	VIN	to	date,	and	detected	HPV	integration	in	71/136	cases	(52.5%	CI	45.4%-59.0%)	of	the	HPV	16	positive	cases.	Lower	rates	of	integration	are	reported	by	the	two	published	studies	specifically	looking	at	HPV	integration	in	VIN.	One	study	investigated	HPV	integration	in	21	cases	of	HPV	16/18	positive	VIN	3	using	the	APOT	technique	(amplification	of	papillomavirus	oncogene	transcripts,	(Klaes	et	al.	1999).	Integrated	transcripts	were	detected	in	8/21	(38.1%)	(90%	CI	21.0%-55.0%)	cases	(Hillemanns,	Wang	2006).	The	other	study	investigated	a	cohort	comprising	22	cases	of	HPV	16	positive	VIN	3,	1	case	of	vaginal	intraepithelial	neoplasia	3	(VaIN	3),	one	case	of	anal	intraepithelial	neoplasia	2	(AIN	2)	and	1	case	of	a	biopsy	that	contained	no	discernible	vulval	pathology.	Two	techniques	were	adopted:	APOT	and	DIPS	(detection	of	integrated	papillomavirus	sequences	(Luft	et	al.	2001).	Viral	integration	was	detected	in	8/25	cases	(32%,	90%	CI	16.6%-47.4%),	(Bryant,	Onions	et	al.	2014).	Research	investigating	HPV	integration	in	CIN	is	more	abundant	and	reported	rates	range	from	11%	to	60%	(Doorbar	et	al.	2012b).	One	possible	explanation	for	this	variation	is	the	disease	grade	in	the	studied	cohort.	Particularly	with	regard	to	the	CIN	studies,	disease	grade	is	often	not	distinguished	making	direct	comparison	with	this	work	difficult.	Another	possible	explanation	is	the	choice	of	assay	used.	Both	the	APOT	and	DIPS	assays	specifically	target	integrated	sequences,	which	can	improve	the	specificity	of	the	assay	by	reducing	the	risk	of	false	positive	results.	However,	these	assays	may	have	reduced	sensitivity	by	increasing	false	negative	results	should	assay	design	not	permit	the	detection	of	all	possible	integration	events.	Furthermore,	these	are	technically	demanding	assays	and	the	integration	events	should	ideally	be	validated	by	cross-junction	PCR,	but	this	is	not	always	performed.	The	presence	of	viral	integration	within	a	cohort	could	also	be	affected	by	the	choice	of	HPV	detection	assay	used.	As	this	study	found,	successful	detection	of	HPV	depends	on	genomic	integrity	at	the	PCR	target	region.	Many	HPV	detection	assays	target	the	L1	region	of	the	virus	and	some	the	E1	region;	both	of	which	are	frequently	involved	in	viral	integration	(Bryant,	Onions	et	al.	2014;	Cricca	et	al.	2009b;	Kalantari	et	al.	1998;	
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Romanczuk	&	Howley	1992;	Wang	et	al.	1992).	Therefore,	HPV	positive	cases	detected	by	these	assays	are	more	likely	to	contain	intact,	rather	than	integrated	virus,	biasing	a	study	towards	selection	of	intact	cases	and	under-representing	cases	of	viral	integration.	This	could	be	of	particular	importance	when	studying	cohorts	of	known	high-grade	disease	when	viral	integration	is	more	likely	to	be	present	(Hudelist	et	al.	2004).	Viral	integration	is	associated	with	HPV	pathogenesis	and	cellular	transformation	(Hillemanns	&Wang	2006;	Jeon	et	al.	1995;	Cricca	et	al.	2009b;	Woodman	et	al.	2007;	van	de	Nieuwenhof,	van	Kempen	et	al.	2009);	it	is	important	therefore	to	consider	why	not	all	samples	testing	positive	for	HPV	16	contained	integrated	virus.	It	is	important	to	understand	that	HPV	integration	is	not	essential	for	disease	to	progress	and	even	when	in	episomal	form,	disease	can	exist.	For	example,	Arias-Pulido	et	al.	found	episomal	HPV	to	be	present	in	61.9%	of	126	cases	of	cervical	carcinoma	in	situ	(Arias-Pulido	et	al.	2006).	However,	other	factors	should	also	be	considered,	firstly,	it	is	possible	that	despite	the	high	prevalence	of	HPV	16	in	this	study	cohort	(81.5%),	HPV	was	only	responsible	for	driving	disease	in	the	52%	containing	integrated	virus.	The	remaining	cases	could	represent	those	in	which	viral	integration	is	yet	to	occur;	viral	integration	may	be	a	late	event	in	HPV	transformation	and	not	required	development	of	high-grade	disease	(Schiffman	&	Wentzensen	2013;	Cullen	et	al.	1991).	The	disease	category	VIN	3	could	represent	a	spectrum	of	disease	grade	itself;	those	cases	of	viral	integration	in	this	cohort	representing	those	cases	closer	to	malignancy.	It	is	also	possible	that	in	a	significant	number	of	cases,	alternative	means	of	viral	transformation	are	taking	place	e.g.	DNA	methylation	(Fernandez	et	al.	2008;	Burgers	et	al.	2007;	Bryant,	Onions	et	al.	2014).	Finally,	another	possibility	is	that	HPV	was	present	but	not	causative	of	disease	in	the	presence	of	alternative	disease	aetiology	e.g.	lichen	sclerosus;	perhaps	some	cases	would	have	been	classified	as	dVIN	if	further	histological	analysis	have	been	available.	In	reality,	the	likelihood	is	that	a	combination	of	these	three	explanations	apply	i.e.	in	some	cases,	the	HPV	infection	is	only	present	as	a	bystander	to	alternative	disease	aetiology;	in	some	cases,	integration	has	not	yet	occurred;	and	finally,	in	other	cases,	alternative	means	of	viral	transformation	such	as	DNA	methylation	are	taking	place.	No	statistically	significant	relationship	was	identified	between	viral	integration	and	patient	age,	smoking	status	or	disease	episode	in	this	study.	Studies	do	exist	reporting	associations	between	increasing	patient	age	and	viral	integration	(Klaes	et	al.	1999;	Bryant,	Onions	et	al.	2014;	Luft	et	al.	2001;	Häfner	et	al.	2008;	Hopman	et	al.	2004),	which	is	thought	to	reflect	longer	duration	of	HPV	infection.	In	the	current	study	the	median	age	of	patients	was	45	years	in	cases	of	intact	HPV	and	47	years	in	integrated	(range	20-81),	but	this	difference	was	not	significant.	Smoking	is	well	established	as	a	co-factor	for	the	
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development	of	CIN	and	cervical	cancer	(Mzarico	et	al.	2015).	The	high	prevalence	of	smoking	(58.8%	current	smokers	and	23.8%	previous	smokers)	reported	by	women	in	this	study,	and	others	(De	Vuyst	et	al.	2009;	Jones	et	al.	2005)	would	suggest	that	smoking	plays	a	similar	aetiological	role	in	VIN.	It	was	hypothesised	that	smoking	could	increase	the	likelihood	of	viral	integration	due	to	diminished	local	host	immunity	but	such	an	association	was	not	identified.		
4.7.5.1.1 Strengths	The	E1/E2	tiling	PCR	methodology	used	in	this	study	is	a	relatively	simple	and	robust	assay.	The	quantity	of	template	DNA	used	was	standardised;	E6	PCR	was	used	to	ensure	the	presence	of	amplifiable	HPV	DNA;	and	positive	and	negative	controls	were	used	in	every	run.	The	data	was	also	subject	to	reproducibility	quality	control	checks.	For	the	E1	tiling	PCR	61%	of	baseline	RT3	VIN	samples	were	run	in	duplicate	at	separate	points	in	time	with	93.8%	concordance.	30%	of	all	E2	fragments	were	performed	in	duplicate	repeat	with	the	following	concordance:	E2-1	fragment	95.1%,	E2-2	fragment	95.1%,	E2-3	fragment	92.6%,	E2-4	fragment	95.1%	and	E2-5	fragment	94.8%	(see	methods	chapter,	section	2.5.2.2).It	is	important	to	note	that,	one	case	included	in	this	study	did	not	amplify	HPV	16	E6	but	repeatedly	tested	positive	using	the	PapilloCheck®	assay.	This	case	also	failed	to	amplify	any	of	the	E1/E2	fragments	and	was	likely	a	false	positive	HPV	16	positive	result.	Finally,	another	strength	of	this	work	was	the	addition	of	a	dual	fragment	
E1	tiling	PCR	to	the	more	conventional	E2	tiling	PCR	assay	(Collins	et	al.	2009).		This	method	detected	an	additional	12	cases	of	HPV	integration	(an	increase	of	9%	in	the	cohort	overall)	that	would	not	have	been	detected	if	the	tiling	E2	PCR	had	been	used	alone.		
4.7.5.1.2 Limitations	An	E1/E2	tiling	PCR	can	only	specifically	ascertain	whether	or	not	the	E1	and	E2	regions	of	the	virus	are	intact	or	disrupted.	Although	it	is	very	likely	that,	when	disrupted,	it	is	a	consequence	of	viral	integration,	it	is	not	the	only	possibility.	The	integrity	of	the	DNA	in	the	sample	may	be	poor	as	a	result	of	sample	processing	leading	to	an	over-estimation	of	the	presence	of	viral	integration.	The	validity	of	the	data	was	supported	by	the	strong	correlation	found	between	viral	integration	and	HPV	DNA	methylation	(section	4.6.3)	(p=<0.000).	Alternatively,	it	is	also	possible	that	the	E1/E2tiling	PCR	may	under-represent	viral	integration	as	these	are	not	the	only	regions	of	the	virus	that	are	vulnerable	to	disruption	as	a	result	of	viral	integration.	Viral	integration	has	been	shown	in	numerous	studies	to	involve	non-E1/E2	regions	of	the	virus,	particularly	the	L1/L2	(Bryant,	Onions	
et	al.	2014;	Corden	1999;	Schiffman	&	Wentzensen	2013)	region.		
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4.7.5.2 HPV	DNA	Methylation	With	regard	to	HPV	DNA	methylation,	this	work	generated	three	main	findings.	Firstly,	there	was	statistically	significant	variation	between	samples	in	the	level	of	HPV	DNA	methylation	at	each	viral	region	within	the	cohort.	Secondly,	conserved	patterns	of	intra-regional	methylation	were	apparent,	consistent	with	existing	reports	in	other	HPV	associated	disease.	Finally,	there	was	no	correlation	between	increased	methylation	and	increased	age,	recurrent	disease	or	smoking.	
4.7.5.2.1 Variable	Levels	of	HPV	DNA	Methylation	at	Genomic	Regions	in	VIN	3	The	overall	level	of	methylation	at	each	region,	for	each	sample	was	calculated	by	taking	the	mean	methylation	of	all	measured	regional	CpG	sites.	The	level	of	methylation	at	each	tested	region	was	found	to	vary	significantly	amongst	samples	(E2	mean	=	26.25%±35.65,	
L1L2	mean	=	28.03%±32.13,	promoter	mean	=	3.143±11.629).	Interestingly,	for	the	E2	and	L1/L2	regions,	levels	of	methylation	identified	two	groups	(Figure	4.7).	Samples	appear	to	be	broadly	split	into	those	with	low	levels	of	methylation	(approximately	<10%)	and	those	with	high	levels	of	methylation	(approximately	>50%)	with	relatively	few	samples	falling	between.	The	same	pattern	was	not	apparent	in	the	promoter	region.		This	is	the	first	study	investigating	regional	HPV	DNA	methylation	within	a	single	disease	grade.	Reports	in	the	literature	exist	correlating	higher	levels	of	E2	and	L1/L2	methylation	with	high-grade	cervical	and	vulval	disease	(Mirabello,	Schiffman	et	al.	2012;	Bryant,	Tristram	et	al.	2014;	Turan	et	al.	2007;	Kalantari	et	al.	2010;	Wiley	et	al.	2005;	Brandsma	
et	al.	2009).		Based	on	this,	it	was	not	unreasonable	to	expect	relatively	consistently	high	levels	of	methylation	in	HPV	16	positive	cases	in	this	cohort	of	VIN	3.	The	possible	explanations	of	variable	regional	methylation	and,	perhaps	even	two	groups	of	methylation,	are	the	same	as	those	describing	why	all	cases	were	not	found	to	contain	HPV	integration	above.	Those	cases	highly	methylated	may	represent:	a. Cases	closer	to	malignant	transformation	within	a	spectrum	of	disease	grade	that	may	exist	within	the	VIN	3	classification		b. Cases	in	which	HPV	DNA	methylation	is	driving	cellular	transformation	as	opposed	to	those	cases	in	which	alternative	viral	characteristics	are	e.g.	viral	integration	c. Cases	with	HPV	driven	disease	as	opposed	to	those	cases	in	which	HPV	is	an	incidental	finding	to	alternative	vulval	disease	aetiology	e.g.	lichen	sclerosus		
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Again,	it	is	most	likely	that	it	is	a	combination	of	these	three	reasons	that	explains	the	variation	in	reality.	Correlations	between	viral	characteristics	exploring	this	further	are	discussed	in	section	4.8.	
4.7.5.2.2 HPV	DNA	methylation	of	the	promoter	region	is	consistently	low	in	VIN	3	It	was	hypothesised	that	HPV	DNA	methylation	of	the	promoter	region	(containing	the	E2BS3	and	the	E2BS4)	would	be	high	in	VIN,	representing	a	mechanism	leading	to	deregulated	oncogene	expression	and	viral	transformation.	This	hypothesis	was	based	on	evidence	that	methylation	of	the	E2BS	inhibits	binding	of	the	E2	protein	(Thain	et	al.	1996;	Kim	et	al.	2003).		However,	methylation	of	this	region	was	found	to	be	consistently	low	(mean	=	3.143±11.629).		This	finding	suggests	that	low/no	methylation	of	the	promoter	may	confer	a	selective	growth	advantage.	Research	reporting	HPV	promoter	region	methylation	in	vulval	intraepithelial	neoplasia	is	contradictory,	some	studies	report	increased	methylation	with	increased	disease	grade	(Brandsma	et	al.	2009;	Kalantari	et	al.	2004;	Bhattacharjee	&	Sengupta	2006;	Ding	et	al.	2009),	and	others	report	the	opposite	(Piyathilake	et	al.	2011;	Badal	et	al.	2003;	Hublarova	et	al.	2009;	Patel	et	al.	2012).	This	current	study	found	almost	universally	low	levels	of	promoter	region	methylation	in	a	large	cohort	of	high-grade	disease	and	therefore,	supports	the	latter.		The	higher	levels	of	methylation	seen	in	the	E2	and	L1/L2	regions	could	suggest	that	methylation	of	these	regions	confers	a	selective	advantage	to	the	cell.	It	is	possible	that	intragenic	methylation	of	E2	directly	represses	transcription	of	the	gene.	E2	expression	is	known	to	repress	the	expression	of	the	E6	and	E7	oncogenes	and	without	it,	E6	and	E7	expression	would	be	unopposed	and	disease	more	likely	to	ensue.	The	L1	and	L2	genes	are	responsible	for	capsid	formation	enduring	the	later	stages	of	the	viral	life	cycle	and	are	not	known	to	play	a	significant	role	in	transforming	infection	(Ozbun	&	Meyers	1997).	
4.7.5.2.3 Conserved	intra-regional	patterns	of	methylation	exist	in	the	RT3	VIN	cohort	The	mean	level	of	methylation	at	each	CpG	site	within	each	region	was	found	to	be	different	and	conserved	patterns	of	methylation	at	each	region	were	apparent,	comparable	to	patterns	reported	by	other	studies	(Bryant,	Tristram	et	al.	2014;	Kalantari	
et	al.	2004).	Methylation	patterns	at	each	genomic	region	were	of	interest	in	this	work	as	this	observation	contributes	to	a	small,	but	growing,	body	of	evidence,	regarding	the	mechanisms	of	HPV	DNA	methylation.	It	is	proposed	that	this	conserved	pattern	of	methylation	is	a	result	of	specific	mechanisms	of	DNA	methylation	targeting	each	CpG	differently.	It	is	possible	that	this	results	from	enzymatic	or	structural	differences	within	each	region	that	might	affect	the	ability	of	DNMT’s	and	meCpG	binding	proteins	to	bind	the	DNA.	Relevant	structural	differences	may	include	nucleosome	position,	nuclear	matrix	
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attachment	regions	and	DNA	secondary	structure.		Methylation	of	genomic	DNA	is	directly	related	to	the	nucleosomal	structure	of	DNA,	which	has	a	helical	pitch	of	10-15	bp	(Chodavarapu	et	al.	2010).	DNMTs	access	the	major	groove	of	nucleosomal	DNA	which	would	allow	better	access	to	DNA	on	the	outside	of	nucleosomes;	consistent	with	differing	methylation	levels	seen	every	10	bp.	Different	methylation	levels	every	10	bp	due	to	nucleosomal	structure	would	account	for	the	“N”	shaped	pattern	for	the	L1/L2	region	seen	in	this	work	as	well	as	the	conserved	pattern	seen	in	the	E2	region	(Figure	4.10,	Figure	4.12).	
4.7.5.2.4 Variation	of	Inter-Regional	HPV	DNA	Methylation	The	median	rank	methylation	of	each	test	region	was	found	to	be	statistically	different	(E2,	L1/L2	and	the	promoter	region).	Mean	methylation	at	E2	and	L1/L2	was	generally	higher	and	more	variable	(26.25%	±	35.82	and	28.03%	±	34.93	respectively)	than	the	promoter	region,	which	was	almost	universally	unmethylated	or	methylated	to	very	low	levels	(3.14%	±	13.44).	These	findings	are	supported	by	similar	patterns	found	in	a	study	of	VIN	investigating	the	same	regions	previously	conducted	by	the	same	laboratory	(Bryant,	Onions	et	al.	2014).	These	differences	could	be	explained	by	selective	growth	advantages/	disadvantages	that	methylation	confers	at	each	region.		
4.7.5.2.5 Patient	Age,	Smoking,	VIN	Disease	Episode	and	HPV	DNA	Methylation	No	statistically	significant	correlation	was	identified	between	HPV	DNA	methylation	and	patient	age,	smoking	status	or	disease	episode.	It	was	hypothesised	that	older	patients	would	have	higher	levels	of	HPV	DNA	methylation.	This	association	is	thought	to	result	from	the	longer	duration	of	infection	making	disease	progression	more	likely	(Clarke	et	al.	2012).This	was	not	found	to	be	the	case;	no	relationship	between	age	and	methylation	was	identified.	This	study	was	not	designed	to	identify	such	associations	but	in	view	of	similar	findings	reported	elsewhere	in	the	literature	(Mirabello	et	al.	2013	Mirabello	et	al.	2012),	it	is	increasingly	likely	that	no	relationship	exists.	Similarly,	patients	with	recurrent	VIN	disease	were	also	hypothesised	to	have	higher	levels	of	methylation	due	to	putative	longer	duration	of	infection	but,	again,	no	relationship	was	identified.	Finally	as	described	previously,	smoking	has	been	associated	with	diminished	local	immunity	and	is	well	established	as	a	co-factor	for	the	development	of	CIN	and	cervical	cancer	(Barton	et	al.	1988;	Giuliano	et	al.	2002;	Holly	et	al.	1986;	Castle	et	al.	2002;	McIntyre-Seltman	et	al.	2005).	Although	smoking	was	common	in	this	studied	cohort	(58.8%	current	smokers	and	23.8%	previous	smokers)	suggesting	a	possible	aetiological	role,	no	association	was	found	between	smoking	and	HPV	DNA	methylation.		
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4.7.5.2.6 Strengths	Pyrosequencing	measures	DNA	methylation	in	a	sequencing-by-synthesis	manner	that	quantitatively	monitors	the	real	time	incorporation	of	nucleotides	through	the	enzymatic	conversion	of	released	pyrophosphate	into	a	proportional	light	signal.	This	quantitative	measurement	is	more	informative	than	other	techniques	available.	The	relatively	simple	protocol	limits	the	influence	of	human	error	and	enables	efficient	workflow	with	high	throughput,	testing	multiple	CpG’s	in	a	single	assay.	Pyrosequencing	is	widely	accepted	as	the	technique	of	preference	for	methylation	studies	avoiding	the	biases	inherent	to	the	cloning	procedure	(Siqueira	et	al.	2012).	Stringent	quality	control	measures	were	applied	to	the	data.	The	pyrosequencing	software	incorporates	internal	quality	control	checks	identifying	those	samples,	which	have	failed	bisulphite	conversion	of	sequencing,	and	therefore	should	be	excluded.	Any	samples	identified	as	‘check’	indicating	that	manual	assessment	for	inclusion	was	required	were	thoroughly	reviewed.	Additionally,	all	samples	were	repeated	in	duplicate	within	a	run	and	only	included	if	the	variation	in	the	results	was	less	than	three	standard	deviations	of	the	mean	standard	deviation	calculated	for	all	CpG	site	for	each	region.	Results	of	quality	control	analyses	are	included	in	methods	chapter.	
4.7.5.2.7 Limitations	The	quality	assurance	checks	applied	to	this	data	impacted	on	the	available	data	for	analysis.	The	promoter	region	withstood	the	checks	better	than	the	E2	and	L1/L2	regions.	High	levels	of	viral	integration	were	found	in	those	cases	that	failed	the	initial	pyrosequencing	(84.4%	for	E2,	65.6%	for	L1/L2	and	62.5%	for	the	promoter).	Viral	integration	was	tested	for	using	a	tiling	PCR	targeting	several	overlapping	fragments	of	the	E1	and	E2	genes,	which	could	explain	why	higher	rates	were	detected	in	those	cases	of	
E2	failure.	It	is	possible	that	the	addition	of	a	L1/L2	region-tiling	assay	would	identify	more	cases	of	integration.	One	possible	explanation	for	the	high	failure	rate	would	be	the	high	levels	of	disrupted	virus	in	the	cohort	of	high-grade	disease.		The	promoter	region	may	be	less	affected	by	viral	disruption	due	to	integration.	Additional	factors	contributing	to	the	high	failure	rate	include	poor	DNA	integrity	of	the	sample	in	general,	human	error	in	running	the	assay	and	overly	stringent	parameters	being	applied	with	regard	to	variation	between	duplicate	repeats.	
4.7.5.3 HPV	Gene	Expression	Expression	levels	of	the	E6		and	E7	but	particularly	the	E2	gene	varied	in	the	cohort	of	VIN	3	compared	to	expression	of	two	stably	expression	human	reference	genes	TBP	and	HPRT.	This	supports	the	findings	of	a	small	published	study	conducted	by	Bryant	et	al.	who	also	
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found	varied	E2/E6/E7	expression	in	a	cohort	of	25	cases	of	high	anogenital	neoplasia	(Bryant,	Onions	et	al.	2014).	Exploratory	analysis	of	E2	expression	relative	to	E6	expression	for	each	sample	was	undertaken	to	further	investigate	the	biological	and	pathological	heterogeneity	in	the	cohort	that	was	indicated	in	the	data	generated	for	viral	integration	and	methylation.	Cases	with	high	E2	expression	relative	to	E6	expression	were	classified	as	‘regulated’	oncogene	expression,	in	view	of	the	controlling	presence	of	E2.	Cases	with	high	E6	expression	relative	to	E2	expression	were	classified	as	‘deregulated’	oncogene	expression	potentially	associated	with	loss	of	E2.		The	majority	of	HPV	16	postive	cases	in	the	cohort	were	found	to	have	high	E6	expression	relative	to	E2	expression	(74.1%	vs.	25.9%)	indicating	that	in	the	majority	of	cases	of	VIN	3,	deregulated	oncogene	expression	was	present.		This	aspect	of	the	work	was	purely	exploratory	and	is	not	a	proven	method	of	identifying	regulated	and	deregulated	oncogene	expression.	There	is	no	established	method	for	accurately	determine	regulated	and	deregulated	gene	expression	and	for	this	reason,	comparison	with	data	in	the	literature	is	not	possible.	The	final	important	finding	was	that	gene	expression	did	not	appear	to	be	a	proxy	marker	for	any	of	the	tested	patient	characteristics.	Although	older	patients	expressed	lower	levels	of	E2	than	younger	patients	and	the	mean	age	of	patients	with	E6>E2	was	higher	than	patients	expressing	E2>E6	(48	years	vs.	43	years)	neither	of	these	findings	were	statistically	significant.	Patients	with	recurrent	disease	were	significantly	more	likely	to	have	higher	levels	of	E6	expression	relative	to	E2	than	patients	with	first	episode	disease	(p	=	0.004).	However,	E6>E2	expression	was	not	a	proxy	marker	for	recurrent	disease	because	in	37/59	cases	of	first	episode	disease,	the	pattern	of	expression	was	also	E6>E2.	There	were	no	correlations	identified	between	gene	expression	and	smoking	status.	
4.7.5.3.1 Strengths	This	study	constitutes	the	largest	cohort	of	VIN	3	cases	in	which	HPV	gene	expression	has	been	assessed.	The	comparison	of	expression	levels	of	individual	genes	within	the	cohort,	as	well	as	the	comparisons	of	expression	levels	between	genes	within	each	sample	represents	a	very	thorough	analysis	of	gene	expression.	In	addition,	the	use	of	Biogazelle	Qbase+	software	facilitated	robust	and	rigorous	analysis	of	the	data.	This	software	uses	expression	levels	of	human	reference	genes	to	‘normalise’	the	expression	level	of	each	GOI,	which	helps	to	reduce	the	impact	that	differing	levels	of	template	DNA	in	each	sample	have	on	expression	level.	The	software	also	generates	expression	levels	for	each	GOI	that	are	relative	to	the	other	samples	in	the	cohort.	This	means	that	the	expression	level	of	a	gene	in	a	cohort	can	accurately	be	compared	between	the	samples.	The	qBase+	software	
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also	incorporates	internal	quality	controls,	which	were	strictly	adhered	to.	These	are	outlined	in	section	4.5.1.	To	further	improve	data	reliability	all	reverse	transcription	(RT)	positive	reactions	were	repeated	in	duplicate	within	a	run.	All	samples	that	generated	data	indicative	of	inadequate	RT	reaction	were	excluded	from	analysis.	
4.7.5.3.2 Limitations	The	mean	RNA	concentration	from	samples	used	in	this	study	was	115	ng/μl	and	the	mean	260/280	nm	ratio	of	absorbance	generated	using	Nanodrop	spectrophotometry	was	2.1	indicating	high	purity	(the	NanoDrop	manufacturers	suggest	that	a	ratio	of	~2.0	is	regarded	as	‘pure’).	However,	assessment	of	RNA	integrity	using	an	Agilent	Bioanalyser	in	a	random	selection	of	10%	of	the	samples	indicated	a	mean	RIN	of	3.34	(Appendix	1).	This	suggests	RNA	of	poor	integrity	and	this	could	reduce	the	accuracy	of	mRNA	quantification.		The	use	of	corrected,	normalised	relative	quantification	of	RNA	expression	assumes	that	for	every	cell	present	containing	the	reference	genes	to	which	the	normalisation	takes	place,	HPV	is	also	present.	This	is	not	necessarily	the	case	and	consequently,	represents	a	limitation	of	the	method.	
4.7.5.3.3 Broader	implications	The	E2	protein	regulates	the	expression	of	the	E6	and	E7	oncogenes.	Loss	of	this	control	is	thought	to	result	from	viral	integration	(as	well	as	epigenetic	mechanisms	such	as	DNA	methylation)	and	is	fundamental	in	the	development	of	a	transforming	infection	(Stanley	2002;	Kessis	et	al.	1993;	Pierry	et	al.	2012).	Expression	of	all	HPV	genes	tested	in	this	cohort	(E2,	E6	and	E7)	varied,	but	the	expression	of	E2	seemed	to	be	particularly	variable.	Using	E2:E6	ratio	as	an	indicator,	there	were	cases	demonstrating	the	presence	of	both	regulated	(E2>E6)	and	deregulated	(E6>E2)	gene	expression	in	the	cohort;	74.1%	expressed	E6>E2	and	25.9%	expressed	E2>E6.	The	varied	gene	expression	found	in	this	cohort	further	supports	the	concept	that	VIN	3	represents	a	biologically	heterogeneous	disease.	Cases	with	relatively	low	E2	expression	may	represent	those	cases	in	which	HPV	is	driving	disease.	Cases	with	relatively	high	E2	expression	may	be	cases	in	which	HPV	is	present	as	a	bystander	to	disease	caused	by	alternative	pathology	or	may	be	cases	of	HPV	associated	VIN	3	that	have	not	yet	reached	the	stage	of	cellular	transformation	and	are	therefore	less	close	to	malignancy.	Although	not	statistically	significant,	trends	were	found	between	increased	age	and	decreased	E2	expression,	and	between	recurrent	disease	and	decreased	E2	expression.	It	is	possible,	that	this	finding	indicates	that	a	transforming	infection	is	more	likely	to	have	developed	with	the	longer	duration	of	HPV	infection	older	patients	and	patients	with	recurrent	disease	may	have	experienced.	Alternatively,	age	is	an	independent	risk	factor	
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for	the	development	of	most	cancers	(Anisimov	2007;	Anisimov	&	Petrov	1987;	Anisimov	2003);	it	may	be	the	case	that	should	an	older	patient	contract	HPV	infection	the	likelihood	of	transformation	is	higher	independent	of	duration	of	infection.		
4.7.5.4 Relationships	Between	Viral	Characteristics	Correlations	were	investigated	between	three	characteristics	of	transforming	HPV	infection	to	further	develop	understanding	of	HPV	pathogenesis.	HPV	integration	was	assessed	using	an	E1/E2	tiling	PCR	data,	high	HPV	DNA	methylation	was	defined	as	mean	methylation	>50%	of	the	E2	and	L1/L2	CpG	sites	and	deregulated	oncogene	expression	was	represented	by	E6	expression	>E2	expression.	Ninety-two	cases	had	valid	results	for	all	assays.	At	least	one	transforming	viral	characteristic	was	present	in	73/92	(79.3%)	and	these	may	be	cases	in	which	HPV	is	driving	disease.	None	of	the	transforming	characteristics	were	detected	in	19/92	(20.7%)	of	cases	and	these	may	be	cases	in	which	HPV	is	an	incidental	finding.		
4.7.5.4.1 Mechanisms	Leading	to	Deregulated	Oncogene	Expression	HPV	integration	(indicated	by	the	presence	of	HPV	disruption)	strongly	correlated	with	cases	of	lower	E2	expression	(p	=	<0.0001)	and	with	cases	of	deregulated	oncogene	expression	(represented	by	the	expression	profile	E6>E2),	(p	=	0.009).	However,	no	relationships	were	identified	between	HPV	integration	and	E6/E7	gene	expression.	Similar	findings	were	reported	in	a	recent	study	of	the	HPV	biology	in	25	cases	of	VIN	(Bryant,	Onions	et	al.	2014).	This	indicates	that	viral	integration	is	associated	with	reduced	E2	expression	but	apparently	not	with	significantly	altered	E6/E7	expression.	It	is	possible	that	in	non-integrated	cases,	alternative	mechanisms	de-regulating	E6/E7	expression	exist.	This	idea	is	supported	by	research	in	cervical	disease	where	evidence	also	exists	that	expression	levels	of	E6	and	E7	are	consistently	maintained	and	what	changes	is	the	expression	of	E2	(Doorbar	2006;	Baldwin	&	Münger	2010;	Münger	&	Howley	2002;	Baker	
et	al.	1987).	Loss	of	E2	expression	has	been	linked	to	increased	stability	of	HPV	16	E6/E7	mRNA	(Jeon,	Lambert	1995;	Jeon	et	al.	1995).	It	is	therefore	possible	that	the	effect	of	loss	of	E2	expression	is	increased	stability	of	E6/E7	mRNA,	which	in	turn	is	what	drives	disease	rather	than	increased	expression	levels	per	se.	This	finding	is	important	when	considering	the	role	of	HPV	gene	expression	as	a	biomarker.	The	varied	expression	of	E2,	compared	to	the	relatively	consistent	expression	of	E6	and	E7	(as	well	as	the	biological	justification)	makes	E2	a	better	biomarker	candidate.	Viral	integration	and	high	HPV	DNA	methylation	were	strongly	correlated	(p	=	<0.0001).	Two	smaller	studies	have	reported	similar	correlations	(Bryant,	Onions	et	al.	2014;	Kalantari	et	al.	2010).	The	reason	for	this	correlation	is	unclear	and	whether	these	
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characteristics	are	independent	of	one	another	or	not	is	difficult	to	determine.	Three	reasons	why	HPV	DNA	methylation	arises	have	been	proposed:		
• Methylation	of	HPV	DNA	in	VIN	HPV	DNA	may	arise	via	de	novo	methylation-mediated	silencing	of	foreign	DNA	upon	host	recognition	of	viral	integration	into	the	host	genome	(Heller	et	al.	1995)	
• Methylation	may	arise	as	a	result	of	activation	of	an	instructive	program	of	methylation	imposed	by	HPV	gene	expression	that	occurs	as	a	result	of	viral	integration	disrupting	the	E2	ORF	(Leonard	et	al.	2012)	
• Methylation	may	arise	as	an	HPV	self-regulatory	mechanism	designed	to	prevent	excessive	oncogene	expression	that	again,	results	from	HPV	integration	disrupting	the	E2	ORF	(De-Castro	Arce	et	al.	2012)	
 All	three	reasons	above	indicate	that	HPV	DNA	methylation	occurs	as	a	result	of	HPV	integration	and	could	therefore	explain	the	correlation	seen	in	this	work	and	others.	It	has	however,	also	been	hypothesised	that	HPV	DNA	methylation	may	represent	an	alternative	mechanism	of	deregulated	oncogene	expression	in	the	absence	of	HPV	integration.	High	levels	of	HPV	DNA	methylation	also	strongly	correlated	with	lower	E2	expression	(p	=	<0.0001)	and	with	deregulated	oncogene	expression	(p	=	0.008	and	p	=	0.004	respectively).	It	is	therefore	feasible	that	high	HPV	DNA	methylation	is	a	mechanism	leading	to	deregulated	oncogene	expression.	Of	the	92	cases	with	data	available	for	all	three	viral	characteristics	66	had	deregulated	oncogene	expression	(E6>E2),	of	which	only	6	cases	(9.1%)	had	high	HPV	DNA	methylation	without	HPV	integration	and	only	11/66	(16.7%)	had	HPV	integration	without	high	HPV	DNA	methylation.	The	presence	of	both	these	characteristics	was	found	in	a	significant	number	of	cases	25/66	(37.9%).	This	data	suggests	the	possibility	that	deregulated	oncogene	expression	can	be	caused	by	both	HPV	DNA	methylation	and	HPV	integration	independently	but	is	more	likely	to	happen	in	samples	with	both	characteristics.	Most	surprisingly	however,	was	that	in	24/66	(36.4%)	cases	of	deregulated	oncogene	expression,	neither	of	the	proposed	mechanisms	was	identified.	Research	in	cervical	disease	offers	a	potential	explanation	for	these	cases.	Although	viral	integration	is	present	in	the	majority	of	cases	of	cervical	cancer,	it	is	not	present	in	all.	Alternative	mechanisms	leading	to	deregulated	oncogene	expression	have	been	identified	(Doorbar	2006).	For	example,	studies	have	shown	that	HPV	associated	cellular	transformation	can	result	from	exposure	to	glucocorticoids	(Pater	et	al.	1988;	Chan	et	al.	1989)	as	well	as	chronic	oestrogen	exposure	(Arbeit,	Howley	1996).	It	is	possible	that	alternative	mechanisms,	such	as	these,	are	relatively	more	important	in	VIN.	Additionally,	although	aberrant	oncogene	expression	can	predispose	to	the	development	
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of	cervical	cancer,	their	expression	alone	is	not	considered	sufficient,	and	E6	and	E7	expression	alone	cannot	fully	transform	human	keratinocytes	in	culture.	It	is	generally	accepted	that	HPV	mediated	carcinogenesis	requires	the	accumulation	of	additional	genetic	changes	caused	by	alternative	means	such	as	age	and	cigarette	smoking	(Collins	et	
al.	2010;	Doorbar	2006)	and	possibly	in	the	case	of	VIN,	other	disease	processes	such	as	lichen	sclerosus.	It	is	however,	important	to	remember	that	the	nature	of	this	work	is	exploratory;	E2:E6	expression	ratio	is	not	a	validated	method	of	determining	deregulated	oncogene	expression	and	inferences	drawn	from	this	data	must	be	interpreted	with	caution.		
4.8 Conclusion	HPV	prevalence	in	this	cohort	of	VIN	3	was	98.2%	and	100%	prevalence	could	not	be	excluded	due	to	inherent	limitations	of	the	methods	used	to	detect	HPV.	Despite	potential	cohort	recruitment	bias	towards	HPV	associated	VIN,	the	median	age	of	the	cohort	was	close	to	that	of	VIN	in	general,	and	this	suggests	significant	bias	was	unlikely.	The	sequential	use	of	multiple	HPV	detection	assays	targeting	different	viral	regions	indicated	that	PCR	target	disruption	(likely	as	a	result	of	viral	integration)	is	an	important	cause	of	false	negative	results	in	VIN,	similar	to	the	seminal	study	in	cervical	cancer	conducted	by	Walboomers	et	al.	1999.	Based	on	these	findings,	it	could	be	hypothesised	that,	as	is	the	case	with	CIN	and	cervical	cancer,	all	VIN	(and	possibly	vulval	cancer	also)	is	too,	associated	with	HPV.	This	hypothesis	is	supported	by	the	fact	that	the	majority	of	studies	investigating	HPV	prevalence	in	VIN	use	detection	assays	that	target	the	L1	region	of	the	virus:	a	region	frequently	found	to	be	disrupted.	However,	this	hypothesis	is	opposed	by	the	absence	of	viral	characteristics	associated	with	HPV	carcinogenesis	in	a	significant	number	of	cases,	indicating	that	HPV	positivity	does	not	necessarily	equate	with	HPV	driven	disease.	Research	exists	demonstrating	that	the	absence	of	HPV	characteristics	typically	associated	with	HPV	carcinogenesis	does	not	necessarily	exclude	the	aetiological	role	of	HPV	in	disease	(Parfenov	et	al.	2014;	Bosch	et	al.	2002).	It	could	be	speculated	that	the	heterogeneous	nature	of	the	biology	of	HPV	observed	in	this	study	represents	one	of,	or	a	combination	of,	three	things:	
• That	while	VIN	3	comprises	a	single	histological	entity,	there	exists	a	spectrum	of	molecular	abnormality	within	it.		
• That	HPV	carcinogenesis	in	VIN	is	biologically	diverse	and	that	HPV	integration	(+/-	HPV	DNA	methylation)	leading	to	deregulated	oncogene	expression	leading	to	cellular	transformation	is	an	over-simplification	of	a	much	more	complex	situation.		
• That	HPV	positivity	does	not	necessarily	equate	with	HPV	driven	disease		
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This	study	was	not	able	to	determine	with	any	certainty	which	of	the	above	explanations	is	most	likely,	it	is	quite	possible	that	in	reality,	a	combination	of	all	three	exists.	However,	the	possibility	cannot	be	ignored	that,	as	is	the	case	in	cervical	disease,	all	VIN	is	associated	with	HPV	infection	but,	in	VIN,	other	factors	contributing	to	carcinogenesis	are	more	important	e.g.	chronic	skin	disease	(Collins	et	al.	2010;	Doorbar	2006;	Pater	et	al.	1988;	Sun	et	al.	2011;	Arbeit,	Howley	1996).	It	may	well	be	the	case	that	lichen	sclerosus	represents	an	alternative	aetiology	of	VIN	independent	of	HPV.	It	could	also	be	the	case	however	that	lichen	sclerosus	provides	the	deficiencies	in	epithelial	integrity	required	by	HPV	in	order	to	reach	its	target	basement	membrane.	Rather	than	driving	VIN	independently	of	HPV,	lichen	sclerosus	perhaps	promotes	HPV	driven	disease.	This	is	supported	by	the	fact	that	HPV	is	not	infrequently	detected	in	cases	dVIN	(de	Sanjosé	et	al.	2013)	and	also	by	the	fact	that	false	negative	HPV	detection	is	more	likely	in	case	of	integrated	virus.	If	lichen	sclerosus	aids	HPV	pathogenesis,	then	viral	integration	is	perhaps	more	likely	to	be	present	and	therefore	HPV	more	likely	to	go	undetected.						
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5 HPV	Characteristics	as	Biomarkers	to	Predict	Response	to	Treatment	of	VIN	
5.1 Introduction	
This	chapter	reports	the	results	of	investigation	into	the	suitability	of	viral	characteristics,	as	potential	biomarkers	to	predict	response	to	treatment	of	VIN	with	two	medications:	cidofovir	and	imiquimod.	The	RT3	VIN	clinical	trial	was	a	phase	II	clinical	trial	that	investigated	the	efficacy	and	safety	of	treating	patients	with	VIN	3	with	cidofovir	and	imiquimod.	The	full	design	and	results	of	this	study	are	discussed	in	chapter	3.	The	principal	findings	of	the	study	however,	were	that	41/72	(57%)	VIN	3	patients	treated	with	cidofovir	responded	and	that	42/69	(61%)	VIN	3	patients	treated	with	imiquimod	responded.	These	response	rates	make	both	cidofovir	and	imiquimod	appealing	treatment	alternatives	to	surgery,	and	worthy	of	investigation	in	a	phase	III	clinical	trial.	The	response	rates	do	however	highlight	the	potential	benefits	of	a	biomarker	(BM)	that	could	identify	women	who	are	more	likely	to	respond	to	treatment,	avoiding	unnecessary	side	effects	and	prolonged	treatment	with	medication	destined	not	to	work.	With	the	rationale	for	biomarker	development	established	four	candidate	viral	biomarkers	were	identified:	1. HPV	positivity		2. HPV	disruption	status		3. HPV	DNA	methylation		4. HPV	gene	expression			Guidelines	for	predictive	biomarker	development	published	by	CRUK	(Figure	5.1)	were	adhered	to.	The	first	section	of	this	chapter	investigates	the	distribution	of	each	biomarker	in	the	RT3	VIN	baseline	cohort	working	towards	BIDD	BM	discovery	–stage	1.	The	second	section	of	this	chapter	describes	the	retrospective	correlation	with	response	to	treatment	of	patients	in	the	RT3	VIN	clinical	trial,	working	towards	BM	discovery	–	stage	2.	All	viral	characteristic	work	was	conducted	using	cases	that	tested	positive	for	HPV	16;	it	is	therefore	only	these	cases	that	are	discussed	from	this	point	on.	It	is	also	of	note	that	all	data	analysed	comes	from	patients	included	in	the	intention	to	treat	analysis	arm	of	the	main	clinical	trial.	This	means	the	analysis	all	patients	enrolled	in	the	trial	who	provided	a	pre	and	post	treatment	biopsy	despite	whether	or	not	they	strictly	adhered	to	the	treatment	regime	assigned	to	them.	 		
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Figure	5.1	–	CRUK	BIDD	Biomarker	Roadmap	
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5.2 CRUK	Biomarker	Discovery	–	Stage	1	To	achieve	BM	development	to	discovery	stage	1	according	to	the	CRUK	guidelines,	the	distribution	of	a	candidate	biomarker	must	vary	in	a	cohort	representative	of	the	target	population.	The	baseline	cohort	from	the	RT3	VIN	clinical	trial	represented	a	suitable	study	cohort	with	all	patients	having	been	diagnosed	with	histologically	confirmed	VIN	3.	There	were	tissue	biopsies	from	167	patients	enrolled	in	the	study	at	baseline,	available	for	analysis.	HPV	positivity	was	investigated	in	all	167	samples	using	four	HPV	detection	assays	(PapilloCheck®,	HPV	16	E6	PCR,	DiaMex	and	type-specific	E7	PCR)	(Section	4.2).	Analyses	of	the	distribution	of	HPV	integration,	HPV	DNA	methylation	and	HPV	gene	expression	were	restricted	to	the	136	HPV	16	positive	cases	identified	through	a	combination	of	PapilloCheck®	data	and	HPV	16	E6	PCR	data.	This	was	because	the	assays	were	designed	to	investigate	the	most	prevalent	genotype	and	because	data	was	only	available	from	these	two	assays	at	the	time	of	this	analysis.		
5.2.1 Variability	in	HPV	Status	HPV	was	detected	in	164/167	(98.2%)	cases.	Full	HPV	genotyping	results	are	detailed	in	section	4.2.	HPV	16	was	detected	in	140/167	(81.4%)	cases	and	represented	the	most	prevalent	genotype	followed	by	HPV	33,	which	was	detected	in	14/167	(8.5%).	With	the	majority	of	cases	testing	positive	for	HPV,	HPV	positivity	alone	was	not	deemed	suitable	for	further	BM	development.	Although	high	(140/167,	81.4%),	HPV	16	positivity	did	demonstrate	varied	distribution	in	the	cohort	and	was	therefore	assessed	further.	
5.2.2 Variability	in	HPV	Disruption	HPV	disruption,	defined	by	the	failure	to	amplify	≥	one	E1/E2	tiling	PCR	fragments,	was	used	detected	in	71/136	(52.2%)	cases,	whereas	65/136	(47.8%)	contained	intact	HPV.	HPV	disruption	was	therefore	deemed	suitable	for	further	BM	development.	Full	analysis	of	HPV	disruption	in	VIN	3	is	available	in	chapter	4,	section4.3.	
5.2.3 Variability	in	HPV	DNA	Methylation	The	methylation	level	of	three	HPV	regions	(E2,	L1/L2	and	the	promoter	region)	was	tested	using	pyrosequencing.	Detailed	analysis	of	HPV	DNA	methylation	in	the	cohort	can	be	found	in	chapter	4	section	4.4.	For	the	E2	region	(n	=	82)	mean	methylation	was	27.2%	±	35.8%	(p	=	<0.000),	for	the	L1/L2	region	(n	=	93),	mean	methylation	was	37.5%	±	34.9%	(p	=	<0.000)	and	for	the	promoter	region	(n	=	122),	mean	methylation	was	3.9%	±	13.44%	(p	=	<0.002)	(Figure	4.7).	Based	on	these	findings,	HPV	DNA	methylation	of	all	regions	was	considered	suitable	for	further	biomarker	development.		
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5.2.4 Variability	in	HPV	Gene	Expression	Investigation	of	HPV	gene	expression	in	136	HPV	16	positive	patients	in	the	RT3	VIN	baseline	cohort	is	fully	detailed	in	section	4.5.	The	range	of	E2	gene	expression	was	CNRQ	0.00	–	3.68,	with	a	mean	CNRQ	of	1.88	±	1.30.		The	range	of	E6	expression	was	0.00	-	2.19	with	a	mean	CNRQ	of	1.01	±	0.48	and	the	range	of	E7	expression	was	0.00	–	2.32	with	a	mean	CNRQ	of	1.2	±	0.49	(Table	4.6).	Figure	4.13shows	the	variation	in	expression	of	each	gene	in	the	cohort	and	enables	visual	comparisons	to	be	made	between	expression	levels	of	each	gene.	The	range	of	both	HPRT	and	TBP	expression	was	CNRQ	0.00	–	0.83,	the	mean	HPRT	and	TBP	CNRQ	were	0.43	±	0.23	and	0.40	±	0.23	respectively.	Expression	of	each	HPV	gene	was	more	variable	than	the	expression	of	the	human	reference	genes,	and	therefore	deemed	suitable	for	further	BM	development.	E2	expression	demonstrated	the	most	variation.	
5.2.4.1 HPV	E2:E6	Gene	Expression	in	VIN	3	This	exploratory	analysis	found	that	in	the	majority	of	cases	(83/112,	74.1%)	E6	expression	was	greater	than	E2	indicating	the	presence	of	deregulated	gene	expression	and	in	29/112	(25.9%)	E2	expression	was	greater	than	E6	indicating	those	cases	with	regulated	oncogene	expression.		E2:E6	expression	ratio	to	distinguish	cases	of	deregulated	oncogene	expression	from	cases	of	regulated	oncogene	expression	was	therefore	considered	suitable	for	further	biomarker	development.	For	more	details	on	gene	expression	data,	see	section	4.5.	
5.2.4.1.1 Distribution	of	‘HPV	Driven	Disease’	With	the	broad	acceptance	that	not	all	VIN	3	is	caused	by	HPV	(Sideri	et	al.	2005)	and	that	HPV	may	be	present	as	a	bystander	to	alternative	disease	aetiology	(de	Sanjose	et	al.	2013),	the	presence	of	≥	one	HPV	characteristics	associated	with	transformation	was	used	to	distinguish	cases	of	HPV	driven	disease	from	cases	of	HPV	independent	disease.	Transforming	HPV	characteristics	were	defined	as	HPV	integration	(represented	by	failure	to	amplify	≥	1	E1/E2	tiling	fragments),	high	HPV	DNA	methylation	(represented	by	mean	methylation	>50%	of	all	E2	and	L1/L2	CpG	sites)	and	deregulated	oncogene	expression	(represented	by	an	exploratory	method	identifying	those	cases	with	E6>E2expression).	Investigation	of	this	potential	biomarker	was	only	possible	for	HPV	16	positive	cases	(for	which	the	assays	were	designed).	Data	for	all	three	characteristics	was	available	for	92/136	cases	following	quality	control	checks	(Chapter	4,	section	2.7.4).	Using	these	definitions,	HPV	driven	disease	was	present	in	73/92	(79.3%)	of	cases,	and	HPV	independent	disease	was	present	in	the	remaining	19/92	(20.7%).	Although	the	majority	
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of	cases	of	VIN	3	were	defined	as	‘HPV	driven’,	a	fifth	of	cases	(20.7%)	were	not,	hence,	this	classification	was	considered	suitable	for	further	BM	development.	
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5.3 BIDD	Biomarker	Discovery–	Stage	2	Retrospective	correlation	between	the	potential	BM	and	response	to	treatment	are	required	to	satisfy	the	criteria	of	biomarker	discovery	stage	2.	This	was	undertaken	for	the	following	candidate	viral	characteristics:	
• HPV	16	status	
• HPV	driven	disease	(determined	by	the	presence	of	≥1	viral	characteristics	associated	with	transformation)	
• HPV	disruption		
• HPV	DNA	methylation	of	the	E2,	L1/L2	and	promoter	regions	
• E2,	E6	and	E7	gene	expression	
• E2:E6	gene	expression	ratio	to	distinguish	regulated	oncogene	expression	from	deregulated	oncogene	expression		Response	to	treatment	with	either	cidofovir	or	imiquimod	was	determined	by	the	absence	of	VIN	in	a	tissue	biopsy	taken	from	the	previously	affected	area	6	weeks	following	the	completion	of	treatment.	The	presence	of	VIN	1	or	greater	was	considered	persistent	disease	and	failure	to	respond.	Full	data	including	the	post	treatment	histology	result	and	baseline	HPV	result	was	available	for	135	patients.	
5.3.1 HPV	16	Positivity	and	Response	to	Treatment	The	proportions	of	HPV	16	positive	patients	who	responded	or	failed	to	respond	to	treatment	with	cidofovir	were	similar	(26/55,	47.3%	vs.	29/55,	52.7%).	This	was	also	the	case	for	treatment	with	imiquimod,	for	which	28/56	(50.0%)	of	patients	responded	and	28/56	(50.0%)	failed	to	respond.	On	the	other	hand,	patients	who	were	HPV	16	negative	were	more	likely	to	respond	to	(8/13,	61.5%),	than	not	to	respond	to	treatment	with	cidofovir	(5/13,	38.5%).	Similarly,	with	imiquimod	8/11	(72.7%)	HPV	16	negative	patients	responded	to	treatment	and	3/11	(27.3%)	failed	to	respond.	A	chi-square	test	was	run	to	determine	whether	the	observed	values	differed	significantly	from	those	expected.	A	Bonferroni	correction	was	applied	to	allow	for	multiple	comparisons,	a	p	value	of	0.017	was	considered	significant.	No	statistically	significant	difference	was	found	for	treatment	with	cidofovir	(p	=	0.335)	or	treatment	with	imiquimod	(p	=	0.167),	(Figure	5.2).	Further	analysis	of	the	24	HPV	16	negative	cases	revealed	that	in	those	cases	that	failed	to	respond	to	treatment	(n=8)	an	alternative	high-risk	HPV	genotype	had	been	detected.	In	those	cases	that	responded	to	treatment	(n=16),	no	HPV	was	detected	in	three	cases	and	low-risk	only	HPV	was	detected	in	2	cases;	alternative	high-risk	genotypes	were	detected	
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in	the	other	10	cases.	It	is	of	note	that	there	were	only	three	cases	in	the	whole	study	cohort	in	which	no	HPV	was	identified,	all	of	whom	responded	to	treatment	(two	with	imiquimod	and	one	with	cidofovir).	Additionally,	there	were	only	five	cases	in	which	low-risk	only	HPV	was	identified	in	the	whole	cohort,	two	of	whom	had	data	suitable	for	this	section	of	analyses	and	both	responded	to	treatment.	Therefore,	all	patients	in	the	cohort	with	no	detectable	high-risk	HPV	responded	to	treatment.														
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Figure	5.1	HPV	16	status	and	response	to	treatment.	Response	to	treatment	defined	as	histologically	confirmed	absence	of	VIN	in	tissue	biopsy	taken	6	weeks	following	treatment.	The	top	graph	shows	cidofovir	data	and	the	bottom	graph	shows	imiquimod	data.	
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5.3.2 HPV	Driven	Disease	and	Response	to	Treatment	The	presence	of	≥	one	of	three	viral	characteristics	(HPV	disruption,	HPV	DNA	methylation	>50%	and	HPV	gene	expression	E6>E2)	was	used	as	an	exploratory	method	to	identify	cases	in	which	HPV	was	driving	disease.	Ninety-two	cases	generated	a	full	viral	data	set	of	which,	78	had	clinical	outcome	data	available	from	a	post-treatment	tissue	biopsy.	Of	those	patients	who	responded	to	treatment	with	cidofovir,	evidence	for	HPV	driven	disease	was	detected	in	17/21	(81.0%)	and	HPV	independent	disease	in	4/21	(19.0%).	In	patients	who	did	not	respond,	evidence	for	HPV	driven	disease	was	detected	in	16/19	(84.2%)	and	HPV	independent	disease	in	3/19	(15.8%).	No	statistically	significant	association	was	identified	using	a	Chi-square	test	incorporating	a	Bonferroni	correction	of	p	=	0.016	to	allow	for	multiple	comparisons	(Chi-square	=	0.073,	p	=	0.787).	Similarly,	for	imiquimod	treatment,	of	patients	who	responded	to	treatment,	evidence	for	HPV	driven	disease	was	detected	in	18/21	(85.7%)	and	HPV	independent	disease	in	3/21	(14.3%).	In	patients	who	did	not	respond,	evidence	for	HPV	driven	disease	was	detected	in	12/17	(70.6%)	and	HPV	independent	disease	in	5/17	(29.4%).	No	statistically	significant	association	was	identified	using	a	Chi-square	test	(Chi-square	=	1.293,	p	=	0.255).	
5.3.3 HPV	E1/E2	Disruption	and	Response	to	Treatment	Valid	data	was	available	for	54	patients	treated	with	cidofovir.	Twenty-seven	(50.0%)	responded	to	treatment	of	whom,	17/27	(63.0%)	had	disrupted	HPV	and	10/27	(37.0%)	had	intact	HPV.		Of	the	twenty-seven	patients	who	did	not	respond	to	treatment,	intact	HPV	was	found	in	the	majority	(15/27,	55.6%)	and	disrupted	HPV	in	12/27	(44.4%),	(Figure	5.3).	This	association	was	not	significant,	(Fisher’s	exact	test	p	=	0.275).	For	patients	treated	with	imiquimod	(valid	data	for	53	patients)	the	opposite	trend	was	observed;	of	patients	who	responded	to	treatment,	15/28	(53.6%)	had	intact	HPV	and	13/28	(46.4%)	had	disrupted	HPV.	In	patients	who	did	not	respond	to	treatment,	14/25	(56.0%)	had	disrupted	HPV	and	11/25	(44.0%)	had	intact	HPV	(figure	5.5).	The	association	between	E1/E2	disruption	and	response	to	treatment	with	imiquimod	was	also	not	significant	(Fisher’s	exact	test,	p	=	0.586).		
Chapter	5	 	 HPV	biomarkers		
	HPV	Biology	in	VIN:	Viral	Biomarkers	to	Predict	Response	to	Treatment			 166	
	
			
	
Figure	5.2	E1/E2	disruption	and	response	to	treatment.	The	top	graph	shows	patients	treated	with	cidofovir	(n=54)	and	the	bottom	graph	patients	treated	with	imiquimod	(n	=	53).	E1/E2	status	was	not	statistically	significantly	associated	with	response	to	treatment	with	either	treatment.	
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5.3.4 HPV	DNA	methylation	and	response	to	treatment	Of	the	136	cases	identified	as	HPV	16	positive,	29	did	not	have	post-treatment	clinical	outcome	data,	therefore	107/136	were	available	for	response	to	treatment	analyses.	Quality	assurance	checks	applied	to	the	methylation	data	further	decreased	the	number	of	cases	with	analysable	data;	for	the	E2	region	63/107	cases	were	available,	for	the	L1/L2	region	73/107	cases	were	available	and	for	the	promoter	region	95/107	cases	were	available.	Levels	of	E2,	L1/L2	and	promoter	region	methylation	were	compared	between	patients	who	responded	and	did	not	respond	to	treatment.	Firstly,	median	methylation	was	calculated	for	responders	and	non-responders	in	each	treatment	arm	and	for	treatment	overall,	then,	a	Mann-Whitney	U	test	was	run	to	determine	any	statistically	significant	difference	between	mean	levels.	A	Bonferroni	correction	to	account	for	multiple	comparisons	was	incorporated	making	a	p	value	of	p	=	0.005	significant.		
5.3.4.1 E2	Methylation	For	treatment	overall	(cidofovir	or	imiquimod),	34/63	(54.0%)	responded	and	29/63	(46.0%)	did	not.	The	mean	level	of	E2	methylation	was	similar	for	responders	and	non-responders	(4.26%	vs.	3.25%).	For	those	patients	treated	with	cidofovir,	17/30	(56.7%)	responded	and	13/30	(43.3%)	did	not.	Median	E2	methylation	was	higher	in	patients	who	responded	to	treatment	than	in	patients	who	did	not	(9.14%	vs.	2.19%	p	=	0.003).	For	patients	treated	with	imiquimod,	17/33	(51.5%)	responded	and	16/33	(48.5%)	did	not.	Median	E2	methylation	was	lower	in	patients	who	responded	to	treatment	than	in	patients	who	did	not	(2.57%	vs.	24.22%),	this	finding	did	not	reach	the	statistical	significance	required	with	a	p	value	of	0.225	(Figure	5.4).	
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Figure	5.3	Median	E2	methylation	in	responders	and	non-responders	to	treatment.	E2	methylation	quantified	using	pyrosequencing.	Overall	treatment	represents	combined	data	from	both	cidofovir	and	imiquimod	treatment	arms.	Whiskers	represent	minimum	and	maximum	values	obtained.
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5.3.4.2 L1/L2	Methylation	For	treatment	overall	(cidofovir	or	imiquimod),	36/73	(49.3%)	responded	to	treatment	and	37/63	(50.7%)	did	not.	Median	L1/L2	methylation	was	similar	between	responders	and	non-responders	(13.17%	vs.	17.09%).	For	cidofovir	treated	patients,	17/39	(43.6%)	responded	to	treatment	and	22/39	(56.4%)	did	not.	Median	L1/L2	methylation	was	found	to	be	higher	in	patients	who	responded	to	treatment	(59.03%)	than	in	patients	who	did	not	(9.62%);	this	finding	was	not	statistically	significant	(p	=	0.431).	For	patients	treated	with	imiquimod,	19/34	(55.9%)	responded	to	treatment	and	15/34	(44.1%)	did	not.	Median	L1/L2	methylation	was	lower	(11.72%)	in	patients	who	responded	to	treatment	with	imiquimod	than	in	those	patients	who	did	not	(42.91%).	This	finding	however,	did	not	reach	statistical	significance	p	=	0.621	(Figure	5.5).						
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Figure	5.4	Median	L1/L2	methylation	in	responders	and	non-responders	to	treatment.	L1/L2	methylation	quantified	using	pyrosequencing.	Overall	treatment	represents	combined	data	from	both	treatment	arms.	Whiskers	represent	maximum	and	minimum	values.	No	statistically	significant	differences	were	identified.						
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5.3.4.3 Promoter	Methylation	For	treatment	overall	(cidofovir	or	imiquimod),	50/95	(52.6%)	responded	to	treatment	and	45/95	(47.4%)	did	not.	Median	promoter	methylation	was	similar	between	responders	and	non-responders	(0.19%	vs.	0.26%).	For	cidofovir	treated	patients,	26/51	(51.0%)	responded	to	treatment	and	25/51	(49.0%)	did	not.	Median	promoter	methylation	was	similar	in	patients	who	responded	to	treatment	(0.20%)	and	in	patients	who	did	not	(0.24%).	This	was	not	statistically	significant	p	=	0.891.	For	patients	treated	with	imiquimod,	24/44	(54.5%)	responded	to	treatment	and	20/44	(45.5%)	did	not.	Median	promoter	methylation	was	lower	(0.16%)	in	patients	who	responded	to	treatment	with	imiquimod	than	in	those	patients	who	did	not	(0.26%).	This	finding	however,	did	not	reach	statistical	significance	p	=	0.205	(Figure	5.6).	Based	on	the	finding	of	consistently	low	promoter	region	methylation	in	the	cohort	and	the	absence	of	correlation	with	treatment	outcome,	development	as	a	biomarker	was	halted	at	this	stage.				
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Figure	5.5	Promoter	region	methylation	and	response	to	treatment.	Promoter	methylation	quantified	using	pyrosequencing.	Overall	treatment	represents	combined	data	from	both	treatment	arms.	Whiskers	represent	maximum	and	minimum	values.	No	statistically	significant	differences	between	medians	were	identified.						 						
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5.3.5 Can	HPV	DNA	Methylation	Distinguish	Responders	from	Non-Responders?	ROC	curve	analysis	was	performed	to	determine	if	methylation	of	the	E2	and	L1/L2	region	could	distinguish	between	patients	who	would	respond	to	treatment	and	those	who	would	not.	Based	on	the	data	above	(section	5.3.4),	increasingly	high	levels	of	E2	and	L1/L2	methylation	were	used	to	distinguish	cidofovir	responders	from	non-responders	and	increasingly	low	levels	for	imiquimod.	The	AUC	value	was	calculated	using	SPSS	and	the	result	was	classified	as	follows:	Increasingly	high	levels	of	E2	methylation	were	found	to	be	‘excellent’	at	distinguishing	cidofovir	responders	from	non-responders	with	an	AUC	value	of	0.919	(95%	CI	0.822-1.000),	p	=	<0.0001.	The	ability	of	increasingly	high	levels	of	L1/L2	methylation	to	distinguish	cidofovir	responders	from	non-responders	was	‘fair	to	poor’	based	on	an	AUC	value	of	0.698	(95%	CI	0.525-0.870),	p	=	0.036	(Figure	5.7,	Figure	5.8).		Increasingly	low	levels	of	E2	methylation	were	found	to	be	‘fair	to	good’	at	distinguishing	imiquimod	responders	from	non-responders	with	an	AUC	of	0.721	(95%	CI	=	0.538-0.903),	p	=	0.031.	L1/L2	methylation	was	not	found	to	be	useful	in	distinguishing	imiquimod	responders	from	non-responders	with	an	AUC	of	0.595	(95%	CI	0.402–0.788),	p	=	0.337	(Figure	5.9,	Figure	5.10).				 					
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Figure	5.6	ROC	curve	analysis	of	increasing	E2	methylation	to	distinguish	cidofovir	
responders	from	non-responders.	N	=	30.	Increasing	level	of	E2	methylation	demonstrates	‘excellent’	ability	to	distinguish	cidofovir	responders	from	non-responders	with	AUC	0.919	(95%CI	0.882–1.00),	p	=	<	0.0001.	
	
Figure	5.7	ROC	curve	analysis	of	increasing	L1/L2	methylation	to	distinguish	cidofovir	
responders	from	non-responders.	N	=	39.	Increasing	level	of	L1/L2	methylation	demonstrated	‘poor	to	fair’	ability	to	distinguish	cidofovir	responders	from	non-responders	with	AUC	0.698	(95%	CI	0.525–0.870),	p	=	0.036.
AUC$=$0.919$
AUC$=$0.698$
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Figure	5.8	ROC	curve	analysis	of	decreasing	E2	methylation	to	distinguish	imiquimod	
responders	from	non-responders.	N	=	33.	Decreasing	E2	methylation	demonstrated	‘fair	to	good’	ability	to	distinguish	imiquimod	responders	from	non-responders	with	an	AUC	of	0.721	(95%CI	0.538–0.903),	p	=	0.031.	
	
Figure	5.9	ROC	curve	analysis	of	decreasing	L1/L2	methylation	to	distinguish	imiquimod	
responders	from	non-responders.	N	=	35.	Decreasing	L1/L2	methylation	demonstrated	‘poor’	ability	to	distinguish	imiquimod	responders	from	non-responders	with	an	AUC	of	0.595	(95%	CI	=	0.402-0.788),	p	=	0.337	
AUC$=$0.721$
AUC$=$0.595$
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5.3.6 Investigation	into	Appropriate	Methylation	‘Cut-Off’	Level	The	data	shown	in	section	5.3.5	indicated	that	E2	methylation	had	the	best	ability	to	distinguish	responders	from	non-responders	to	either	treatment.	However,	response	to	treatment	with	cidofovir	was	associated	with	higher	levels	of	methylation	and	the	opposite	was	true	for	response	to	imiquimod	(low	methylation	levels).	The	ROC	analysis	was	used	to	determine	potential	cut-off	levels	of	methylation	based	on	sensitivity	and	specificity	that	could	be	used.	
5.3.6.1 Cidofovir	The	ROC	curve	analysis	of	sensitivity	and	specificity	of	different	E2	methylation	cut-off	levels	to	distinguish	cidofovir	responders	from	non-responders	are	shown	in	Table	5.1.	Three	cut-off	levels	were	selected	to	investigate	further	based	on	relative	sensitivity	and	specificity:	firstly	E2	methylation	>2%,	secondly,	E2	methylation	>4%	and	finally	E2	methylation	>5%.	Sensitivity,	specificity,	PPV	and	NPV	specific	to	these	three	cut	off	levels	were	calculated	and	are	shown	in	Table	5.2.	The	potential	clinical	utility	of	these	E2	methylation	cut	off	values	are	indicated	by	this	analysis;	E2	methylation	>4.0%	appeared	offer	the	best	compromise	between	sensitivity,	specificity,	PPV	and	NPV.	The	benefits	and	limitations	of	each	level	are	discussed	in	detail	in	the	discussion	section	of	this	chapter.		
5.3.6.2 Imiquimod	The	ROC	curve	analysis	of	sensitivity	and	specificity	of	different	E2	methylation	cut-off	levels	to	distinguish	imiquimod	responders	from	non-responders	are	shown	in	Table	5.3.	Two	cut-off	levels	were	selected	to	investigate	further.	A	cut-off	of	E2	methylation	<10%	appeared	to	offer	the	best	compromise	between	sensitivity	and	specificity	at	this	stage.	A	second	cut-off	of	E2	methylation	<4.0%	was	also	assessed	as	this	would	represent	the	cohort	in	which	cidofovir	treatment	would	not	be	offered	based	on	the	same	analysis.	Sensitivity,	specificity,	PPV	and	NPV	specific	to	these	cut	off	levels	were	calculated	and	are	shown	in	Table	5.4.	Potential	clinical	utility	of	these	E2	methylation	cut	off	values	are	indicated	by	this	analysis;	E2	methylation	<10.0%	appeared	to	offer	the	best	compromise	between	sensitivity,	specificity,	PPV	and	NPV.	The	benefits	and	limitations	of	each	level	are	discussed	in	detail	in	the	discussion	of	this	chapter.					
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Table	5–1	Sensitivity	and	specificity	of	different	E2	methylation	cut-off	levels	to	discriminate	
between	cidofovir	responders	and	non-responders.	
	*Data	generated	from	ROC	analysis.	Three	potentially	clinical	useful	E2	methylation	level	cut-off	points	(identified	by	the	red	lines).	The	smallest	cut-off	value	represents	the	minimum	E2	methylation	value	obtained	-1	and	the	largest	cut	off	point	represents	the	maximum	value	+1.	Cut-off	values	between	these	are	the	average	of	two	consecutive	ordered	observed	test	values,	generated	by	SPSS	ROC	analysis.		 			
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Table	5–2	Analysis	of	potential	clinical	utility	of	three	E2	methylation	cut-off	levels	to	
predict	response	to	treatment	with	cidofovir.	
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	 	 Cidofovir	response	 Cidofovir	non-response	 Total	
E2
	m
et
h	
≥	
2.
0%
	
E2	meth	>	2.0%	 17	 7	 24	
E2	meth	<2.0%	 0	 6	 6	
Total	 17	 13	 30	
	 Sensitivity	 Specificity	 PPV	 NPV	
E2	meth	>2.0%	 100.0%	 46.15%	 70.8%	 100.0%	
	 	 Cidofovir	response	 Cidofovir	non-response	 Total	
E2
	m
et
h	
≥	
4.
0%
	
E2	meth	>	4.0%	 15	 2	 17	
E2	meth	<4.0%	 2	 11	 13	
Total	 17	 13	 30	
	 Sensitivity	 Specificity	 PPV	 NPV	
E2	meth	>4.0%	 88.2%	 84.6%	 88.2%	 84.6%	
	 	 Cidofovir	response	 Cidofovir	non-response	 Total	
E2
	m
et
h	
≥	
5.
0%
	
E2	meth	>	5.0%	 12	 1	 13	
E2	meth	<5.0%	 5	 12	 17	
Total	 17	 13	 30	
	 Sensitivity	 Specificity	 PPV	 NPV	
E2	meth	>5.0%	 70.6%	 92.3%	 92.3%	 70.6%	
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Table	5–3	Sensitivity	and	specificity	of	different	E2	methylation	cut-off	levels	to	distinguish	
imiquimod	responders	and	non-responders	
	Data	generated	from	ROC	analysis.	Two	potentially	clinical	useful	E2	methylation	level	cut-off	points	(identified	by	the	red	lines).	The	smallest	cut-off	value	represents	the	minimum	E2	methylation	value	obtained	-1	and	the	largest	cut	off	point	represents	the	maximum	value	+1.	Cut-off	values	between	these	are	the	average	of	two	consecutive	ordered	observed	test	values,	generated	by	SPSS	ROC	analysis.		
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Table	5–4	Analysis	of	potential	clinical	utility	of	two	different	E2	methylation	cut-off	levels	to	
distinguish	imiquimod	responders	from	non-responders	
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E2	meth	<4	.0%	 12	 6	 18	
E2	meth	>4.0%	 5	 10	 15	
Total	 17	 16	 33	
	 Sensitivity	 Specificity	 PPV	 NPV	
E2	meth	<4.0%	 70.6%	 62.5%	 66.7%	 66.7%	
	 	 Imiquimod	response	 Imiquimod	non-response	 Total	
E2
	m
et
h	
≤	
or
	>
10
.0
%
	
E2	meth	<10.0%	 14	 7	 21	
E2	meth	>10.0%	 3	 9	 12	
Total	 17	 16	 33	
	 Sensitivity	 Specificity	 PPV	 NPV	
E2	meth	<10.0%	 82.4%	 56.3%	 66.7%	 75.0%	
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5.3.7 HPV	gene	expression	and	response	to	treatment	Mean	CNRQ	for	each	gene	(E2,	E6	and	E7)	was	calculated	for	patients	who	responded	and	patients	who	did	not	respond	to:	a.	treatment	overall	(cidofovir	or	imiquimod),	b.	cidofovir	and	c.	imiquimod.	A	Mann-Whitney	U	test	was	then	used	to	determine	if	there	was	a	statistically	significant	difference	between	gene	expression	in	responders	and	non-responders.	A	Bonferroni	correction	to	account	for	multiple	comparisons	was	incorporated	making	a	p	value	of	p	=	0.005	significant.		
5.3.7.1 E2	gene	expression	There	were	96	cases	with	available	E2	gene	expression	data	and	clinical	outcome	data.	Regarding	treatment	overall,	mean	E2	gene	expression	was	similar	between	responders	and	non-responders	(CNRQ	1.8	±	1.3SD	vs.	CNRQ	1.9	±1.4SD).For	cidofovir	treatment	mean	E2	CNRQ	was	lower	(1.5	±	1.3SD)	in	responders	than	non-responders	(1.9	±	1.3SD);	this	difference	was	not	statistically	significant.	For	imiquimod	treatment,	mean	E2	expression	was	higher	in	responders	than	non-responders	(CNRQ	2.1	±1.2SD	vs.	CNRQ	1.8	±	1.4SD),	but	this	difference	was	not	statistically	significant	(p	=	0.699).		Similar	E2	gene	expression	levels	were	present	in	responders	and	non-responders	for	all	treatments	(overall,	cidofovir	or	imiquimod)	therefore,	E2	gene	expression	was	deemed	unsuitable	for	further	biomarker	development.	
5.3.7.2 E6	gene	expression	There	were	98	cases	with	available	E6	gene	expression	data	and	clinical	outcome	data.	Regarding	treatment	overall	(cidofovir	or	imiquimod),	mean	E6	gene	expression	was	the	same	in	both	responders	and	non-responders	(CNRQ	1.0	±	0.5SD).	For	cidofovir,	mean	E6	CNRQ	was	the	same	between	responders	and	non-responders	(CNRQ	1.0	±0.5SD).	For	imiquimod,	mean	E6	expression	was	similar	between	responders	and	non-responders	(CNRQ	0.9	±	0.5SD	vs.	CNRQ	1.0	±	0.5SD).	Similar	E6	gene	expression	levels	were	present	in	responders	and	non-responders	for	all	treatments	(overall,	cidofovir	or	imiquimod)	therefore,E6	gene	expression	was	deemed	unsuitable	for	further	biomarker	development.	
5.3.7.3 E7	gene	expression	There	were	97	cases	with	available	E7	gene	expression	data	and	clinical	outcome	data.	Regarding	treatment	overall	(cidofovir	or	imiquimod),	mean	E7	gene	expression	was	similar	between	responders	and	non-responders	(CNRQ	1.1	±	0.5SD	vs.	CNRQ	1.2	±	0.5SD).		For	cidofovir,	mean	E7	expression	was	similar	between	responders	and	non-responders	(CNRQ	1.1	±	0.6SD	vs.	CNRQ	1.2	±	0.4SD).	For	imiquimod,	mean	E7	expression	was	also	similar	between	responders	(CNRQ	1.1	±	0.4SD)	and	non-responders	(CNRQ	1.2	±	0.5SD).	Similar	E7	gene	expression	levels	were	present	in	responders	and	non-
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responders	for	all	treatments	(overall,	cidofovir	or	imiquimod)	therefore;	it	was	deemed	unsuitable	for	further	biomarker	development.	
5.3.8 E2:E6	expression	ratio	and	response	to	treatment	
E2:E6	expression	ratio	was	used	in	an	exploratory	capacity	to	identify	cases	of	regulated	oncogene	expression	(E2>E6)	and	cases	of	deregulated	oncogene	expression	(E2<E6).	Rates	of	regulated	vs.	deregulated	gene	expression	were	compared	between	responders	and	non-responders	to	a.	treatment	overall	(cidofovir	or	imiquimod),	b.	cidofovir	and	c.	imiquimod.		
5.3.8.1 Treatment	overall	For	treatment	overall,	rates	of	regulated	and	deregulated	gene	expression	were	similar	between	responders	and	non-responders.	E2>E6	expression	was	detected	in	14/49	(28.6%)	responders	and	12/44	(27.3%)	non-responders.	E2<E6	expression	was	detected	in	35/49	(71.4%)	responders	and	32/44	(72.7%)	non-responders.	
5.3.8.2 Cidofovir	The	proportions	of	cases	with	E2>E6	expression	and	E2<E6	expression	were	similar	between	patients	who	responded	and	did	not	respond	to	treatment	with	cidofovir.	E2>E6	was	present	in	6/25	(24.0%)	patients	who	responded	to	treatment	and	6/22	(27.3%)	who	did	not.	E6>E2	expression	was	detected	in	19/25	(76.0%)	of	patients	who	responded	to	treatment	and	in	16/22	(72.7%)	who	did.	Based	on	this	finding,	E2:E6	expression	ratio	was	not	deemed	suitable	for	further	development	as	a	BM	to	predict	response	to	treatment	with	cidofovir.	
5.3.8.3 Imiquimod	Similar	proportions	ofE2>E6	and	E2<E6	cases	were	detected	amongst	imiquimod	responders	and	non-responders.	E2	>E6	expression	was	detected	in	8/24	(33.3%)	of	responders	and	in	6/22	(27.3%)	of	non-responders.	E6>E2	expression	was	detected	in	16/24	(66.7%)	of	responders	and	16/22	(72.7%)	of	non-responders.		As	was	the	case	with	cidofovir,	further	development	of	E2:E6	expression	as	a	BM	to	predict	response	to	treatment	with	imiquimod	was	not	deemed	appropriate.	
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5.4 Discussion	
5.4.1 Principal	Findings	The	principal	finding	of	this	work	was	that	E2	andL1/L2	methylation	significantly	correlated	with	response	to	treatment	with	both	cidofovir	and	imiquimod	but	at	opposing	levels.	The	level	of	E2	methylation	was	found	more	successfully	distinguish	responders	from	non-responders	for	both	treatments	and	demonstrated	potential	clinical	utility	as	a	predictive	biomarker.	Additional	findings	were:	
• Associations	(which	did	not	reach	statistical	significance),	were	found	between	response	to	treatment	with	cidofovir	and	the	presence	of:	
o Disrupted	virus	
o Relatively	low	levels	of	E2	expression	
• Associations	(which	did	not	reach	statistical	significance),	were	found	between	response	to	treatment	with	imiquimod	and	the	presence	of:	
o Intact	virus	
o Relatively	high	levels	of	E2	expression	
• All	non-HR	positive	cases	of	VIN	responded	to	treatment		The	pharmacology	of	cidofovir	and	imiquimod	is	different.	The	proposed	mechanism	of	action	of	these	drugs	in	HPV	related	VIN	is	also	therefore	different	and	they	are	therefore	discussed	separately	below.		
5.4.1.1 E2	Methylation	and	Response	to	Treatment	with	Cidofovir	Mean	E2	methylation	was	significantly	higher	in	patients	who	responded	to	treatment	(38.4%)	with	cidofovir	than	patients	who	did	not	(2.4%).	ROC	analysis	of	the	data	demonstrated	the	ability	of	E2	methylation	to	distinguish	responders	from	non-responders	with	an	AUC	of	0.919.	Further	analysis	of	the	data	revealed	the	potential	utility	of	E2	methylation	as	a	predictive	biomarker	in	the	treatment	of	VIN	3	with	cidofovir.	Several	potential	‘cut-off’	methylation	levels	were	investigated	and	a	level	of	4%	conferred	a	good	balance	between	sensitivity	(88.2%)	and	specificity	(84.6%).		A	biological	explanation	for	the	correlation	between	high	levels	of	E2	methylation	and	response	to	treatment	is	difficult	to	determine.		It	is	also	impossible	to	be	certain	if	it	is	the	level	of	methylation	per	se,	that	is	important	to	the	action	of	cidofovir	or,	if	methylation	is	a	surrogate	marker	of	another	relevant	process.	It	is	possible	that	the	action	of	cidofovir	in	this	context	is	as	a	de-methylating	agent.	Decitabine	is	a	drug	used	to	treat	myelodysplatic	blood	conditions	and	exerts	its	effect	through	its	incorporation	into	DNA	and	blocking	the	
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activity	of	DNA	methyltransferases	(DNMTs)	leading	to	de-methylation.		Decitabine	is	a	cytidine	deoxynucleoside	analogue,	similar	to	cidofovir	and	therefore	it	is	possible	that	cidofovir	acts	similarly	in	this	setting	(Gros	et	al.	2012).	This	theory	is	supported	by	a	small	study	of	five	cases	of	failed	cidofovir	treatment	in	recurrent	respiratory	Papillomatosis	(caused	by	HPV	11),	which	found	that	all	cases	were	uniformly	unmethylated	(Gall	et	al.	2011).		It	is	also	possible	that	E2	methylation	is	a	surrogate	marker	of	another	relevant	process.	This	is	consistent	with	the	hypothesis	that	response	to	cidofovir	may	be	dependent	on	the	absence	of	functioning	p53/pRb.	This	hypothesis	was	developed	based	on	a	growing	body	of	evidence	in	the	literature	supporting	the	concept	that	the	selectivity	of	action	of	cidofovir	for	transformed	cells	(both	HPV	positive	and	negative)	compared	to	normal	cells	is	due	to	the	absence,	or	altered	function,	of	normal	DNA	repair	pathways	(Andrei	et	al.	2015).	It	has	been	hypothesised	that	these	abnormal	DNA	repair	pathways	are	a	result	of	aberrant	p53/pRb	signalling	(Andrei	et	al.	2015).	It	has	been	shown	that	cidofovir	can	generate	double-stranded	breaks	in	cellular	DNA	that	can	be	repaired	by	normal	cells,	but	not	in	tumour	cells	(de	Schutter	et	al.	2013).	The	same	study	demonstrated	that	higher	amounts	of	cidofovir	were	incorporated	into	the	genomic	DNA	of	transformed	cells	compared	to	normal	cells,	despite	the	fact	that	the	intracellular	levels	of	cidofovir	metabolites	were	similar.	This	suggests	that	the	increased	levels	of	incorporated	cidofovir	are	not	a	result	of	altered	metabolism	of	the	drug.	It	was	not	possible	to	measure	levels	or	function	of	either	p53	or	pRb	in	this	study.	However	HPV	characteristics	that	could	be	associated	with	aberrant	p53/pRb	were	investigated.	It	is	broadly	accepted	that	the	level	of	p53/pRb	is	reduced	through	ubiquitination	via	the	HPV	E6	and	E7	oncoproteins,	which	can	become	deregulated	as	a	result	of	HPV	integration	and/or	HPV	DNA	methylation	(Doorbar	2006).	HPV	integration	and	increased	methylation	could	therefore	identify	cases,	which	are	more	likely	to	contain	lower	levels	of	p53/pRb,	and	may	be	more	likely	to	respond	to	cidofovir.	The	strong	correlation	between	increased	E2	methylation	and	response	to	treatment	could	therefore	be	because	E2	methylation	is	as	a	surrogate	marker	of	absent/low	level	p53/pRb.	This	is	supported	by	the	fact	that	patients	who	responded	to	treatment	were	more	likely	to	have	disrupted	HPV	and	lower	levels	of	E2	expression	than	patients	who	did	not	respond	(although,	unlike	E2	methylation,	these	finding	did	not	reach	statistical	significance).	However,	it	was	not	supported	by	the	absence	of	correlation	between	deregulated	oncogene	expression	and	response	to	treatment.	Both	the	lack	of	significance	in	the	associations	found	between	viral	integration,	low	E2	expression	and	response	to	treatment	and	the	absence	of	an	association	between	deregulated	oncogene	expression	
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and	response	to	treatment	could	be	explained	by	limitations	in	the	methodology	(see	below).	
5.4.2 E2	Methylation	and	Imiquimod	Contrary	to	the	case	with	cidofovir,	mean	E2	methylation	was	statistically	significantly	
lower	in	patients	who	responded	to	imiquimod	(11.6%	vs.	40.0%).	ROC	analysis	of	the	data	demonstrated	the	ability	of	E2	methylation	to	distinguish	responders	from	non-responders	with	an	AUC	of	0.721.	Further	analysis	of	the	data	revealed	the	potential	utility	of	E2	methylation	as	a	predictive	biomarker	in	the	treatment	of	VIN	3	with	imiquimod.	Several	potential	‘cut-off’	methylation	levels	were	investigated	and	a	level	of	10%	conferred	a	good	balance	between	sensitivity	(82.4%)	and	specificity	(56.3%).		It	is	again	difficult	to	be	certain	whether	it	is	the	level	of	E2	methylation	per	se	that	is	important	in	the	activity	of	imiquimod,	or	whether	E2	methylation	is	a	surrogate	marker	for	another	important	process	or	viral	state.	The	pharmacology	of	imiquimod	and	the	pathology	of	HPV	indicate	that	it	is	more	likely	to	be	the	latter.	Imiquimod	acts	as	an	immunomodulator	by	activating	TLR7,	which	in	turn,	enhances	the	innate	immune	system	by	stimulating	the	synthesis	of	pro-inflammatory	cytokines,	especially	IFNα.	INFα	is	able	to	enhance	cell-mediated	cytoloytic	activity	against	viral	targets	(Stanley	2002;	Diaz-Arrastia	et	al.	2001;	Edwards	1998).	However,	the	enhanced	host	immune	response	needs	direction	in	order	to	be	effective.	It	is	plausible	that	a	proliferative	HPV	infection	provides	this	direction.	It	has	been	demonstrated	that	treating	VIN	with	imiquimod	when	HPV	exists	in	a	mixed	physical	state	(i.e.	episomal	and	integrated	virus)	results	in	clearance	of	the	episomal	HPV	but	not	the	integrated	(Herdman	et	al.	2006;	Pett	et	al.	2006).	The	success	of	HPV	is	often	attributed	to	its	ability	to	hide	from	normal	host	defence	mechanisms	permitting	persistent	infection	(Doorbar	2006).	Persistent	infection	is	associated	with	the	development	of	high-grade	intraepithelial	neoplasia	and	certain	viral	characteristics	such	as	HPV	integration	and	increased	HPV	DNA	methylation.	It	is	therefore	plausible	that	these	HPV	characteristics	confer	successful	evasion	of	host	immunity.	It	is	possible	that	cases	of	episomal	HPV	infection	(in	which	a	proliferative	HPV	infection	is	present)	are	more	likely	to	generate	pathogen	associated	molecular	patterns	(PAMPs)	on	the	cell	surface.	Based	on	this,	it	was	hypothesised	that	response	to	treatment	with	imiquimod	would	be	more	likely	in	cases	with	evidence	of	episomal	HPV	infection.	Specific	identification	of	episomal	HPV	was	not	possible	in	this	project.	However,	HPV	integration	frequently	results	in	disruption	of	the	E2	and/or	E1	regions	of	the	virus,	therefore	intact	E1/E2	was	used	to	identify	cases	of	episomal	HPV.	Additionally,	studies	(including	this	one)	have	shown	that	low	levels	of	HPV	DNA	methylation	strongly	
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correlate	with	the	presence	of	intact	(episomal)	HPV	(Oka	et	al.	2013):	relationships	between	HPV	DNA	methylation	and	response	to	treatment	were	also	explored.	Likewise,	the	work	of	this	thesis,	also	demonstrated	that	higher	levels	of	E2	expression	correlated	with	intact	HPV	(see	section	4.6.1),	the	biomarker	potential	of	E2	expression	was	also	investigated.		As	was	hypothesised,	intact	E1/E2,	low	HPV	DNA	methylation	and	high	E2	gene	expression	were	all	associated	with	response	to	treatment	with	imiquimod.	Statistical	significance	however,	was	only	present	for	the	association	between	E2	and	L1/L2	DNA	methylation	and	response.	Potential	reasons	for	the	lack	of	statistical	significance	in	the	associations	between	intact	E1/E2	and	high	E2	expression	are	explored	in	the	limitations	section	of	this	discussion	(below).	
5.4.3 Strengths	The	bio-resources	used	were	of	high	quality,	originating	from	tissue	biopsies,	and	the	application	of	stringent	quality	assurance	ensured	only	high	quality	data	was	assessed	(see	methods	chapter	4).		
5.4.4 Limitations	The	biomarker	potential	of	the	HPV	characteristics	was	investigated	using	clinical	outcome	data	from	all	patients	enrolled	in	the	trial	who	provided	a	pre	and	post	treatment	biopsy,	even	if	they	did	not	strictly	adhere	to	the	treatment	regime.		This	has	advantages	and	disadvantages.	The	advantage	is	that	the	estimation	of	real-world	clinical	utility	is	potentially	more	accurate.	The	disadvantage	is	that,	the	performance	of	the	biomarkers	in	the	optimum	setting	may	be	underestimated.	In	the	cidofovir	arm	of	the	study,	78/89	patients	adhered	to	the	treatment	regime;	in	the	imiquimod	arm,	78/91	patients	adhered	to	the	treatment	regime.	Patients	who	did	not	adhere	to	the	treatment	regime,	typically	reduced	dosing	due	to	side	effects.		The	assay	designed	to	detect	HPV	disruption	was	a	tiling	PCR	that	targeting	multiple	fragments	of	the	E1	and	E2	genes.	False	positive	test	results	could	be	generated	by	this	assay	as	a	result	of	DNA	with	poor	integrity.	Additionally,	a	positive	result	would	also	be	generated	in	the	event	of	intact	E2	but	disrupted	E1;	the	biological	significance	of	this	may	not	be	relevant	in	this	context.	However,	intact	E2	with	disrupted	E1	was	only	detected	in	four	cases	in	the	section	of	analyses	and	is	unlikely	to	have	had	a	significant	impact	on	the	data.		Among	the	gene	expression	data,	there	were	a	number	of	cases	that	generated	a	non-specific	PCR	product	during	RT-qPCR.	All	these	samples	were	found	to	have	disruption	in	
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the	E2	region.	It	was	desirable	to	include	these	cases	in	the	analysis	to	ensure	that	the	sample	was	not	skewed	towards	investigating	cases	with	intact	virus.	These	samples	were	considered	to	contain	no	E2	mRNA	and	were	given	a	CNRQ	value	of	0,	representing	no	expression.	This	aspect	of	the	methodology	could	also	affect	the	accuracy	of	the	data	and	could	also	hide	statistically	significant	correlations.	Finally,	the	use	of	E2:E6	expression	ratio	to	identify	cases	of	regulated	(E2>E6)	expression	and	deregulated	(E6>E2)	was	exploratory	and	was	not	well-validated.	It	is	quite	feasible	that	deregulated	gene	expression	is	not	accurately	represented	by	an	E6>E2	expression	ratio.	
5.4.5 Broader	Implications	Reported	complete	response	rates	in	VIN	treated	with	cidofovir	range	from	15%	-	47%	(see	background,	table	1.3).	A	review	of	the	literature	suggests	that	complete	response	to	imiquimod	ranged	from	20.0%	-	100.0%	(see	background,	table	1.4).	The	most	recent	clinical	trial	with	which	this	work	is	associated	(RT3	VIN,	chapter	3),	demonstrated	complete	response	in	41/89	(46.0%)	patients	treated	with	cidofovir	and	42/91	(46.0%)	of	patients	treated	with	imiquimod.	A	biomarker	that	could	identify	patients	more	likely	to	respond	to	treatment	is	an	attractive	prospect.		This	is	the	first	study	investigating	the	potential	role	of	viral	characteristics	as	biomarkers	in	the	treatment	of	VIN.	HPV	E2	DNA	methylation	meets	all	of	the	criteria	laid	out	in	the	CRUK	biomarker	development	roadmap	(Figure	5.1)	up	to	the	point	of	BM	qualification	stage	2.	E2	methylation	varied	in	the	RT3	VIN	cohort,	which	is	representative	of	the	cohort	to	which	the	BM	would	apply.	The	assay	was	accurate	and	reproducible	(see	methods,	section	2.5.2).	Strong	correlations	between	high	E2	methylation	and	response	to	treatment	with	cidofovir	and	low	E2	methylation	and	response	to	treatment	with	imiquimod	were	identified	retrospectively.	Finally,	the	relationship	between	E2	methylation	and	clinical	outcome	indicated	potential	clinical	utility	as	a	predictive	BM	in	a	prospective	analysis	of	a	retrospective	tissue	collection.	However,	prior	to	further	qualification	in	the	context	of	a	clinical	trial	utilising	the	E2	methylation	as	a	BM	in	the	randomisation	process,	its	‘fitness	for	purpose’	needs	to	be	addressed.	The	criteria	determining	whether	or	not	a	BM	is	fit	for	purpose	have	not	been	formally	defined.	Such	criteria	may	include	cost	efficiency,	ease	of	incorporation	into	the	clinical	setting,	efficiency	of	the	assay	testing	the	BM	and	patient	coverage.	Cost	efficiency	analyses	are	beyond	the	scope	of	this	PhD.	Incorporating	the	assay	into	the	clinical	setting	is	feasible.	Testing	could	be	carried	out	on	remaining	biopsy	material	following	histological	assessment.	Consideration	would	have	to	be	given	to	the	quality	of	the	DNA	being	extracted	if	this	were	the	case.	Alternatively,	a	slightly	larger	diagnostic	biopsy	than	is	currently	standard	(3-4	mm)	could	be	taken	and	divided	into	sections	for	histology	and	for	methylation	analysis.	The	equipment	required	is	relatively	compact	
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within	a	laboratory	setting,	the	assay	is	subjectively,	moderately	labour	intensive	requiring	a	total	of	approximately	4	hours	of	single	operator	work	split	over	the	course	of	2	days	and	the	assay	itself	is	high-throughput	(in	its	current	form,	47	cases	can	be	run	at	a	time	in	duplicate).	The	efficiency	of	the	E2	methylation	pyrosequencing	assay	in	its	current	form	means	that	the	patient	coverage	is	quite	low.	In	the	cohort	of	VIN	3	available	to	this	study	(likely	to	be	broadly	representative	of	VIN	3	overall)	percentage	E2	methylation	could	not	be	analysed	for	72/135	(53.3%)	patients(Figure	5.11).	In	the	majority	of	cases	(28/135,	22.4%),	it	was	because	HPV	16	was	not	detected	in	the	biopsy	and	the	assay	is	currently	designed	to	test	E2	methylation	in	the	HPV	16	genotype	only.	Among	HPV16-negative	cases,	14/28	(50.5%)	were	positive	for	HPV	33,	which	was	the	second	most	prevalent	genotype	detected.	It	could	therefore	be	worthwhile,	to	modify	the	assay	to	include	cases	of	HPV	33	E2	methylation.	It	was	noted	that	all	cases	testing	negative	for	a	high-risk	genotype	(n=5)	responded	to	treatment;	four	of	these	five	patients	were	treated	with	imiquimod	and	one	with	cidofovir.	It	would	be	worth	investigating	the	outcome	of	HR	HPV	negative	cases	in	larger	study	cohort	to	determine	how	best	to	manage	these	patients.	Twenty-six	cases	were	identified	as	fails	by	the	pyrosequencing	software	due	to	‘insufficient	DNA’;	this	is	normally	because	there	is	a	problem	with	the	integrity	of	the	template	DNA.	Of	these	26	cases,	23/26	(88.5%)	were	found	to	have	disrupted	E1/E2	regions,	this	is	a	difficult	issue	to	overcome.	One	option	might	be	to	treat	these	cases	as	highly	methylated	in	view	of	the	strong	correlation	between	viral	integration	and	high	methylation	that	was	identified	in	chapter	5,	section	4.7.5.4,this	would	not	provide	the	same	sensitivity	and	specificity	profile	and	advantages	of	increased	patients	coverage	would	need	to	be	considered	against	the	disadvantages	of	reduced	sensitivity	and	specificity.	The	remaining	eighteen	cases	failed	internal	quality	control	steps	of	the	pyrosequencing	software	due	to	varying	degrees	of	sequence	variation	in	the	DNA.	Several	measure	could	be	taken	to	improve	this	including	optimisation	of	the	assay	(i.e.	PCR	conditions,	primer	quality,	reagent	quality)	as	well	as	taking	care	to	optimise	the	quality	of	the	DNA	obtained	from	tissue	biopsies	as	much	as	is	possible.				
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Figure	5.10	Analysis	of	cases	generated	a	'failed'	pyrosequencing	result.		The	incorporation	of	a	biomarker	such	asE2	methylation	in	to	the	clinical	management	of	patients	with	VIN	could	have	significant	value.	VIN	has	malignant	potential;	therefore	time	to	efficient	treatment	is	important.	A	biomarker	such	as	this	could	significantly	reduce	time	wasted	trying	medications	destined	to	fail,	resulting	in	better	outcomes	for	women	(due	to	earlier	treatment)	and	more	cost	effective	approaches	for	the	healthcare	team	(fewer	failed	approaches,	less	risk	of	progression	to	malignant	disease).	This	would	also	avoid	unnecessarily	subjecting	women	to	treatments	with	significant	side	effects	profiles.	The	RT3	VIN	clinical	trial	demonstrated	that	72.6%	of	women	reported	adverse	events	of	grade	2	or	above	(NCI	CTCAE	v	3.0).	This	emphasises	the	advantage	of	targeting	therapy	to	those	patients	in	whom	it	is	more	likely	to	work.		
5.4.5.1 Future	Work	Two	overall	approaches	could	and	should	be	taken	by	future	work	in	this	area.	Firstly,	further	development	of	E2	methylation	as	a	predictive	BM	in	the	treatment	of	VIN	with	cidofovir	and	imiquimod	could	be	undertaken	in	the	form	of	a	prospective	clinical	trial	utilising	the	biomarker	in	randomisation	(in	accordance	with	the	CRUK	BIDD	road	map).	Prior	to	this,	measures	would	need	to	be	taken	to	address	the	issues	described	above	relating	to	the	pyrosequencing	assays	‘fitness	for	purpose’.	It	would	be	clinically	and	statistically	valuable	to	include	neoplasia	of	additional	anogenital	sites	e.g.	anus,	in	this	study.	Secondly,	with	the	knowledge	that	cidofovir	and	imiquimod	appear	to	be	generating	a	clinical	response	in	two	biologically	defined	sub-groups	that	combined	comprise	the	majority	of	cases	of	VIN	3,	a	treatment	combining	these	two	medications	in	one	application	is	potentially,	a	very	attractive	prospect.		
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6 Final	Conclusion	The	RT3	VIN	clinical	trial	found	that	approximately	50%	of	cases	of	VIN	3	treated	with	cidofovir	completely	responded	and	likewise,	approximately	50%	of	cases	treated	with	imiquimod	responded.	A	biomarker	that	could	identify	patients	more	likely	to	respond	to	treatment	would	be	advantageous	in	several	ways	including:	avoidance	of	unnecessary	side	effects;	offering	patient	centred	care;	enabling	effective	treatment	and	avoiding	the	need	for	surgery.	With	the	knowledge	that	HPV	was	implicated	in	the	pathogenesis	of	the	majority	of	cases	of	VIN	3,	this	study	investigated	the	biology	of	HPV	in	the	disease	and	HPV	physical	characteristics	as	potential	predictive	biomarkers	to	treatment	response.		This	study	found	high	HPV	prevalence	(98.2%)	in	167	cases	of	VIN	3.	Further	to	this,	it	found	that	disruption	of	the	HPV	genome	was	a	common	event,	present	in	52.2%	cases	of	HPV	16	positive	disease	and	that	viral	disruption	correlated	with	false	negative	HPV	test	results	with	a	commercially	available	HPV	detection	assay	(PapilloCheck®).	Application	of	multiple	HPV	detection	assays	targeting	different	HPV	genotypes	and	genomic	regions	increased	detection	of	HPV	from	81.4%	to	98.2%.	This	finding	has	three	important	implications.		Firstly,	that	the	choice	of	HPV	detection	assay	used	in	both	the	research	setting	and	clinical	setting	should	be	carefully	considered	to	minimise	the	impact	that	HPV	disruption	has	on	false	negative	HPV	rates;	assays	targeting	multiple	regions	of	the	HPV	genome	should	be	utilised	when	possible.	Secondly,	this	study	demonstrates	the	possibility	that,	as	for	high-grade	CIN,	all	VIN	is	associated	with	the	presence	of	HPV	infection;	HPV	could	be	implicated	in	the	pathogenesis	of	all	cases	of	VIN.	This	hypothesis	is	worthy	of	further	investigation.	Finally,	HPV	positivity	overall	was	not	a	suitable	candidate	biomarker	in	this	disease;	failing	to	fulfil	the	required	criterion	of	variability	in	a	cohort	representative	of	the	cohort	to	which	the	biomarker	would	apply.	HPV	16	was	the	most	prevalent	genotype	detected,	found	in	140/167	(83.8%)	of	cases,	supporting	findings	from	previous	studies.	HPV	16	positivity	was	therefore	variable	in	the	cohort	but	no	correlation	was	identified	with	response	to	treatment	with	either	medication	following	retrospective	correlation	with	clinical	outcome.		Several	physical	characteristics	of	HPV	were	investigated	in	detail	in	this	study:	viral	disruption,	DNA	methylation	and	gene	expression.	These	characteristics	were	chosen	for	study	based	on	the	knowledge	that	viral	integration,	high	DNA	methylation	and	deregulated	oncogene	expression	are	physical	characteristics	associated	with	higher	grade	intraepithelial	disease	(Clarke	et	al.	2012;	Wiley	et	al.	2005;	Kalantari	et	al.	2008;	Park	et	al.	1991;	Klaes	et	al.	1999;	Hudelist	et	al.	2004;	Cricca	et	al.	2009a;	Bryant,	Tristram	et	al.	2014)	and	a	sound	biological	explanation	indicating	their	role	in	the	transforming	potential	of	HPV	(Doorbar	et	al.	2012b).	Despite	the	uniform	histological	
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grade	of	disease	(VIN	3)	in	the	studied	cohort	there	was	heterogeneous	HPV	biology	detected	in	all	three	physical	characteristics.	As	observed	in	some	previous	investigations,	this	study	found	strong	correlations	between	these	viral	characteristics.	Median	E2	expression	was	significantly	lower	in	cases	of	viral	disruption	(p=<0.0001);	increasing	levels	of	HPV	E2	DNA	methylation	significantly	correlated	with	decreasing	levels	of	E2	expression	(r=-0.679,	p=<0.0001)	and	median	E2	methylation	was	significantly	higher	in	cases	of	viral	disruption	that	in	cases	of	intact	virus	(80.6%	vs.	3.2%,	p=<0.0001).	This	is	the	largest	study	demonstrating	the	relationships	between	these	viral	characteristics	and	contributes	significantly	to	the	understanding	of	how	HPV	drives	disease.	It	supports	findings	that,	in	some	cases	of	HPV	infection,	the	virus	becomes	integrated	into	the	host	genome	(and	therefore	disrupted)	and	that	this	is	associated	with	high	levels	of	HPV	DNA	methylation.	These	high	levels	of	HPV	DNA	methylation	may,	or	may	not	be	a	direct	result	of	integration	into	the	host	genome.	It	also	shows	that	both	viral	integration	and	high	DNA	methylation	are	associated	with	reduced	E2	gene	expression.	It	is	broadly	acknowledged	that	the	E2	protein	plays	a	role	in	the	regulation	of	the	expression	of	the	E6	and	E7	oncogenes	and	its	loss	of	expression	leads	to	deregulated	oncogene	expression	and	potentially	transformation	of	the	cell	into	a	malignant	state.	However,	this	study	also	found	that	there	were	a	significant	number	of	HPV	positive	cases	in	the	cohort	in	which	none	of	these	viral	characteristics	were	detected.	VIN	3	therefore	would	appear	to	represent	a	spectrum	of	HPV	biology,	which	is	an	important	finding	that	has	two	possible	explanations.	Firstly,	although	VIN	3	indicates	those	cases	of	VIN,	which	have	a	higher	risk	of	developing	into	a	vulval	malignancy,	the	majority	of	cases	do	not	progress	to	cancer.	This	could	be	due	to	the	varying	HPV	biology	within	the	disease	grade	and	it	could	be,	that	cases	of	VIN	3	with	the	presence	of	HPV	characteristics	associated	with	a	transforming	potential	are	actually	at	increased	risk	of	developing	a	malignancy.	It	is	possible	therefore	that	detection	of	viral	characteristics	associated	with	a	transforming	potential	(HPV	integration/disruption,	increased	DNA	methylation	and	reduced	E2	expression)	in	the	specimen	is	a	more	accurate	way	of	identifying	cases	at	increased	risk	of	progression.	HPV	DNA	methylation	has	been	extensively	researched	in	this	capacity,	and	does	appear	to	be	able	to	distinguish	cases	of	high	grade	CIN	from	cases	with	low-grade	disease	(Clark	et	al.	2012).	A	small	amount	of	work	also	exists	demonstrating	a	similar	of	role	of	HPV	DNA	methylation	in	other	anogenital	and	oropharyngeal	disease	(Wiley	et	al.	2005;	Kalantari	et	
al.	2010;	Lorincz	et	al.	2013;	Sun	et	al.	2011;	Ding	et	al.	2009;	Mirabello	et	al.	2013).	The	findings	of	this	study	indicate	that	HPV	DNA	methylation	(as	well	potentially	HPV	disruption	and	decreased	E2	expression)	may	serve	a	similar	purpose	in	vulval	disease.	An	alternative	possibility	is	that	cases	without	any	detectable	transforming	physical	characteristics	are	cases	in	which,	HPV	is	not	responsible	for	driving	disease	and	is	an	
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incidental	finding	in	disease	caused	by	alternative	aetiology	e.g.	lichen	sclerosus.	If	this	were	the	case,	then	it	could	be	argued	that	these	cases	may	have	the	highest	risk	of	malignancy	in	view	of	the	fact	that	lichen	sclerosus	has	been	more	commonly	found	in	association	with	vulval	malignancy	than	HPV	(Eva	et	al.	2009;	McCluggage	2009).	More	research	is	required	in	this	area	to	accurately	determine	the	VIN	disease	process	and	to	answer	these	questions.	In	view	of	the	distinct	possibility	that	all	VIN	in	this	cohort	could	have	been	HPV	positive,	it	may	be	that	as	for	CIN	in	the	cervix,	HPV	is	also	necessary	for	the	development	of	VIN	and	that	lichen	sclerosus	and	other	similar	chronic	skin	conditions	augment	the	process.	Finally,	the	most	important	finding	of	this	research	was	the	potential	role	of	HPV	E2	DNA	methylation	in	guiding	topical	treatment	choice	(cidofovir	or	imiquimod)	in	VIN.	All	viral	physical	characteristics	tested	were	variable	in	the	cohort	and	therefore	fulfilled	that	criterion	of	biomarker	development.	Further	to	this,	a	positive	result	for	any	of	the	three	physical	characteristics	associated	with	HPV	transforming	potential	was	associated	with	response	to	treatment	with	cidofovir;	the	opposite	being	true	for	treatment	with	imiquimod.	However,	following	retrospective	correlations	in	the	prospectively	collected	cohort,	HPV	E2	DNA	methylation	represented	the	most	powerful	predictor	of	response	for	both	treatments.	E2	methylation	>4%	was	able	to	predict	response	to	treatment	with	cidofovir	with	a	sensitivity	of	88.2%	and	a	specificity	of	84.6%.	Conversely,	E2	methylation	<4%	was	able	to	predict	response	to	treatment	with	imiquimod	with	a	sensitivity	of	70.6%	and	a	specificity	of	62.5%.	This	finding	indicates	that	these	drugs	are	active	in	opposing	HPV	biological	states	and	that	their	biologically	guided	use	could	result	in	much	higher	response	rates	overall.	This	could	potentially	reduce	dependence	on	surgical	excision	in	the	management	of	this	disease	and	offer	a	more	satisfactory	treatment	approach	for	patients,	healthcare	professionals,	and	for	the	NHS	overall.	Further	research	is	required	to	take	this	into	clinical	practice	and	a	large	prospective	study	using	E2	methylation	to	allocate	patients	to	treatment	arms	would	be	the	obvious	next	step.	Another	possibility	also	exists;	a	formulation	combining	the	two	drugs	may	have	the	same	efficacy	and	obviate	the	need	for	a	biomarker.	This	is	an	attractive	option	and	would	potentially	speed	up	access	to	treatment,	negating	the	need	to	wait	for	a	biomarker	result,	as	well	as	being	a	potentially	more	cost	effective	option.	A	potential	challenge	with	a	double	therapy	approach	might	be	increased	levels	of	side	effects	that	may	be	intolerable	to	patients.		It	is	clear	that	HPV	E2	methylation	represents	a	biological	state	in	intraepithelial	disease	that	has	potential	utility	as	a	predictive	biomarker	of	treatment	response.	It	is	also	likely	that	E2	methylation	is	a	marker	of	disease	grade.	Incorporation	of	E2	HPV	DNA	methylation	testing	into	clinical	practice	in	the	future	would	appear	to	be	advantageous	in	
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the	management	of	intraepithelial	neoplasia	of	the	cervix,	the	vulval,	the	vagina,	the	anus	and	the	penis	which,	combined	represent	a	significant	disease	burden	in	the	UK.	Not	only	could	it	serve	to	identify	those	patients	with	higher-grade	disease	with	an	increased	risk	of	malignant	progression	but	also	to	determine	mode	of	management.	Both	imiquimod	and	cidofovir	could	be	suitable	for	use	in	the	treatment	of	all	these	conditions,	all	of	which	are	currently	managed	by	surgical	excision.	With	the	new	found	knowledge	that	~50%	efficacy	rates	reported	for	each	drug	are	due	to	their	activity	in	opposing	HPV	biological	states,	their	use	in	intraepithelial	neoplasia	more	broadly	should	be	investigated.																							
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8 Appendix	1	–	RNA	integrity	number	(RIN)	values	for	a	random	selection	of	baseline	
sample	generated	by	the	Agilent	Bioanalyzer	of	RNA.	(Scale	=	0-10	(10	=	best	quality)).																										
Sample	
ID	
Date	of	
extraction	
Nanodrop	
RNA	Conc.	
260/280	 260/230	 RIN	
number	
RT1	 06/11/09	 69	 2.2	 2.6	 7.5	
RT11	 21/12/09	 238	 2.1	 0.9	 2.2	
RT21	 28/01/10	 201	 2.1	 2.2	 1.2	
RT31	 12/02/10	 184	 2	 2	 7.8	
RT41	 20/08/10	 27	 2.2	 1.2	 n/a	
RT51	 28/08/10	 82	 2.0	 1.9	 4.3	
RT61	 20/08/10	 55	 2	 1.7	 n/a	
RT71	 12/01/11	 71	 2.1	 2	 1	
RT81	 28/01/11	 37	 2	 1.4	 n/a	
RT91	 08/02/11	 105	 2	 1.9	 1.5	
RT101	 10/03/11	 279	 2.1	 2.3	 2.4	
RT111	 30/03/11	 126	 2.1	 1.17	 1.5	
RT121	 05/04/11	 46	 2	 0.9	 1	
RT131	 12/04/11	 62	 2.1	 1.9	 1	
RT141	 10/05/11	 79	 2	 1.4	 4.2	
RT151	 24/05/11	 299	 2.	 2.1	 4.3	
RT161	 31/05/11	 78.1	 2	 1	 1	
RT171	 09/06/11	 137	 2.1	 2	 3.3	
RT181	 09/06/11	 280	 2	 2.1	 n/a	
RT191	 21/06/11	 49	 2	 1.8	 1.2	
RT200	 22/06/11	 180	 2	 2.1	 2.4	
RT211	 17/08/11	 21	 2.1	 1.1	 1	
RT221	 01/12/11	 267	 2.1	 2.1	 5.7	
RT231	 13/12/11	 164	 2	 1.3	 3.3	
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9 Appendix	2	–	RT3	VIN	Paper	
